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Abstract 
The AZURE trial was the first adjuvant breast cancer trial to report a novel interaction 
between the anti-tumour efficacy of zoledronic acid (ZOL) and menopausal status of 
patients. It showed a significant reduction in disease recurrence events in and outside of 
bone, in those clinically  >5 years postmenopausal, compared to an increase in non-bone 
recurrences in all others. Data from neoadjuvant studies had also shown an enhanced 
anti-tumour effect of ZOL in oestrogen receptor negative (ER-ve) tumours.  Three main 
questions arose from these data and were the focus of this thesis; firstly how can 
postmenopausal status be accurately defined in patients?, secondly, which reproductive 
hormone is interacting with the drug?, and thirdly, what are the molecular mechanisms? 
Follicle stimulating hormone (FSH), oestradiol and inhibin A were evaluated from 806 
patients recruited to AZURE.  With all 3 hormones in postmenopausal range, ZOL 
treatment resulted in an improved invasive disease free survival compared to control (HR 
0.809, 95%CI 0.537-1.22).  No single hormone was predictive of an interaction with 
ZOL.  A low pretreatment FSH and oestradiol were borderline significant for a shorter 
time to bone and distant recurrence respectively.  Evaluation of serum, pre- and post 
neoadjuvant FEC100chemotherapy +/- ZOL in 40 patients recruited to the ANZAC trial, 
identified changes in the tumour suppressor activin (↑) and tumour promoter follistatin 
(↓) in postmenopausal patients and those with ER-ve primary tumours. The direct effect 
of ZOL on these proteins in breast cancer cell lines in vitro and in vivo, showed a 
reduction in follistatin secretion from ER-ve cell lines only, which was diminished in the 
presence of inhibin A.  Moreover, ZOL and inhibin A altered levels of these proteins in 
the bone microenvironment, with a reduction in bone follistatin levels after ZOL only in 
ovariectomised mice.  In addition, inhibin A decreased bone activin levels. 
These data suggest that pretreatment evaluation of reproductive hormones can assist in 
selection of postmenopausal patients for adjuvant ZOL, and breast cancer cells may 
preferentially home to premenopausal bone (low FSH), preferring distant non-bone sites 
in postmenopausal women (low oestradiol). ZOL has novel direct and indirect effects on 
activin and follistatin levels in the tumour and bone microenvironment that is influenced 
by ER status of tumor cells and presence of inhibin A.  	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Chapter 1. Introduction. 
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1.1	  Breast	  cancer-­‐	  tumour	  spread	  is	  an	  early	  phenomenon.	  
 
1.1.1	  Breast	  cancer	  -­‐	  burden	  of	  disease.	  
Breast cancer is the most common cancer in women, with ~50,000 new cases of breast 
cancer diagnosed in the UK in 2010.  Over 80% of all diagnoses are made in women over 
the age of 50.  Women in the UK now have a lifetime risk of 1 in 8 for the development 
of breast cancer (CRUK 2013).  Outcomes for these women depend on the stage of the 
disease at presentation.  The concept of ‘stage’ includes an assessment of established 
adverse prognostic factors including size of breast tumour, involvement of local lymph 
nodes and spread to distant organs. Advancing stage includes an increase in the size of 
the primary tumour, increased involvement of lymph nodes and local structures with 
cancer, and stage IV involves spread outside of the breast to distant organs (Table 1.1).  
Survival correlates with stage of disease and 5 year survival rates are 90% for stage 1, 
70% stage II, 50% stage III and 13% stage IV.  Reassuringly, data from Cancer Research 
UK showed that in over 17,000 women diagnosed with breast cancer in 2006-2009, the 
majority presented with stage I or II disease, with <10% stage III and only 5% stage IV 
(CRUK 2013).  However, even in early stage disease, tumour cells may have spread from 
the primary and their survival in distant sites will depend on intrinsic tumour factors and 
also factors in the microenvironments in which they locate.   
 
1.1.2	  Dissemination	  of	  tumour	  cells	  in	  early	  breast	  cancer.	  
Breast carcinomas occur when normal breast epithelial cells develop somatic mutations 
that are not effectively removed by DNA repair mechanisms, resulting in accumulation of 
mutations in daughter cells. Over time, often decades, these mutations accumulate and the 
cells ultimately change from normal epithelial cells to invasive carcinoma (Weinberg 
2007).  This clonal model of tumour progression indicated that over time, cancers would 
develop sufficient genetic aberrations that promoted not only their survival, but also their 
ability to migrate through local tissues and seed to and survive in distant organs.   
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Table 1.1.  Stage of breast cancer at diagnosis according to tumour size and spread 
to local and distant structures. 	  
	  	  
Table adapted from TNM staging of breast cancer. CRUK website. 
www.cancerresearchuk.org 
  
Stage& Descrip-on&
I&
A"
"
B"
"
Tumour<2cm"and"no"spread"outside"breast"
"
Tumour<2cm"with"tumour"cells"detectable"in"
local"lymph"nodes"
II&
A"
"
"
B"
"
Tumour"<2cm"and"in"1:3"lymph"nodes"
Tumour"2:5cm"no"lymph"nodes"involved"
"
Tumour"2:5cm"with"tumour"cells"detectable"
in"lymph"nodes"
Tumour"2:5cm"and"in"1:3"lymph"nodes"
Tumour">5cm"no"lymph"nodes"involved"
III&
A"
"
"
"
"
B"
"
Tumour"any"size"and"in"4:9"lymph"nodes"
Tumour">5cm"with"tumour"cells"detectable"in"
lymph"nodes"
Tumour">5cm"and"in"1:3"lymph"nodes"
"
Tumour"spread"to"skin"or"chest"wall"and"<9"
lymph"nodes"
"
Tumour"has"spread"to"skin"and"chest"wall"and"
>10"lymph"nodes"or"to"distant"lymph"nodes"ie"
collar"bone"or"breast"bone"
IV& Tumour"any"size"with"spread"to"distant"organs"
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However, challenges to this theory include the observation that disseminated tumour cells 
from the bone marrow of breast cancer patients without established metastatic disease, 
have fewer genetic mutations than the primary tumour (Schmidt-Kittler, Ragg et al. 2003).  
In addition, a series of experiments using fluorescent-activated cell sorting (FACS), 
identified a sub-population of breast tumour cells that were more tumorigenic than the 
bulk of the tumour mass.  These cells were positive (+ve) for CD44 on their cell surface, 
and when injected sub-cutaneously into NOD/SCID mice, formed tumour colonies when 
only 100 cells were injected compared to >20,000 of the low CD44 expressing tumour 
cells that did not form tumours.  The tumours that formed from the CD44+ve cells 
contained a mixed population of CD44+ve and –ve cells (Al-Hajj, Wicha et al. 2003).  
These data suggested that a small minority of cancer ‘stem’ like cells were responsible for 
forming the bulk of the tumor cells, and that the majority of the tumour cells lack 
proliferative potential.  It therefore is plausible that within very early breast tumours, 
possibly before clinical detection, there will be a sub-population of cancer stem cells 
(CSC), which have the capacity to proliferate and form new tumour colonies at distant 
sites. CSC have been shown to be more resistant to commonly used anti-cancer therapies, 
including radiotherapy and chemotherapy (Pinto, Widodo et al. 2013), and 
overexpression of CD44 in MCF7 cells confers resistance to endocrine therapy with 
tamoxifen (Hiscox, Baruha et al. 2012).  These data would explain, in part, why early 
breast cancers treated with multi-modality curative treatment including surgery, 
radiotherapy and chemotherapy can still recur, sometimes decades after completion of 
‘curative’ treatment. 
 
It has been accepted for over 125 years that certain tumours seed to specific distant sites, 
as first described by Stephen Paget in 1889 (Paget 1889).  Breast cancer often spreads to 
bone in a process involving breakdown and migration through stroma, followed by 
intravasation and avoidance of host immune system, and ultimately extravasation and 
survival in bone (Suva, Washam et al. 2011) (Fig 1.1). However, only 0.01% of the 
tumour cells that enter the circulation will form tumour colonies in bone.   Expression of 
receptors on breast cancer cells such as CXCR4, have been identified as promoting a 
‘bone homing’ tumour cell phenotype.  CXCR4 mediates homing to organs that express 
high levels of its ligand CXCL12, such as bone (Allinen, Beroukhim et al. 2004).   	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Figure 1.1.  Process of spread of breast cancer from primary site to bone. 
 
This multistep process involves local tumour progression and stromal invasion, followed 
by intravasation and evasion of host immune system and survival of shear forces within 
the circulation and ultimately extravasation at the metastatic site with utilisation of host 
stromal cells at this new site to assist survival.  <0.01% of cells that enter the circulation 
will be able to form bone metastases and these cells may have stem cell like properties 
rendering them more able to survive and proliferate. 
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Gene signature studies on primary tumours have not identified a single gene or genetic 
signature that predict if a primary breast tumour will form bone metastasis (Holen 2012), 
therefore although the intrinsic properties of the cancer cells will play a key role in 
promoting survival and spread, environmental factors at distant sites such as bone, may 
also influence survival and growth of tumour cells.   
 
1.1.3	   Host	   stromal	   cells	   affect	   tumour	   cell	   survival	   in	   both	   the	   primary	   and	   bone	  
microenvironment. 
It is well established that stromal cells pay a key role in modification of tumour cell 
survival, migration and proliferation, both in the primary tumour and in distant/secondary 
tumour microenvironments. The primary breast tumour comprises multiple cell types 
including tumour cells, fibroblasts, macrophages, stromal cells, neutrophils, blood vessels 
and extracellular matrix (Psaila, Kaplan et al. 2006) which all play a role in facilitating or 
hindering tumor cell proliferation and migration (Fig 1.2).  Cancer associated fibroblasts 
promote tumour growth and angiogenesis when injected with MCF-7 breast cancer cells 
in vivo (Orimo, Gupta et al. 2005), and tumour associated macrophages assist 
neovascularisation by increasing tumour secretion of vascular endothelial growth factor 
(VEGF) (Bingle, Lewis et al. 2006), and tumour invasiveness by secretion of matrix 
metalloproteins (MMPs) leading to break down of stroma (Bingle, Brown et al. 2002). 
 
In addition, primary tumours contain bone-derived cells including haematopoetic stem 
cells (HSC) and endothelial stem cells (ESC) allowing communication between the 
primary tumour and bone (Barcellos-de-Souza, Gori et al. 2013).  These HSC are thought 
to ‘prime’ future metastatic sites, and chemokines secreted from the primary tumours can 
influence the location of these cells therefore controlling the site of future metastases.  
This was evidenced in vivo by intradermal injection of Lewis lung cancer cells into 
C57Bl/6 mice that were treated with daily intraperitoneal conditioned medium from B16 
melanoma cells or serum free medium starting 2 days prior to tumour cell injection.  
Animals treated with conditioned medium developed a metastatic profile more 
characteristic of melanoma rather than the Lewis lung cancer cells (Kaplan, Riba et al. 
2005).  This concept of a ‘premetastatic niche’ remains to be confirmed in bone. 
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Figure 1.2 The microenvironment of the primary breast tumour 
 
 
The microenvironment contains a plethora of host cells, in addition to tumour cells, which 
can modify tumour cell survival, proliferation and local invasion. 
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Once breast cancer cells home to bone, they localise to areas within the bone that are 
highly vascularised such as trabecular bone (Holen 2012), where they interact with the 
host bone cells. In addition to the stromal cells already described, the unique bone 
microenvironment includes the bone forming osteoblasts and the bone resorbing 
osteoclasts.  Osteoclasts are large multinucleated cells derived from haematopoietic 
progenitor cells that, upon contact with the bone surface, secrete proteolytic enzymes 
such as cathepsin K and H+ Cl- that degrade the bone matrix. Osteoblasts are derived from 
mesenchymal progenitor cells and lay down new unmineralised matrix in the resorption 
pits made by osteoclasts (Boyce 2012).  The coupling of bone formation and resorption is 
critical to prevent pathological excess of either process that could alter bone volume and 
architecture.  One such coupling mechanism is Receptor Activator of Nuclear factor κβ 
(RANK):osteoprotegerin (OPG) system; RANK ligand is secreted by osteoblasts and 
binds to RANK on the surface of pre-osteoclasts to promote differentiation, this is 
prevented by osteoblast secretion of the RANK ligand soluble decoy ligand OPG, thus 
creating an on:off mechanism by which osteoblasts can control osteoclast activity 
(Dougall, Glaccum et al. 1999; Kong, Yoshida et al. 1999). Denosumab, a monocloncal 
antibody against RANK ligand has recently been approved for therapeutic use in bone 
metastases from breast and other solid tumours. 
 
When tumour cells have developed autonomous cell growth in bone, following 
acquisition of an adequate blood supply, they form small colonies and secrete factors that 
affect both bone cell types and disrupt the normal coupling of formation to resorption. 
Osteoclasts are stimulated by tumour secreted parathyroid-related protein (PTHrP), which 
increases local production of RANK ligand (Kingsley, Fournier et al. 2007).  The 
increase in osteoclast bone resorption releases growth factors such as transforming 
growth factor β (TGFβ) which are stored in bone matrix which further increase tumour 
secretion of PTHrP (Mourskaia, Dong et al. 2009).  Other tumour secreted factors such as 
bone morphogenetic proteins (BMPs), activate osteoblasts directly which subsequently 
release more RANK ligand to initiate osteoclast differentiation (Dai, Keller et al. 2005). 
These interactions create what is termed as ‘the vicious cycle’ of bone metastasis (Mundy 
1997), a tumour induced self-propagating breakdown of bone.  
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These changes represent the end of a spectrum of interactions between bone cells and 
tumour cells, However, the interaction of tumour cells with osteoblasts and osteoclasts in 
early stages of spread to bone, when tumour cells lack autonomous growth, is yet to be 
determined.  Recent evidence has shown that breast tumour cells that localise to bone 
after intracardiac injection in vivo have early effects on osteoclasts and osteoblasts that 
are in direct contact with the tumour cells, increasing the numbers of the former and 
decreasing the numbers of the latter.  These changes occurred before lytic lesions were 
evident on imaging, suggesting that tumour cells can modify bone cells from an early 
stage (Brown, Ottewell et al. 2012).  These early interactions may prove to be critical in 
determining tumour cell fate, either elimination or survival in a dormant state prior to 
expansion and proliferation either in bone or in other metastatic sites.  
 
1.1.4	  Dormancy	  and	  quiescence	  of	  disseminated	  tumour	  cells	  in	  bone	  
On arrival in bone, tumour cells interact with bone stromal marrow cells to colonise a 
niche in which they are attached and can survive.  Bone marrow stromal cells including 
osteoblasts, osteoclasts, fibroblasts and adipocytes, regulate self-renewal, proliferation 
and migration of hematopoetic and mesenchymal stem cells under normal physiological 
conditions (Kollet, Dar et al. 2006; Miura, Gao et al. 2006). HSCs bind to osteoblasts in 
vitro (Crean, Meneski et al. 2004) and it is thought that they need to be in direct contact 
with osteoblasts to ensure survival (Shiozawa, Havens et al. 2008) (Fig 1.3). It is possible 
that disseminated tumor cells may localise to the HSC and MSC niche and use the same 
stromal adhesion and environmental signals to enable them to survive. It has been shown 
that tumour cell lines with bone homing properties express the receptor for annexin II that 
osteoblasts use to adhere to hematopoetic stem cells, and knockdown of this receptor in 
prostate cells prevented bone metastasis after intacardiac injection (Shiozawa, Havens et 
al. 2008).  Others have shown that expanding the osteoblast niche with the use of PTH, 
increased the number of disseminated tumour cells in bone from sub-cutaneous prostate 
tumours in vivo (Shiozawa, Pedersen et al. 2011). Additional receptor-ligand interactions 
involve the Notch-Jagged pair; bone homing tumour cells overexpress Jagged which 
binds to Notch expressed by osteoblasts and osteoclasts facilitating tumour cell invasion 
and growth in bone (Sethi, Dai et al. 2011). 
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Figure 1.3.  The hematopoetic stem cell niche 
 
Hematopoetic stem cells (HSC) migrate out of the blood stream and adhere to osteoblasts 
via ligand receptor interactions such as the adhesion Jagged-Notch receptor.  Osteoblasts 
play an important role in regulation of HSC via secretion of soluble factors, which control 
proliferation and maintain quiescence.  After changes in environmental signals, activation 
of HSCs occurs, which then re-enter the circulation to bring about their effector functions 
in other organs. 
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After attaching to bone, the tumour cells are under the influence of local environmental 
factors that may be very different to those of the primary site, and can induce stress 
signals in the tumour cells that facilitate a state of quiescence/dormancy (Wikman, 
Vessella et al. 2008).  These cells are not dividing and show cell cycle arrest, however, 
this state is not permanent and they can revert to a dividing phenotype under activating 
factors that are yet to be identified (Vessella, Pantel et al. 2007).  This could subsequently 
result in development of established bone metastases or the cells may re-enter the 
circulation and seed to other distant organs (Shiozawa, Havens et al. 2008) (Fig 1.4). 
 
1.1.5	  Clinical	  implications	  of	  breast	  tumour	  growth	  in	  bone	  -­‐	  the	  need	  for	  prevention.	  
Once bone metastases are identified radiologically or clinically, the disease is incurable 
with a median survival of 2 years following clinical diagnosis of bone metastases 
(Coleman 2005).  The impact of the ‘vicious cycle’ on patients is profound; breast cancer 
cells in bone cause lytic bone destruction, which leads to skeletal related events (SREs) 
including hypercalcaemia, pathological fracture, spinal cord compression and the need for 
radiotherapy to bone (Coleman 2007).  Approximately 60% of breast cancer patients with 
bone metastases will experience a pathological fracture with a median time to first SRE 
of 15 months (Hortobagyi, Theriault et al. 1998), therefore patients will be living long 
enough to not only experience the morbidity associated with SREs but also potentially 
develop subsequent further SREs. SREs are associated with an increased mortality and 
therefore therapeutic intervention is essential (Coleman 2006). The prevention of bone 
metastasis has therefore been a focus of research over the past decade, however, in early 
breast cancer one of the major challenges is identifying which patients are likely to 
develop bone metastases and require tailored anti-cancer therapy.   
Disseminated tumour cells are detectable in the bone marrow of a third of patients with 
early breast cancer without any clinical manifestations of bone metastasis (Braun, Vogl et 
al. 2005).  Presence of DTCs in the bone marrow correlates with a poorer prognosis for 
both disease free survival and overall survival, and 50% of patients with detectable DTCs 
will relapse during 10 years post diagnosis (Braun, Vogl et al. 2005).  The persistence of 
DTCs can occur in ~15% of patient after completion of primary therapy and are an 
independent adverse prognostic factor for both disease free survival and overall survival 
at 5 years (Janni, Vogl et al. 2011).  The additional challenge is that these DTCs may be 
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Figure 1.4.  Breast cancer cells home to bone and may remain dormant prior to 
proliferation and formation of metastases. 
 
Tumour cells home to vascular areas within bone where they interact with bone cells and 
can enter a state of dormancy/quiescence for many years prior to growth.  They are in 
close contact with bone and are thought to occupy the HSC and MSC niches (left).  
Following unknown triggers, the tumour cells re-gain the ability to proliferate and 
ultimately form bone metastases or spread to other metastatic sites (right). 
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in state of dormancy/quiescence and often do not express the proliferation antigen Ki67 
(Pantel, Schlimok et al. 1993).  Moreover, DTCs express high levels of CD44, suggesting 
a cancer stem cell phenotype (Balic, Lin et al. 2006), thus conferring resistance to 
chemotherapy used in the treatment of early breast cancer.   	  
1.2	  Systemic	   treatment	  of	  early	  breast	   cancer	  –	   the	  emergence	  
of	  bisphosphonates.	  
 
1.2.1	  Historical	  development	  of	  systemic	  adjuvant	  therapies.	  
Systemic chemotherapy was first used in early breast cancer (adjuvant chemotherapy) in 
the 1960s, however, it was not until the 1970s when it became standard treatment 
following the first randomised study conducted by Gianni Bonadonna (Bonadonna, 
Brusamolino et al. 1976). The study evaluated the activity of combination chemotherapy 
with cyclophosphamide, methotrexate and 5-fluorouracil in the adjuvant setting, after 
surgery for node positive breast cancer, and demonstrated an increased survival with 
adjuvant chemotherapy.  Over the next decades, research increased the number of 
systemic therapies available for adjuvant breast cancer therapy including new 
chemotherapy drugs such as taxanes (reviewed in Di Leo (Di Leo, Ciarlo et al. 2004)), 
endocrine therapies like aromatase inhibitors and tamoxifen (Howell, Cuzick et al. 2005) 
and monoclonal antibodies to the HER2 receptor (Romond, Perez et al. 2005).  All of 
these therapies directly target proliferating tumour cells, however, with increasing 
evidence that the bone microenvironment may be a potential sanctuary for disseminated 
tumour cells that may be resistant to conventional systemic anti-cancer, disruption of the 
interactions between tumour cells and the bone stromal cells became an attractive 
prospect.   
 
The first large adjuvant breast cancer clinical trials evaluating the addition of bone 
targeted therapy with drugs called bisphosphonates began in the 1990s. Three large trials 
assessed the use of the bisphosphonate clodronate, for 2-3 years, in addition to standard 
adjuvant therapy.  The results were conflicting with two trials reporting an improved 
overall survival with clodronate (Powles, Paterson et al. 2006; Diel, Jaschke et al. 2008) 
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but the third reporting an increase in extraosseous metastases (Saarto, Vehmanen et al. 
2004) (Fig 1.5).  As a result of these inconclusive outcomes, further clinical trials opened  
 
 
 
 
 
 
 
 
Figure 1.5 Recurrence events and mortality from adjuvant clodronate trials in early 
breast cancer. 
 
Three pivotal trials conducted by Diel (Diel, Jaschke et al. 2008), Saarto (Saarto, 
Vehmanen et al. 2004) and Powles (Powles, Paterson et al. 2006) evaluated addition of 
clodronate to standard adjuvant therapy and showed conflicting results.  Data points 
represents ratio of events at 5 years with 95% CI if quoted in original paper from these 3 
trials.  Events are grouped into bone, non-bone and mortality.  * = Significant p value. 
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recruiting larger numbers of patients to clodronate (NSABP-B-34), or utilising the newer 
more potent bisphosphonate zoledronic acid in addition to standard adjuvant therapies 
(AZURE, SUCCESS, NATAN, AZAC) (summarized in Wilson et al (Wilson and 
Coleman 2011)). 
 
1.2.2	  Mechanism	  of	  action	  of	  zoledronic	  acid	  
Bisphosphonates have been extensively utilised in pathological bone disease including 
osteoporosis and Pagets disease after they were first discovered in the 1960s to prevent 
pathological calcification (Francis, Russell et al. 1969).  Bisphosphonates have a 
pyrophosphate-carbon-pyrophosphate backbone with two additional side groups attached 
to the carbon atom.  The first side group is commonly a hydroxyl group which has high 
affinity for calcium, but the variations in the second side group have separated the 
bisphosphonates into those that contain a nitrogen side arm i.e zoledronic acid and those 
that do not i.e clodronate (Rogers, Gordon et al. 2000) (Fig 1.6).  Zoledronic acid has a 
potency in humans that is around 40 fold greater than that of clodronate (Russell, Watts et 
al. 2008) and binds avidly to the bone surface, with a half life in serum of ~2 hours, with 
drug rapidly bound to bone or cleared by the kidneys (Lin 1996).  The drug then remains 
bound to bone and is taken up by osteoclasts during the resorption process.  The effect of 
zoledronic acid on osteoclasts has been well documented, inducing apoptosis in these 
cells both in vitro and in vivo (Hughes, Wright et al. 1995), by inhibition of key enzymes 
within the mevalonate pathway.  The mevalonate pathway is responsible for cholesterol 
synthesis in mammals and is also responsible for post-translational modification of 
proteins including prenylation of small GTPases such as Rho, Ras and Rac (Luckman, 
Hughes et al. 1998).  Zoledronic acid inhibits farnesyl pyrophosphate (FPP) synthase 
(van Beek, Pieterman et al. 1999) (Fig 1.6), preventing prenylation of small GTPases, 
which are responsible for many cellular functions in osteoclasts including apoptosis and 
cell membrane integrity (Coxon and Rogers 2003).  This negative effect on bone 
resorbing osteoclasts explains the effective clinical use of bisphosphonates in 
osteoporosis, and this clinical application was extended to the oncology setting with 
subsequent evidence that zoledronic acid could prevent bone loss associated with 
established bone metastases and bone loss associated with anti-cancer therapy (reviewed 
by Coleman et al (Coleman, Rathbone et al. 2013) (Coleman 2004)).  
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Figure 1.6 Structure and effect of zoledronic acid on the mevalonate pathway. 
 
Zoledronic acid is a nitrogen containing bisphosphonate (A) and inhibits FFP synthase 
preventing downstream prenylation of small GTPases including Rho, Ras and Rac (B).  
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What has been of great interest is the potential ability of zoledronic acid to have an anti-
tumour effect and prevent the formation of bone metastases in the adjuvant setting.  There 
is a wealth of in vitro and in vivo evidence to suggest both an indirect anti-cancer effect of 
zoledronic acid by modification of the bone microenvironment, but also a direct anti-
tumour effect in breast cancer. 
 
1.2.3	  Zoledronic	  acid	  modifies	  the	  bone	  microenvironment	  –	   implications	  for	  tumour	  
survival.	  
There is evidence that zoledronic acid can directly affect many cells found within the 
bone microenvironment.  In vitro, zoledronic acid (20µM) has been shown to reduce the 
ability of MSC to proliferate after 48 hours of treatment, with a corresponding 45% 
decreased ability to migrate through fibronectin coated membranes in response to serum.  
In addition, MCSs treated with zoledronic acid had an impaired ability to attract ER+ve 
MCF7 breast cancer cells due to a decreased secretion of chemo-attractants such as  
RANTES and IL-6 (Gallo, De Luca et al. 2012). In vivo, zoledronic acid showed a trend 
to increasing HSC number in male C57BL/6 mice aged 4- and 16-weeks treated with 
200µg/kg of zoledronic acid weekly for 4 weeks, which was due to an increase in the 
osteoblastic numbers rather than a reduction in HSC mobilization or an alteration in the 
bone vasculature (Soki, Li et al. 2013). Zoledronic acid has well documented cytotoxic 
effects on osteoclasts, as previously discussed, but has also been reported to effect 
osteoblasts.  Studies report conflicting results on the effects of zoledronic acid on 
osteoblasts with in vitro evidence that zoledronic acid (5µM) reduced viability of MG63, 
a human osteoblast cell line, and prevented normal functioning of these cells as evidenced 
by a reduction in gene expression of alkaline phosphatase and osteocalcin (Basso, Silveira 
Turrioni et al. 2013). This inhibitory effect of zoledronic acid on osteoblast viability has 
been confirmed in other studies and can prevent breast cancer cells from migrating in 
response to osteoblast-secreted factors (Kaiser, Teufel et al. 2013).  In contrast, human 
osteoblast differentiation appeared to be enhanced by zoledronic acid (Koch, Merkel et al. 
2011).  The difference in effect in these studies may be due to different doses of 
zoledronic acid.   Corrado et al showed that zoledronic acid doses <0.1µM enhance 
human osteoblast proliferation, but at concentrations greater than this, there was an 
inhibition of cell proliferation and apoptosis of human osteoblasts (Corrado, Neve et al. 
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2010).  Alterations in osteoblast numbers may affect tumour growth since these cells 
contribute to the HSC and MSC niche as previously discussed. 
 
Zoledronic acid has also been reported to affect other cells that are present within the 
bone microenvironment, including macrophages and endothelial cells.  Zoledronic acid 
inhibits proliferation of endothelial cells in vitro (Wood, Bonjean et al. 2002), although 
this has not been demonstrated in vivo.  Macrophages are able to take up bisphosphonates 
due to their phagocytic properties and, in vitro, change from a pro-tumour phenotype to 
an anti-tumour phenotype upon treatment with zoledronic acid (Tsagozis, Eriksson et al. 
2008; Veltman, Lambers et al. 2010), with supportive evidence that tumour associated 
macrophages absorb (Rogers, Wind et al. 2013), and are attenuated by zoledronic acid in 
vivo (Melani, Sangaletti et al. 2007; Coscia, Quaglino et al. 2010).   
 
The implication of this effect of zoledronic acid for tumour growth in the bone 
microenvironment is evidenced from in vivo animal studies and clinical studies evaluating 
the effect on disseminated tumour cells in bone marrow.  In animal models, the 
evaluation of the effect of zoledronic acid using preventative treatment protocols 
(treatment initiated before or on the day of breast tumour cell injection), models the effect 
of the drug in early breast cancer, in the absence of bone metastasis.  Administration of 
preventative zoledronic acid daily (3µg/kg) or weekly (20µg/kg) commenced 24 hours 
prior to tail vein injection with a bone homing subclone of MDA-MB-231 oestrogen 
negative (ER-ve) breast cancer cells to female balb/c nude mice significantly reduced 
skeletal tumour burden (Daubine, Le Gall et al. 2007).  Similar effects were found with 
another bisphosphonate, ibandronate (10µg/kg/day); when used on a preventative 
protocol in male athymic rats injected with MDA-MB-231 cells, ibandronate decreased 
the number of metastases (Neudert, Fischer et al. 2003).  In a similar experiment using 
olpadronate 1.6µmol/kg/day starting 2 days before the intracardiac injection of MDA-
MB-231 cells, the formation of bone metastases was significantly less compared to 
untreated controls (van der Pluijm, Que et al. 2005).  Some studies have shown an 
increase in tumours sitting outside, but in close contact to bone, in association with a 
decrease in skeletal metastases with the administration of bisphosphonates; female balb/c 
nude mice treated with risedronate 4µg/day starting 7 days prior to intracardiac injection 
of MDA-MB-231 cells showed a significant reduction in the number of bone metastases, 
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however, there was an associated increase in tumour burden located outside bone (Sasaki, 
Boyce et al. 1995). A similar effect to this was noted using the same preventative model 
but an alternative bisphosphonate YH529 (Sasaki, Kitamura et al. 1998).  These data 
show that use of bisphosphonates in ‘early’ breast cancer, before metastases have formed, 
can reduce the number of bone metastases but they could potentially cause the tumour 
cells to move to sites outside of bone. 
 
In clinical studies both zoledronic acid and ibandronate are reported to decrease the 
number of DTCs in bone marrow aspirates from breast cancer patients (Table 1.2) (Aft, 
Naughton et al. 2010; Rack, Juckstock et al. 2010; Hoffmann, Aktas et al. 2011; Banys, 
Solomayer et al. 2013).  Since DTCs have not developed autonomous growth, it is likely 
that this effect is mediated through bisphosphonate-induced changes in the bone 
microenvironment, rather than a direct anti-tumour effect. Further evidence of the indirect 
anti-tumour effect of zoledronic acid, via modification of the bone microenvironment, has 
been shown in large adjuvant breast cancer clinical trials as discussed in section 1.3. 
1.2.4	  Zoledronic	  acid	  has	  direct	  anti-­‐tumour	  effects	  in	  breast	  cancer	  	  
The intrinsic properties of tumour cells that ensure their survival is the ability to 
proliferate, limit apoptosis, invade and adhere to stroma and ensure an adequate blood 
supply by stimulating neoangiogenesis.  Zoledronic acid has been shown to adversely 
affect all of these intrinsic tumour properties in breast cancer cell lines.  Zoledronic acid 
(50µM) can inhibit proliferation and induce apoptotic cell death in both ER+ve and ER-
ve breast cancer cell lines (Woodward, Neville-Webbe et al. 2005; Rachner, Singh et al. 
2010; Almubarak, Jones et al. 2011; Ibrahim, Mercatali et al. 2012) (Fromigue, Lagneaux 
et al. 2000; Senaratne, Pirianov et al. 2000).  The doses of zoledronic acid used in these 
studies are often higher than those that would be expected to be attainable in vivo 
(>10µM) or in the clinical setting (>1-2µM).  Epithelial to mesenchymal transition, a 
process necessary for invasion of tumour cells, was inhibited in triple negative breast 
cancer cells in response to treatment with zoledronic acid (Schech, Kazi et al. 2013) and 
invasion of MDA-MB-231 cells can be inhibited by zoledronic acid at low doses (<1µM) 
(Boissier, Ferreras et al. 2000).  Inhibition of invasion by zoledronic acid at low doses is 
thought to be due to effects on the mevalonate pathway, compared to higher 
concentrations, which may be acting via inhibition of matrix metalloproteinases  
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Table 1.2 Summary of breast cancer clinical trials evaluating the effect of 
bisphosphonates on disseminated tumour cells (DTCs) in bone marrow aspirates. 
 
 
 
Key; ER=oestrogen receptor, Q4/52= every 4 weeks, ZOL=zoledronic acid, OS=overall 
survival, DFS= disease free survival, BSAP= bone specific alkaline phosphatase, BMD= 
bone mineral density, PO= oral administration, *statistically significant p value <0.05. 
  
Author' Pa*ent'
popula*on'
Treatment'
protocol'
Outcome'
measure'
Results' Comments'
Banys&et&
al&(2013)&
N=&96.&
DTC+ve&marrow&at&
baseline.&
Majority&T1N0&&
2/3&postmenopausal&
25%&ER+ve,&HER2Kve&
&
Standard&
adjuvant&
therapy&+/K&
ZOL&Q4/52&for&
24&months&
Primary;&Change&in&DTC&
number&at&12&
Secondary;&change&in&
DTC&number&at&24&
months,&safety,&bone&
mets&free&survival,&DFS.&
DTC&count&12&
months;&control&
27%,&ZOL&12%.&
DTC&count&24&
months;&control&
16%,&ZOL&0%*&
&
Pa\ents&with&persistence&of&
DTCs&at&12&months&post&
diagnosis&had&a&shorter&OS*&
(no&change&in&DFS)&
A^&et&al&
(2010)&
N=120&
Any&DTC&status&at&
baseline&
All&pa\ents&>T2N1&
50%&postmenopausal&
56%&ERKve&
NeoKadjuvant&
epirubicin&
(75mg/
m2)+docetaxel&
(75mg/m2)&x4&+&
adjuvant&
epirubicin&x2&
+/K&4mg&ZOL&
Q3/52&for&12&
months&
Primary;&Change&in&DTCs&
at&3&months&
Secondary;&changes&in&
NTx,&osteocalcin,&BSAP,&
BMD&baseline,&3,&and&12&
months&
DTC&count&at&3&
months;&control&
47%,&ZOL&30%.&
DTCs&detectable&at&baseline&
in&43%&ZOL,&48%&control.&
&
In&pa\ents&who&were&DTCKve&
at&baseline,&appearance&of&
DTCs&at&3&months&occurred&
in&40%&control,&13%&ZOL*&
&
No&signiﬁcant&eﬀect&of&ZOL&
on&DFS&or&OS&
&
Rack&et&al&
(2008)&
N=31&
DTC+ve&>6&months&
since&diagnosis&
&
Monotherapy&
with&ZOL&
Q4/52&for&6&
months&
Primary;&Change&in&DTCs&
at&8&months&
DTCs&declined&to&
persist&in&13%&
Hoﬀmann&
et&al&
(2011)&
N=54&
DTC+ve&marrow&2K10&
years&post&diagnosis&
Monotherapy&
with&PO&
ibandronte&
(50mg/day)&for&
6&months&
Primary;Change&in&DTC&
at&6&months&
DTCs&found&in&
18/54&pa\ents.&
A^er&6&months&
ibandronate&3/17&
remained&DTC&
+ve&
Pa\ents&with&DTC+ve&
marrow&a^er&6&months&
ibandronate&con\nued&
therapy&for&a&further&6&
months&with&complete&
eradica\on&of&DTCs&&
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(Clezardin, Ebetino et al. 2005).  Zoledronic acid has also been shown to reduce 
endothelial cell proliferation and angiogenesis in vitro (Wood, Bonjean et al. 2002).  The 
direct anti-tumour effect of zoledronic acid has also been shown in in vivo models of 
tumours implanted outside bone.  4T1 breast cancer cells spontaneously metastasise to 
viscera and treatment of mice implanted with 4T1 cells with zoledronic acid IV 5µg every 
fourth day from day 7-19 resulted in significantly less visceral metastases in lung and 
liver (Hiraga, Williams et al. 2004).  These data are in contrast to data published by 
Ottewell et al who showed, in a murine model of sub-cutaneous MDA-MB-436 tumours; 
treatment with zoledronic acid 100µg/kg weekly for 6 weeks did not alter tumour size 
compared to saline control (Ottewell, Monkkonen et al. 2008).  These contrasting results 
may reflect the differing sensitivities of breast cancer cell lines to zoledronic acid and the 
different dosing regimes of the drug. 
 
The direct anti-tumour effects of zoledronic acid in clinical studies can be gained from 
the neo-adjuvant setting, when serial tumour biopsies can show cellular effects, often in 
combination with chemotherapy.  There is both in vitro and in vivo data showing a 
synergistic relationship between zoledronic acid and chemotherapy.  Neville-Webbe et al 
showed that treatment of MCF7 cells with 0.05µM doxorubicin followed 24 hours later 
by 25µM zoledronic acid for 1 hour increased apoptosis compared to control, either drug 
alone or zoledronic acid followed by doxorubicin (Neville-Webbe, Rostami-Hodjegan et 
al. 2005).  Other cell lines including MCF7 and MDA-MB-436 have shown synergy with 
zoledronic acid and paclitaxel (Jagdev, Coleman et al. 2001; Neville-Webbe, Evans et al. 
2006).  These results have been confirmed in vivo, with the combination of weekly 
doxorubicin (2mg/kg) followed 24 hours later by zoledronic acid (100µg/kg) causing 
maximal inhibition of growth in sub-cutaneous tumours in mice inoculated with MDA-
MB-436 cells and treated for 6 weeks (Ottewell, Monkkonen et al. 2008).  The results of 
neo-adjuvant clinical trials showing a direct anti-tumour effect of zoledronic acid are 
discussed further in section 1.3. 
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1.3	   Adjuvant	   and	   neoadjuvant	   breast	   cancer	   clinical	   trials	   of	  
zoledronic	  acid	  in	  addition	  to	  standard	  therapy.	  	  
1.3.1	   Adjuvant	   Zoledronic	   acid	   clinical	   trials	   –	   modification	   of	   the	   bone	  
microenvironment	  is	  influenced	  by	  menopausal	  status.	  
Several adjuvant clinical trials have evaluated the addition of zoledronic acid to standard 
therapy for breast cancer patients.  The largest of these trials include AZURE (n=3340), 
ABCSG-12 (n=1803) and ZO-FAST (n=1065) (Fig 1.7).  AZURE recruited patients with 
Stage II/III breast cancer.  The population was a mixed menopausal status; 
premenopausal (45%), unknown menopausal status (9.7%), <5 years since menopause 
(14.7) and >5 years since menopause (31%), and included both ER+ve patients (78.9%) 
and ER-ve patients (21%).  Patients were randomised to receive standard adjuvant 
therapy +/- zoledronic acid at decreasing frequency of dosing for 5 years.  The primary 
endpoint was disease free survival (DFS) with secondary endpoint of overall survival 
(OS), and the results of the 59-month follow up were published in 2011 (Coleman, 
Marshall et al. 2011).  There was no significant difference between the control and 
zoledronic acid groups for DFS or OS, However, the results of a pre-planned subgroup 
analysis showed a heterogeneity of treatment effect according to menopausal status on 
DFS.  Patients who were >5 years postmenopausal showed a significantly improved DFS 
with the addition of zoledronic acid (ZOL) to standard therapy (ST) (DFS; ST 71%, 
ST+ZOL78.2%, HR 0.75, 95%CI 0.59-0.96 p=0.02), but this effect was not seen in any 
other patient groups (DFS; ST 77.2%, ST+ZOL 74.1%, HR 1.15, 95%CI 0.97 to 1.36 
p=0.11).  Patients who were >5 years post menopause also had a significant improvement 
in OS (ST 78.7%, ST+ZOL 84.6%, HR 0.74, 95%CI 0.55 to 0.98 p=0.04).  These data 
were driven by extraskeletal disease recurrence, being decreased in patients >5 years 
since menopause but increased in all other patients. A recent update of the AZURE 
results following 966 DFS events and a median follow up of 84 months, has now 
demonstrated that there is a significant reduction in bone metastasis in the overall 
population with addition of zoledronic acid (HR 0.81, 95% CI 0.68-0.97 p=0.022) that is 
not influenced by menopausal status, but the effects of zoledronic acid on extra skeletal 
distant recurrence continued to show a decrease in women >5 years postmenopausal but 
an increase in all other patients (Fig 1.8)(R. Coleman, R. Burkinshaw et al. 2013). 
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Figure 1.7 Trial schematics of the largest adjuvant clinical trials of zoledronic acid. 
 
Key; ZOL=zoledronic acid, Q3-4/52= every 3-4 weeks, Q3 or 6/12 = every 3 or 6 months, 
TAM = tamoxifen 20mg daily, ANA = anastrazole 1mg daily, SD= standard deviation, 
DFS= disease free survival, Δ = change 
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Figure reproduced from Coleman RE, Hinsley S, Dodwell D et al. Cancer and Bone Society conference, 
2013, Miami, Florida; abst LBA001 
 
 
 
Figure 1.8 Extraskeletal distant recurrences according to menopausal status at 
diagnosis from the AZURE trial. 
 
Women who had experience menopause >5 years prior to initiation of zoledronic acid had 
a HR of 0.77 indicating that the use of zoledronic acid in this population was reducing 
extraskeletal recurrences.  All other menopausal groups had a HR of >=1.0 suggesting no 
effect or an increase in extraskeletal recurrences. 
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These data were supported by the results of the ABCSG-12 trial. The population recruited 
to this trial differed to that of AZURE I that they were all premenopausal women with 
oestrogen receptor positive disease, but all patients in ABSCG-12 were treated with 
goserelin, which induced a chemical menopause prior to being randomised to receive 
tamoxifen/anastrazole +/- zoledronic acid every 6 months for 3 years.  The primary 
endpoints were DFS and secondary endpoints OS and bone mineral density (BMD) 
assessment.  The results of 62-month follow up were published in 2011, focusing on DFS 
and OS outcomes (Gnant, Mlineritsch et al. 2011).  Zoledronic acid significantly 
improved DFS compared to endocrine therapy alone (92% vs 88% p=0.008).  This 
improvement in DFS was for recurrences both in bone and outside of bone.  A pre-
planned subgroup analysis according to age a study entry demonstrated a significant 
beneficial effect of zoledronic acid on DFS in women >40 years (HR 0.58, 95% CI 0.4-
0.83), and these effects were not seen in women <40 years (HR 0.94, 95%CI 0.57-1.56) 
(Fig 1.9). Overall survival did not alter with the addition of zoledronic acid. 
 
The data from ABCSG-12 and AZURE have been further supported by ZO-FAST, which 
reported the 60-month follow up analyses in 2013 (Coleman, de Boer et al. 2013).  ZO-
FAST evaluated addition of zoledronic acid 4mg every 6 months to the aromatase 
inhibitor letrozole 2.5mg/day for 5 years.  The patients were all postmenopausal with 
oestrogen positive disease, and initiated zoledronic acid at the start of the letrozole (early) 
or delayed the start of zoledronic acid until evidence of BMD loss or fracture.  The 
primary endpoint of this study was change in BMD at 12 months but pre-planned 
secondary analyses included DFS and OS.  At 60-month follow up, patients who started 
zoledronic acid with letrozole had a 34% decrease in DFS events (HR 0.66 95%CI 0.44-
0.97 p=0.0375).  There were fewer local (0.9% vs 2.3%) and distant recurrences (5.5% 
vs7.7%) in the early zoledronic acid treatment group vs delayed zoledronic acid.  There 
was no difference in OS between the two treatment groups.  Exploratory analyses 
according to menopausal status at randomisation showed that women >5 years 
postmenopausal or >60 years has a substantially improved OS with early vs delayed 
zoledronic acid (HR 0.5; p=0.0224).  This effect was not seen in women who were 
recently postmenopausal due to chemotherapy induced ovarian toxicity, oophorectomy or 
ovarian suppression (Fig 1.10). Women > 5 years postmenopausal or ages >60 also had 
the largest increase in lumbar spine BMD with early zoledronic acid compared to recently  
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Figure reproduced with permission (see appendix) from Gnant M, Mlineritsch B, Stoeger H et al.  Lancet 
Oncology 2011; 12:631-41 
 
 
 
Figure 1.9 Disease free survival according to nodal status and age at randomization 
from the ABCSG-12 trial. 
 
 
Nodal status did not significantly affect the anti-tumour efficacy of zoledronic acid, 
however, women aged >40 had an improved DFS with zoledronic acid compared to those 
without.  This effect was not seen in women aged<40.  
  
	  	  	  	  
	   27	  
 
 
 
 
 
 
 
 
 
 
 
Figure reproduced with permission (see appendix) from Coleman R, de Boer R, Eidtmann H et al. Annals 
of oncology 2013;24:398-405 
 
 
 
Figure 1.10.  Overall survival by menopausal status at randomization in the ZO-
FAST trial. 
 
Women who were >5years postmenopausal or aged >60 had an improved OS with 
immediate zoledronic acid.   This effect was not seen in women who were recently 
postmenopausal due to chemotherapy induced ovarian failure, oophorectomy or ovarian 
suppression. 
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postmenopausal women whose lumbar spine density remained stable with early 
zoledronic acid.  These data show that in women with established menopause, zoledronic 
acid has more of an effect on bone volume/density in addition to an increase anti-tumour 
effect compared to recently postmenopausal women.   
 
Together these data show that a subgroup of patients with established menopause and 
therefore low levels of ovarian hormones may be deriving an increased anti-tumour 
benefit from adjuvant zoledronic acid.  Interestingly, the differential anti-tumour effect of 
zoledronic acid according to menopausal status is not a drug specific phenomenon, as 2 
adjuvant clodronate studies have also shown improved outcomes in postmenopausal 
women.  Powles et al treated 1069 Stage I-II, pre- and postmenopausal breast cancer 
patients with adjuvant clodronate 1600 mg daily for 2 years, and in a subgroup analysis 
they showed that both the 2 year bone metastasis free survival and OS were significantly 
improved in postmenopausal women receiving clodronate compared to those receiving 
placebo. This effect was not seen in premenopausal patients (Powles, Paterson et al. 
2006). In another adjuvant clodronate trial, NSABP-B34, 3323 patients with Stage I/III 
breast cancer were randomised to receive clodronate 1600mg daily for 3 years or placebo, 
with the primary endpoint being DFS.  With a median follow up of 90 months, DFS was 
similar between both groups, however, women aged >50 showed a significantly reduced 
bone (HR 0.64, 95%CI 0.4-0.95 p=0.047) and non-bone (HR 0.63, 95% CI 0.43-0.91 
p=0.014) metastasis free survival (Paterson, Anderson et al. 2012).   
 
A meta-analysis of DFS data from 8735 postmenopausal women recruited to 7 different 
adjuvant bisphosphonate trials with zoledronic acid, clodronate and ibandronate, showed 
that there was a significant DFS benefit for zoledronic acid with a DFS reduction of 24% 
(p=0.0006), and this lessened to 18% when the clodronate and ibandronate studies were 
included, but the DFS improvement with bisphosphonates remained significant 
(p=0.0075)(Gregory W 2012).  These data support the notion that the anti-tumour effect 
of adjuvant bisphosphonates is likely to be via their modification of the bone 
microenvironment, rather than a specific pharmacological property of the drugs, since 
both non-nitrogen and nitrogen-containing bisphosphonates have similar effects.  
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1.3.2	   Neoadjuvant	   zoledronic	   acid	   clinical	   trials	   –	   evidence	   for	   a	   direct	   anti-­‐tumour	  
effect. 
Data on the anti-tumour effects of zoledronic acid has been derived from both prospective 
neo-adjuvant clinical trials and retrospective analysis from other datasets. 
A retrospective analysis of 205 patients who received neoadjuvant chemotherapy (CT)+/- 
zoeldronic acid (ZOL) in the AZURE trial reported evidence of a direct anti-tumour 
effect of zoledronic acid.  The primary end point of this analysis was residual invasive 
tumour size (RITS) and secondary endpoints included number of positive lymph nodes. 
Multivariate analysis of mean RITS showed a significant difference between the two 
treatment groups with a mean RITS of 27.4 in the CT alone groups vs 15.5 CT+ZOL with 
a mean difference of 12mm (95%CI 3.5-20.4 p=0.0059).  Other factors that were 
significantly associated with a lower RITS were treatment duration. There was also a 
trend towards a lower RITS in patients with ER-ve tumours, although this did not reach 
statistical significance (p=0.0609).  No significant difference in positive axillary lymph 
nodes was found according to treatment group (Coleman, Winter et al. 2010).   
 
An exploratory biomarker study of the effects of zoledronic acid 4mg IV given 24 hours 
after the first cycle of neoadjuvant FEC100 chemotherapy (ANZAC study) was recently 
reported (Winter, Wilson et al. 2013). 40 patients with invasive primary breast cancer in 
situ were included in the study and groups were matched for tumour stage, ER- and Her2- 
receptor status and menopausal status.  Primary tumour biopsies were taken at baseline, 
day 5 and day 21, with a primary outcome measure of change in apoptotic index in the 
primary tumour between baseline and day 5.  Secondary tumour endpoints included 
changes in proliferation measured by Ki67, growth index (Ki67/apoptosis) and changes in 
serum vascular endothelial growth factor (VEGF).  There was no significant difference in 
apoptotic index or Ki67 baseline to day 5 between treatment groups.  However, there was 
a significant increase in Ki67 at day 21 compared to baseline in the patients receiving 
zoledronic in addition to chemotherapy (+184%), an effect not seen in those receiving 
chemotherapy alone (-26.9%).  Serum VEGF was significantly lower at day 5 compared 
to baseline in patients receiving zoledronic acid+chemotherapy compared to 
chemotherapy alone (median change pg/ml; -16.8 vs -73.7 p=0.035).  The authors 
conclude that in this biomarker study there is no definite evidence for a direct anti-tumour 
effect of zoledronic acid, which may be due to timing of sample collection and the use of 
only a single treatment with zoledronic acid. 
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A phase II trial evaluated the efficacy and safety of addition of 4mg zoledronic acid every 
3 weeks for 12 months commencing with first cycle of neo-adjuvant chemotherapy in 120 
women with invasive breast cancer.  The primary endpoint included pathological 
complete response (pCR) in primary tumour.  There was no significant difference in pCR 
rates in the overall population according to treatment received, however, patients with 
ER-ve tumours showed a trend to higher pCR rates than ER+ve patients (ER-ve pCR 
rates; ZOL 28%, no ZOL 10%) (Aft, Naughton et al. 2010).  The secondary endpoints 
were DFS and OS and were recently reported following 62-month follow up data (Aft, 
Naughton et al. 2012). No significant difference was detected in either secondary 
endpoint between treatment groups; however, they reported significant differences in the 
response to zoledronic acid according to ER status, with ER –ve patients showing a 
significant improvement in DFS and OS with zoledronic acid treatment, an effect not 
seen in ER+ve patients (Fig 1.11).  The lack of benefit from zoledronic acid in the ER+ve 
patients is in contrast to the results of the adjuvant studies ZO-FAST and ABCSG-12 
which recruited only ER+ve patients, but all of those patients were either naturally or 
chemically postmenopausal whereas the ER+ve population in this trial were young 
(median age 47) and not receiving ovarian suppressive therapy.  The ER-ve population 
still showed an improved DFS and OS with zoledronic acid, despite not all being 
postmenopausal, which the authors suggest may indicate that the responsiveness of ER–
ve tumour status to zoledronic acid is not dependent upon a postmenopausal status, and 
may indicate a direct anti-tumour effect of zoledronic acid in this sub population. These 
data, generated in both adjuvant and neoadjuvant clinical trials, suggest that zoledronic 
acid may potentially have an enhanced indirect anti-tumour effect via modification of the 
bone microenvironment in women who are naturally or chemically postmenopausal and 
could have an enhanced direct anti-tumour effect in ER-ve breast cancer.  The molecular 
mechanisms underpinning this differential effect of zoledronic acid are yet to be 
determined. 
 
 
 
 
 
 
 
 
	  	  	  	  
	   31	  
 
 
 
 
 
 
 
 
 
Figure reproduced from Aft RL, Naughton M, Weilbaecher K et al.  Br J Cancer 2012;107:7-11. Article 
distributed under Creative Commons license. 
 
 
 
 
 
Figure 1.11 Disease free survival (DFS) and overall survival (OS) according to ER 
status and treatment received. 
 
Patients with ER-ve tumours had a significant improvement in DFS (A) and OS (B) with 
the addition of zoledronic acid, an effect not seen in patients with ER+ve tumours. 
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1.4	   Why	   are	   menopause	   and	   ER	   status	   influencing	   the	   anti-­‐
tumour	  efficacy	  of	  zoledronic	  acid?	  
 
1.4.1	  Premenopausal	  to	  postmenopausal	  transition	  –	  dynamic	  changes	  in	  both	  ovarian	  
and	  pituitary	  hormones.	  
The hypothalamic pituitary axis (HPG) is a physiological feedback mechanism whereby 
the secretion of ovarian hormones (oestrogen, inhibins and progesterone) are controlled 
by the hypothalamus via pituitary gland secretion of follicle stimulating hormone (FSH) 
and lutenising hormone (LH), with resulting negative feedback from the ovarian 
hormones on both pituitary and hypothalamus. Oestogen inhibits release of 
gonadotrophin releasing hormone (GnRH) and inhibins inhibits FSH (Fig 1.12). 
Oestrogen is a steroid hormone with different isoforms; oestradiol is the predominant 
form in premenopausal women and is produced by ovaries, compared to oestrone 
produced from the adrenal cortex in postmenopausal women (Nelson and Bulun 2001).  
Inhibins (A and B) are primarily secreted by ovaries during reproductive life (Stenvers 
and Findlay 2010). The changes in these hormones up to and after the final menstrual 
period have been well characterized (Hale and Burger 2009), and reproductive aging is 
associated with a decrease in ovarian secretion of inhibins and oestrogen with a rise in 
FSH, due to loss of negative feedback. The rise in FSH occurs prior to the final menstrual 
period (FMP), and can occur up to 3-10 years before menopausal transition (Burger, Hale 
et al. 2007), which has been attributed to a decline in inhibins (Klein, Houmard et al. 
2004).   
At the time of the FMP oestrogen and inhibins fall, and the majority of women will have 
undetectable levels of inhibins (Burger, Dudley et al. 2002), however, the decline in 
oestradiol is slower and it can remain detectable in serum, with currently available assays, 
for up to 5 years post FMP (Burger, Dudley et al. 1999) (Table 1.3). 
 
The differing levels of endocrine hormones in pre- and postmenopausal women will have 
differential effects on organs such as bone, due not only to their endocrine effect but also 
due to differential changes in associated paracrine factors.  These paracrine factors may in 
turn modify both tumour growth and response to therapy. 
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Figure 1.12.  The hypothalamic pituitary gonadal axis. 
 
Secretion of the ovarian hormones oestrogen, progesterone and inhibin are stimulated by 
follicle stimulating hormone and lutenising hormone released from the pituitary under 
hypothalamic control.  The ovarian hormones have negative feedback effects of the 
pituitary and hypothalamus thus ensuring regulation of this physiological system. 
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Table 1.3 Changes in endocrine/paracrine agents with alteration in reproductive 
status.  (Serum levels described relative to mid reproductive age).   
 
Typical serum levels are depicted in brackets and are adapted from Burger et al (Burger, Dudley et al. 
2002). 
 
	  
	   Mid	  
reproductive	  
age	  
Late	  
reproductive	  
age	  
Early	  
menopause	  
transition	  
Late	  
menopause	  
transition	  
Established	  
menopause	  
FSH	  
Normal	  
(10)	  
Elevated	  
(20)	  
Elevated	  
(40)	  
Elevated	  
(50)	  
Elevated	  
(100)	  
LH	   Normal	   Normal	   Elevated	   Elevated	   Elevated	  
Oestradiol	  
	  
Normal	  
(300)	  
Normal	  
(300)	  
Normal	   to	  
elevated	  
(300)	  
Decreased	  
(150)	  
Decreased	  
(<50)	  
Progesterone	   Normal	   Normal	   Normal	   Decreased	   Decreased	  
Inhibin	  B	  
Normal	  
(50)	  
Decreased	  
(40)	  
Decreased	  
(35)	  
Decreased	  
(30)	  
Undetectable	  
	  
Inhibin	  A	  
Normal	  
(25)	  
Normal	  
(25)	  
Decreased	  
(15)	  
Decreased	  
(10)	  
Undetectable	  
	  
Units of measurement; FSH = iu/l; E2= pmol/l; inhibin A/B=ng/l 
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1.4.2	  Effects	  of	  female	  hormones	  on	  bone	  turnover.	  
The effects of menopause on bone are well documented, with a loss of bone density 
postmenopausal, associated with increased fracture risk (Melton, Alothman et al. 2003).  
The cause of this bone loss was for many years, attributed solely to the effects of 
oestrogen (Manolagas 2000), and supplementation with oestrogen by hormone 
replacement therapy negated these effects (Riis, Overgaard et al. 1995).  However, it has 
been increasingly recognized that bone loss occurs in the perimenopausal phase, when 
oestradiol levels are still high, and this has been shown to be due to a decline in inhibins 
and an associated increase in FSH (Riggs, Melton et al. 2008).   
Inhibins suppress osteoclast and osteoblast activity in vitro via inhibition of RANKL 
(Gaddy-Kurten, Coker et al. 2002), suggesting that in the presence of inhibins, bone 
turnover may be reduced.  In vivo studies have shown an anabolic effect of continuous 
administration of inhibin A on the skeleton via an increase in osteoblast activity [Nicks,  
2010 #673].  In a cross sectional study of women aged 21-85 (n=188), endocrine 
hormones were correlated to changes in serum markers of bone formation; bone specific 
alkaline phosphatase (BSAP), and bone resorption; carboxyterminal telopeptide of type I 
collagen (CTX). Inhibin A was shown to be the most accurate predictor of changes in 
bone formation and resorption being negatively correlated with levels of BSAP and CTX 
(Perrien, Achenbach et al. 2006).  FSH increases osteoclast differentiation in vitro (Zhu, 
Tourkova et al. 2012), and in vivo treatment of ovariectomised 14-week old mice with an 
antibody to β-subumit of FSH, which blocks the biological activity of FSH, prevented 
OVX-induced bone loss after 4 weeks of treatment.  Dynamic histomorphometry showed 
inhibiting FSH increases all bone formation parameters and inhibits bone resorption 
parameters (Zhu, Blair et al. 2012).  Clinical studies have confirmed the link between a 
high FSH and increased serum markers of bone turnover in large cross sectional studies.  
Levels of osteocalcin (a marker of bone formation) and N-telopeptide of type I collagen 
(NTx) (a marker of bone resorption) were correlated with serum changes in female 
hormones in perimenopausal women (n=2375). High FSH was significantly associated 
with high NTx and a high osteocalcin, indicating that changes in FSH may be 
contributing to the changes in bone density at perimenopause (Sowers, Greendale et al. 
2003).  Inhibins were not measured in this study therefore it is not possible to separate the 
effect of a rising FSH versus a decline in inhibins.  In the cross sectional study by Perrien 
et al showing that inhibin A was the most accurate predictor of changes in bone formation 
and resorption, FSH was also measured.  FSH correlated with bone resorption markers 
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(CTx) but not bone formation markers (BSAP) in perimenopausal women, and did not 
correlate with any bone turnover markers in pre- or postmenopausal women (Perrien, 
Achenbach et al. 2006).  These data therefore suggest a direct stimulatory effect of FSH 
on osteoclastogenesis in vitro and in vivo, with additional inhibition of osteoblastogenesis 
in vivo, however, further longitudinal clinical studies evaluating both inhibins and FSH 
are needed to determine if the inhibitory effects on osteoblastogenesis are mediated 
through a high FSH or concurrently low inhibins. 
 
These data suggest there will be significant endocrine differences in the bone 
microenvironment in pre- and postmenopausal women, which may differentially 
influence the survival and growth of disseminated tumour cells in bone.  This may be a 
direct effect of different hormone levels on bone cell number and activity, as previously 
discussed, but may also be due to changes in the soluble paracrine growth factors in bone 
which are under the influence of the female hormones inhibin A and B. 
 
1.4.3	  Inhibins	  interact	  with	  members	  of	  the	  TGFβ 	  superfamily	  of	  paracrine	  peptides	  –	  
implications	  for	  breast	  cancer	  cell	  growth.	  
The ovarian hormones inhibin A and B do not have an identified intracellular downstream 
signaling pathway, but bring about their effector functions by inhibiting members of the 
TGFβ superfamily of signaling peptides.  These paracrine proteins are abundant in many 
tissues, including bone, and include activin, TGFβ, bone morphogenetic proteins, anti 
mullerian hormone and nodal, with effector functions of cell cycle regulation, 
differentiation and growth (Bierie and Moses 2010).  Activin and TGFβ each bind to their 
respective type II receptors, but both recruit the same type I receptor which results in 
phosphorylation of the receptor associated Smads 2/3 (Liu and Feng 2010).  This 
interaction between ligand and type II receptor is prevented by inhibins (Vale, Wiater et 
al. 2004).  Activin is also bound to a single chain glycosylated peptide, follistatin, which 
prevents its biological activity and it must be cleaved from follistatin to allow receptor 
ligand interaction.  Activins biological activity is therefore prevented by both inhibins and 
follistatin (de Kretser, Buzzard et al. 2004) (Fig 1.13).  
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Figure 1.13.  Inhibin interacts with the activin type II receptor to bring about its 
effector functions. 
 
 
Inhibin binds to the activin type II receptor (ActRII) and prevents activin from binding.  
In addition to inhibin, activin is also inhibited by follistatin, a single chain glycosylated 
peptide which binds to activin in the circulation and extracellular spaces and prevents 
activin from binding to ACRII.  In the absence of inhibin and follistatin, activin binds to 
ActRII and induces phosphorylation of the receptor associated Smads 2/3, these undergo 
translocation to nucleus to affect DNA transcription.  In breast cancers this pathway has a 
tumour suppressive role. 
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Paracrine	  changes	  in	  the	  tumour	  microenvironment	  have	  a	  direct	  effect	  on	  breast	  
cancer	  cell	  growth-­‐	  influence	  of	  ER	  status. 
Activin is produced by both ER+ve and ER-ve breast cancer cells in vitro.  It acts as a 
tumour suppressor, and early studies suggested the tumour suppressive action was 
greatest in ER+ve cells due to loss of activin signaling mechanisms in ER-ve cells 
(Kalkhoven, Roelen et al. 1995).  However, these early studies did not evaluate breast 
cancer cell secretion of the activin inhibitor follistatin.  Follistatin has been shown to 
cause insensitivity to the growth inhibitory effects of exogenous activin in ER-ve cells, 
which can be reversed by removal of follistatin from culture medium (Razanajaona, 
Joguet et al. 2007). The tumour suppressive effect of activin has been further shown in 
clinical breast cancer samples, wherean association was shown between loss of activin 
receptor (ActRII) expression and increasing grade of tumour (Jeruss, Sturgis et al. 2003), 
indicating that tumour cells down regulate their response to the growth inhibition from 
activin as they become more aggressive.  In breast cancer patients without metastases, 
serum activin levels are raised and these levels fall after breast cancer surgery.   However, 
serum levels of activin do not correlate with poor prognostic factors such as lymph node 
involvement or tumour grade, indicating activin is secreted as a consequence of 
malignancy but is not the cause (Reis, Cobellis et al. 2002). 
 
TGFβ1 is produced by breast cancer cells in vitro at significantly higher levels than 
benign breast tissue (Travers, Barrett-Lee et al. 1988). In contrast to its effect in 
established bone metastases, in early breast tumour development its role is that of a 
tumour suppressor as shown in transgenic mouse models in which blockade of the TGFβ 
receptor II (TGFβRII) increased the number of spontaneous mammary tumours (Yang, 
Dukhanina et al. 2002).  TGFβ therefore appears to have both a tumour suppressive 
action in early tumorigenesis and a tumour promoting action in later stages of 
tumourigenesis. 
 
The activin/TGFβ receptor associated Smad2 protein has been shown to be a tumour 
suppressor in clinical breast cancer specimens, with a loss of phosphorylated Smad2 
correlating with a decreased disease free survival in women with early stage disease (Xie, 
Mertens et al. 2002). 
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Paracrine	  changes	  in	  the	  bone	  microenvironment	  can	  affect	  breast	  cancer	  cell	  growth.	  
The role of activin in bone is almost directly opposite to that of inhibins, with in vitro 
data showing that activin enhances osteoclast formation via increasing RANK expression 
(Sugatani, Alvarez et al. 2003).  The effect of activin on osteoblast formation in vitro is 
less well defined, with reports that it both stimulates (Gaddy-Kurten, Coker et al. 2002) 
and inhibits (Eijken, Swagemakers et al. 2007) osteoblast formation.  Inhibiting activin in 
vivo by delivery of a soluble activin receptor fusion protein has similar effects to that of 
inhibins, resulting in an increased bone volume via an increase in osteoblast number, 
suggesting that activin inhibits osteoblastogenesis (Chantry, Heath et al. 2010). 
 
TGFβ1 has differential effects on osteoblasts and osteoclasts in vivo by increasing the 
former and decreasing the latter (Edwards, Nyman et al. 2010).  TGFβ1 is also secreted 
by osteoblasts into the bone matrix and is subsequently liberated upon osteoclastic bone 
resorption.  This release of TGFβ attracts osteoblasts to sites of resorption and TGFβ 
therefore plays an integral role in the coupling of bone formation to bone resorption 
(Iqbal, Sun et al. 2009). 
 
Effects of activin and TGFβ1 on breast cancer cell growth in bone have been reported in 
studies using in vivo models. Breast cancer cells in bone increase PTHrP secretion in 
response to TGFβ that promotes osteoclastogenesis (Buijs, Stayrook et al. 2011), 
suggesting a tumour promoting action of TGFβ in established bone metastases.  TGFβ 
also increased expression of CXCR4 on MDA-MB-231 cells which promotes bone 
homing, adhesion to bone and formation of bone metastases in vivo, an effect which is 
lost if TGFβ is inhibited in the cell line (Dunn, Mohammad et al. 2009).  Delivery of a 
soluble activin receptor fusion protein to intact mice, prior to intracardiac inoculation 
with MDA-MB-231 cells, prevented the development of osteolytic bone lesions 
indicating that low levels of activin in bone may prevent the formation of bone metastasis 
(Chantry, Heath et al. 2010).  These results suggest that modifying the bone environment 
by inhibiting bone turnover prior to the arrival of tumour cells may prevent bone 
metastases. Whether this is mediated through administration of activin inhibitors or other 
compounds such as bisphosphonates, the results are similar.  Knockdown of the activin 
receptor in the same MDA-MB-231 cells prior to intracardiac injection did not affect the 
formation of bone metastasis compared to parental cell line (Chantry, Heath et al. 2010), 
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However, another group showed that knockdown of the activin/TGFβ receptor associated 
intracellular protein Smad2 in MDA-MB-231 resulted in a more aggressive phenotype 
with rapid formation of bone metastasis (Petersen, Pardali et al. 2010). Breast cancer cells 
therefore appear to be influenced by the activin/TGFβ pathway, with increased tumour 
propensity if Smad2 levels are decreased. 
 
Together these data suggest that the paracrine factors, TGFβ, activin and the activin 
inhibitor follistatin, may have relevant effects on tumour proliferation in early breast 
cancer.  The effects on breast cancer cells in either the local primary tumour environment 
or the bone microenvironment may alter according to the levels of the female hormone 
inhibin A and B, which are high in premenopausal women and low in postmenopausal 
women.  It is not known if zoledronic acid can affect these paracrine proteins in either the 
primary tumour or bone microenvironment, or if the absence or presence of female 
hormones can interact with the drug to alter activin, follistatin, TGFβ or the ratio between 
these. 
1.5	  Summary	  and	  Hypothesis	  
 
As discussed there is emerging clinical data that bisphosphonates such as zoledronic acid 
can improve outcomes in early breast cancer in 2 groups of patients; postmenopausal 
women and patients with ER-ve breast tumours.  Zoledronic acid is likely to be routinely 
incorporated into clinical practice for neo/adjuvant treatment of these patients, and 
therefore there is a need to understand how reproductive hormones and the ER status of 
breast cancers interact with the drug to alter its anti-tumour action. 
 
In postmenopausal women the effects of zoledronic acid may be mediated through 
modification of the bone microenvironment, with subsequent effects on DTCs either by 
alteration in bone cell activity or number, or availability of the soluble paracrine growth 
factors TGFβ, activin and the activin inhibitor follistatin.  This beneficial effect may 
dependent upon a postmenopausal endocrine profile with low levels of the ovarian 
hormones oestradiol and inhibins.  In women with ER-ve tumours, the beneficial effect of 
zoledronic acid may be mediated through direct effects on the soluble paracrine growth 
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factors TGFβ, activin and the activin inhibitor follistatin in the local tumour environment, 
which are not occurring in ER+ve tumours. 
 
Therefore the hypothesis of this research was; Zoledronic acid can affect TGFβ , 
activin and the activin inhibitor follistatin in both the primary tumour environment and 
in bone, but these effects are differentially altered according to presence or absence of 
female hormones and ER status of primary tumours.  
1.6	  Aims	  
 
Chapter 3; AZURE translational study; To evaluate if biochemical classification of 
menopausal status using FSH, oestradiol and inhibin A is more reliable than patient 
reported clinical classification in selecting patients for adjuvant zoledronic acid.  To 
assess the predictive value of a treatment interaction with zoledronic acid for each 
individual hormone.  To assess the prognostic value of each individual hormone for bone 
and distant breast cancer recurrence.  
 
Chapter 4; ANZAC endocrine sub-study study; To assess if serum levels of TGFβ, 
activin and follistatin are altered by zoledronic acid in patients being treated with 
neoadjuvant chemotherapy +/- zoledronic acid.   To evaluate if alterations in the serum 
levels of the paracrine proteins are affected by menopausal status or ER status at baseline. 
 
Chapter 5; To evaluate if ER+ve and ER-ve breast cancer cells secrete TGFβ, activin or 
follistatin in vitro and the effects of these proteins on proliferation.  To assess if 
zoledronic acid differentially affects these paracrine factors according to ER status of 
cancer cells in vitro and in vivo. 
 
Chapter 6; To evaluate the effects of inhibin A on bone volume, bone cell number and 
bone levels of activin and follistatin in vivo.  To assess the effects of zoledronic acid on 
bone cell number and bone levels of activin and follistatin in vivo. 
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Chapter 2. Materials and Methods. 
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2.1	  Materials	  	  
Laboratory equipment 
Access 2 immunoassay Beckman Coulter 
Antigen retrieval citrate bath Dako 
Centrifuge Beckman Coulter 
Cobas e602 autoanalyser Roche 
Cytospin Shandon 
Desktop X-ray microtomograph Skyscan 1172 
Developer Curix 60, AGFA 
Gel plate holder BioRad 
GentleMACS cell dissociator Miltenyi Biotec 
GS-710 Calibrated Imaging Densitometer  BioRad 
Incubator Heraeus Instruments 
Inverted fluorescent microscope Leica DMI 4000B 
Inverted light microscope Leica Leitz DMRB 
Mini-Protean Cell BioRad 
Mistral table centrifuge 2000 MSE 
MRXII plate reader 4.25 Dynex technologies 
Neubauer haemocytometer Weber 
Power pack basic BioRad 
Sample separator (0.75mm/1.5,mm) The Gel Company 
Spectra Max M5 fluorescent plate reader Molecular Devices 
Technico Maxi table centrifuge Fisher 
Thermomixer comfort Eppendorf 
Vortexer Fisions 
 
 
Software 
CTAN software CT-analyser Skyscan 
Endnote referencing tool Version 4 
Image J software Version 1.45s 
Microsoft Excel Version 14.2.0  
Microsoft PowerPoint Version 2011 
Microsoft Word Version 14.2.0 
Osteomeasure Osteometrics 
PRISM graphpad software Version 5.0d 
SPSS software Version 19 
 
 
Plastics and disposables 
6 well plate Corning Inc 
96 well plate Corning Inc 
ALZET 2006 sub cut osmotic pumps Durect corporation 
Autoclave tape 3M 
Bijoux tubes Starstedt 
Biomax MS film Kodak 
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C tubes (gentleMACS) Miltenyibiotec 
Cell scraper Starstedt 
Cell strainer 0.45µm BD Biosciences 
Chamber slides Thermo Scientific 
Conical tubes BD Falcon 
Cytoclips Shandon 
Eppendorf 1.5ml Starstedt 
Filter paper Sigma-Aldrich 
Microscope slides VWR International 
Needles (21, 23, 25 gauge) Becton Dikinson UK 
Non woven sterile swabs Shermond healthcare supplies LTD 
Petri dish Nunc AS 
Pipette tips (10,200,1000µl) Costar 
Polypropylene 6-0 sutures PROLENE 
PVDF transfer membrane Immmobilon 
Reflex 7 surgical clips Cell point scientific Inc 
Strippets (5,10,25ml) Costar 
Surgical Blade Swann Morton 
Syringe filter 0.4µM Life Sciences 
Syringe, 1ml, 5ml, 20ml Becton Dickinson UL 
T75 flask Corning Inc 
Tissue culture flasks, T75 Nalgene Nuc ltd 
Universal tube BD Falcon 
 
 
Laboratory chemicals and solutions 
0.5M Tris-HCL Geneflow limited/national diagnostics 
1.5M Tris-HCL Geneflow limited/national diagnostics 
1% SDS Biorad 
3% H202 VWR chemicals 
Acetic acid VWR chemicals 
Acrylamide 30% Geneflow limited/national diagnostics 
Ammonium persulphate Sigma-Aldrich 
Bicinchoninic acid solution Sigma-Aldrich 
Bovine serum albumin Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
Butan-1-ol Fisher 
Caesin Vector labs  
Cell titre 96 Aqueous solution Promega 
Copper sulphate Sigma-Aldrich  
DAB peroxidase substrate Vector 
Dimethyl formaldeyhde Sigma-Aldrich 
Dithiothreitol Sigma-Aldrich 
DMEM media Gilbco Invitrogen Corp 
DMSO Sigma-Aldrich 
Eosin Merck 
Fetal calf serum Sigma-Aldrich 
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Fluorescein avidin Vector 
Glycerol Fisher 
Glycine Fisher  
Goat serum Vector 
Haematoxylin Merck 
Horse serum Vector 
HRP detection Pierce Supersignal West Dura substrate 
Mammalian lysis kit reagent Sigma-Aldich 
Methanol Fisher 
Milk powder Marvel 
Napthol Sigma-Aldrich 
Paraformaldehyde Sigma-Aldrich 
Pararosaniline Sigma-Aldrich 
Phosphatase inhibitor Sigma-Aldrich 
Protease inhibitor Sigma-Aldrich  
PVDF membrane Immobilon 
RPMI media 1640 +glutamax Gilbco Invitrogen Corp 
Sodium acetate Alfa Aesar 
Sodium nitrate Sigma-Aldrich 
Sodium Tartrate Dihydrate Alfa Aesar 
Sterile PBS 1x Gilbco Invitrogen Corp 
Supersignal Pierce 
Temed Sigma-Aldrich 
Texas red avidin Vector 
TRIS Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Trypsin EDTA PAA laboratories 
Trypsin enzyme digestion kit MenaPath 
Tween 20 BDH 
Vectastain ABC kit Vector 
Vectashield with DAPI  Vector 
 
 
Cell lines 
MCF7 European Collection of Cell cultures  
MDA-MB-436 European Collection of Cell cultures  
MDA-MB-231 European Collection of Cell cultures  
T47D European Collection of Cell cultures  
 
 
Antibodies, recombinant proteins and pharmacological products 
Amphotericin PAA 
Follistatin rabbit anti human antibody Novus Biologicals 
GAPDH mouse anti human antibody Abcam 
Geranylgeranyl (GGOH)  Sigma-Aldrich 
Goat anti-rabbit secondary Vector 
HRP mouse anti-goat secondary Vector 
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HRP rabbit anti-goat secondary Invitrogen 
Isofluorane 100% vapor Abbott 
Penicillin/streptomycin PAA 
Pentobarbitone Animal care Ltd 
PhosphoSmad2 (c terminus and linker) rabbit 
anti human antibodies 
Cell signaling 
Rapla goat anti human antibody Santa Cruz 
Recombinant human follistatin protein R&D 
Recombinant human inhibin A protein NIBSC Health protection agency 
Recombinant human/mouse activin A protein R&D 
SB 431542 Tocris bioscience 
Septrin 40mg/200mg 5ml paediatric suspension Laboratories genopharm 
Smad 2 rabbit anti human antibody Cell signaling 
Vetergesic 0.3mg/ml Alsto animal health 
Zoledronic acid Novartis 
 
 
Commercial kits 
Human follicle stimulating hormone (FSH) RIA Roche  
Human follistatin ELISA R&D 
Human Inhibin A ELISA Beckman Coulter 
Human Inhibin A ELISA Cloud-Clone Corp 
Human oestradiol RIA Roche 
Human TGFb1 ELISA R&D 
Human, mouse, rat activin A ELISA R&D 
Human/mouse phospho-smad2/3immunoassay R&D 
Mouse follicle FSH ELISA USCN Life Science 
Mouse follistatin ELISA Cloud-Clone Corp 
Mouse inhibin A ELISA USCN Life Science 
Mouse TRAP Assay Immunodiagnostics systems 
Mouse/rat P1NP EIA Immunodiagnostics systems 
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2.2	  Methods 
 
2.2.1	  In	  vitro	  methodology.	  
2.2.1.1	  Maintenance	  of	  cell	  lines.	  
Cells were maintained in liquid nitrogen until required.  Upon removal from liquid 
nitrogen they were defrosted by agitating in a water bath maintained at 37oC, and 
subsequently transferred to a universal container with 9mls RPMI +10% foetal calf serum 
(FCS).  The suspension was centrifuged at 1000rpm for 5 minutes, medium was then 
removed and the cell pellet re-suspended in required medium prior to transfer into a T75 
flask. 
 
Cells were maintained in T75 flasks in incubators at 37 oC, 5% CO2.  Medium was 
supplemented with 10% FCS.  RPMI or DMEM was used dependent upon the 
experimental design.  Cells were split under sterile conditions in positive pressure hoods 
at confluence.  To split cells, firstly they were washed with sterile PBS and following 
discarding of the PBS, 5mls of trypsin (0.05%) –EDTA (0.02%) added.  Flasks were 
returned to the incubator for a time dependent on the cell line used (typically 5 minutes 
for MDA-MB-231s and 10 minutes for MCF7s).  Detachment from the flasks was 
confirmed by light microscopy, and 5mls medium added, with the resultant cell 
suspension pipetted into a universal container to be centrifuged at 1000rpm for 5 minutes.  
Supernatant was then removed and cell pellet re-suspended in 10mls medium, with a 
required volume of resultant suspension added to fresh medium in a T75 flask, to create a 
total volume of 10mls per flask.   
2.2.1.2	  	  Cell	  lines.	  
MDA-MB-231 and MDA-MB-436 human breast cancer cell lines were used as oestrogen 
receptor negative (ER–ve) cell lines.  Two oestrogen receptor positive (ER +ve) human 
breast cancer cell lines were used, MCF7s and T47Ds.  The choice of cell line was 
dependent upon the experimental plan, with the majority of experiments carried out on 
the MDA-MB-231 cells and MCF7 cells. 
2.2.1.3	  Counting	  cells	  using	  a	  haemocytometer.	  
Cell counts were performed using trypan blue and a haemocytometer. Trypan blue is an 
exclusion dye which is not taken up by cells with an intact cell membrane and thus 
distinguishes viable cells from dead cells stained blue.  A single cell suspension was 
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formed by trypsinising a T75 flask.  10ul of cell suspension was mixed with 10ul trypan 
blue in an eppendorf.  10ul of the suspension+trypan blue was then pipetted onto the 
haemocytometer.  An inverted light microscope was used to count the number of viable 
cells in four primary squares.  To calculate the number of cells/ml medium the cell count 
was divided by 4 and multiplied by the volume from which the cell suspension originated.  
Cell count was then multiplied by 2 to account for the 50% dilution with trypan blue and 
finally multiplied by 10,000 for final cell count/ml medium.  The cell suspension was 
then centrifuged, and a volume of fresh medium added to create the desired concentration 
of cell suspension. 
2.2.1.4	  Cell	  plating.	  
Cell count was performed using trypan blue and haemocytometer.  The resultant cell 
pellet was then re-suspended in a volume of media to form a 1x106 cells/ml suspension, 
and the following cell numbers plated dependent on cell type and plate used (cell 
numbers were determined by time course growth curves performed for each individual 
cell line in RPMI+10%FCS in 6 or 96 well plates and in chamber slides); 
• For experiments using a 6 well plate, 1x105 MDA-MB-231 or MDA-MB-436 
cells were seeded per well and 2x105 MCF7 or T47D cells. 
• For experiments using 96 well plates, 1.5x103 MDA-MB-231 cells were seeded 
per well and 3x103 MCF7 cells. 
• For experiments using chamber slides, 2x104 MDA-MB-231 cells per chamber 
and 4x104 MCF7 cells were seeded. 
Prior to addition of drug or recombinant protein the cells were allowed to settle in 
medium+10%FCS for 24 hours.  Medium was then removed and replaced by serum free 
medium to synchronise cell cycle, for 24 hours.  The drug/protein of interest was then 
added in medium containing 10%FCS. 
 
2.2.1.5	  Addition	  of	  drug	  and	  recombinant	  proteins	  to	  cell	  lines. 
After cell plating the following were added to wells dependent on the aim of the 
experiment.  Concentrations of drug, inhibitor and recombinant proteins were chosen 
based on previously published data.  Note all suspensions were sterile filtered before use; 
• Zoledronic acid; stock solution (10mM) was diluted to 25µM by adding 12.5µl of 
stock to 5mls media or 50µM by adding 25ul of stock to 5mls media.  
	  	  	  	  
	   49	  
• 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide(SB-
431542); Powder was reconstituted with ethanol to 2mM/L stock.  15µl of stock 
was added to 2850µl 1x PBS to form a 10µm/l solution.   
• Recombinant human Inhibin A; Lypophylised powder was dissolved in 1.6mls 
PBS to form a 3µg/ml stock. A 1µg/ml stock was formed by diluting 100µl of 
3µg/ml stock to 200µl PBS.  To form a 30µg/ml concentration, 30µl of 3µg/ml 
stock was added to 2.97mls media.  To form a 10µg/ml concentration, 30µl of 
1µg/ml was added to 2.97mls media. 
• Recombinant human/mouse/rat Activin A; Lypophylised powder was dissolved in 
200µl PBS +0.1%BSA to form a 50,000ng/ml stock.  2µl stock was diluted with 
18µl media to form a 5000ng/ml stock.  9µl of 5000ng/ml stock was diluted in 
4491µl media to make a 10ng/ml stock.  Using the 10ng/ml concentration 
dilutions were made as shown in table 2.1. 
• Recombinant human follistatin 315; Lypophylised powder was dissolved in 250µl 
of PBS+0.1%BSA to form a 100µg/ml stock.  2µl stock was dissolved in 18µl 
media to form a 10,000ng/ml concentration. 20µl of this concentration was added 
to 4980µl media to make a 40ng/ml stock.  Using the 40ng/ml concentration 
dilutions were made as shown in table 2.1.2.2.2	  In	  vitro	  sample	  processing. 
	  
2.2.2	  In	  vitro	  sample	  processing.	  
2.2.2.1	  Cell	  lysis	  and	  protein	  assay.	  
Cell suspension was centrifuged at 1000rpm for 5 minutes. Supernatant was discarded 
and cell pellet re-suspended in 100µl mammalian cell lysis buffer. A further 
centrifugation step yielded the lysed protein suspension.  Phosphatase and protease 
inhibitors were added as required. 
Bicinchoninic protein assay; Bovine serum albumin (BSA) 1mg/ml serves as stock from 
which serial dilutions form the standard curve.  Standard protein concentrations range 
from 10µg/ml to zero.  Standards were prepared by adding 10µl in duplicate to the first 2 
columns of a 96 well plate.  10µl of sample was added in duplicate to wells at 100%, 50% 
and 25% concentration.  200µl BCA reagent was added (1 part CuSO4, 50 parts 
bicinchoninic acid solution) to each well and the plate incubated for 30 minutes at 
ambient temperature.   
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Table 2.1 Dilutions of activin (10ng/ml) and follistatin (40ng/ml) for in vitro work.  
 
Activin is shown in black and follistatin in blue.  
 
 
 
 
 
 
 	  	  	  	  
  
Desired	  concentration	  activin/follistatin	   Amount	  of	  10ng/ml	  activin	  stock	  /	  40ng/ml	  follistatin	  stock	  	  
Amount	  of	  RPMI+10%FCS	  	  	  	  6000pg/ml	  /	  24000pg/ml	   2700ul	   1800ul	  1800pg/ml	  /	  7200pg/ml	   810ul	   3690ul	  600pg/ml	  /	  2400pg/ml	   270ul	   4230ul	  180pg/ml	  /	  720pg/ml	   81ul	   4419ul	  60pg/ml	  /	  240pg/ml	   27ul	   4473ul	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A colour change to purple indicated the presence of protein.  This colour change is the 
result of reduction of Cu2+ions to CU1+ions by peptide bonds in protein.  The 
bicinchoninic acid chelate bind to each Cu1+ ion and form the purple colour.  The 
quantification of amount of purple colour was performed using a microplate reader at 
wavelength 562nm, with protein levels extrapolated from the standard curve. 
2.2.2.2	   Protein	   separation	   by	   SDS	   page	   and	  western	   blot	   for	   detecting	   proteins	   in	   cell	  
culture.	  
The principle of SDS-PAGE is that proteins which have been denatured by sodium 
docecyl sulfate (SDS) can be separated by an electric field using a polyacrylamide gel 
electrophoresis (PAGE).  SDS is negatively charged and binds to polypeptide chains in 
differing amounts relative to the molecular mass.  The negatively charged proteins are 
attracted to a positively charged anode. The gel separates the proteins according to 
molecular mass with smaller proteins travelling further down the gel compared to larger 
proteins.  Following protein separation the samples can be further processed to Western 
blot to probe for specific proteins of interest using antibodies. 
 
Proteins were denatured by adding 1ml of sample buffer (10ml 0.5M Tris, SDS 2g, 6.4ml 
glycerol, bromophenol blue) to 25mg dithiothreitol and adding 100µl of resultant mixture 
to 300µl protein sample.  The sample was heated at 95oC for 5 minutes and then 
transferred to ice.   
12% separating gels and stacking gels were formed by addition of the following 
substrates in the volumes shown in table 2.2.   
10µl of denatured protein was added to each well plus a molecular weight marker.  Gels 
were run in running buffer (0.25M Tris, 0.2M glycine, 1% SDS, distilled water 500ml) at 
200V for 1 hour to ensure adequate separation of proteins according to mass.  Gels were 
then equilibrated with methanol activated PVDF membrane, filter paper and pads and 
transferred in transfer buffer (0.25M Tris, 0.2M glycine, distilled water 500ml) at 70V for 
70 minutes.  Membranes were then removed and blocked in appropriate blocking solution 
for 1 hour at ambient temperature.  Primary antibodies were then added and incubated 
overnight at 4oC. 
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Table 2.2.  Substrates and volumes required to form a 12% separating gel. 
 
	  	  	  	  	  
 
 
 
 	  
  
 Separating Gel Stacking gel 
Distilled water 3.35ml 6.1ml 
1.5M Tris-HCL pH 8.8 2.5ml - 
0.5M Tris-HCL pH 6.8 - 2.5ml 
10%SDS 100µl 100µl 
30% Acrylamide 4ml 1.3ml 
20%APS 50µl 100µl 
TEMED 5µl 10µl 
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After discarding the primary antibody, membranes were washed x3 in PBS-tween.  
Secondary antibodies were then added in blocking solution for 1 hour (see table 2.3).  
Completion of the experiment involved x5 washes and addition of chemiluminescence 
with exposure of membranes, in the dark room, to photographic film with subsequent 
automated development of the film. 
2.2.2.3	   Enzyme	   linked	   immunoabsorbance	   assays	   (ELISAs)	   for	   quantification	   of	   protein	  
levels	  in	  cell	  culture	  supernatant.	  
The principle of an ELISA is as follows: 
Antibodies to the protein of interest coat each well of a 96 well plate.  Sample is then 
added and the specific protein within the sample binds to the immobilised antibody.  
Addition of a further detection antibody binds the antibody:protein complex.  The 
detection antibody is then bioconjugated to a second antibody linked to an enzyme.  
Addition of an enzyme substrate at the end of the assay results in a colour change to 
produce a visible signal that can be quantified using a plate reader at specific absorbance. 
 
Human Follistatin (FS288, FS300, FS315); Follistatin is a paracrine glycoprotein 
expressed in many tissues.  It binds the protein activin and neutralises its 
biological activity, it also inhibits other members of the TGFβ superfamily of 
signaling proteins.  The follistatin ELISA was carried out according to 
manufacturers instructions.  Standards were mixed by diluting 160,000pg/ml 
follistatin stock with calibrator diluent RD5-21 to form serial dilutions ranging 
from 16,000pg/ml to zero.  100µl of assay diluent was added to each well which 
was pre-coated with antibody specific for follistatin.  100µl of standard or sample 
was added per well in duplicate.  The plate was incubated at 4oC for 3 hours.  
Following incubation the plate was washed x4 using a squirt bottle.  200µl of 
follistatin conjugate was added to each well and the plate incubated at 4oC for a 
further 2 hours.  Washing was repeated and 200µl of substrate solution was added 
with the plate maintained in darkness for 20minutes.  Final steps involved addition 
of 50µl stop solution to each well and the optical density was read at 450nm using 
a microplate reader.  Follistatin levels were determined from the standard curve.  
Mean minimum detection limit is 29pg/ml  (10-83pg/ml).  All intra-assay CV’s 
were below 15%. 
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Table 2.3 Antibodies and concentrations used for western blotting 
 
 
Gap DH and Rap1a concentration was chosen based on previous experience within the laboratory  
group.  Phospho-Smad2 concentration was optimised from suggested doses in the product literature.  
An#gen& Gel&
(%)&
Primary&an#body& Secondary&an#body&
Gap&DH& 12& Mouse&polyclonal&an#body&
1:20,000&
Goat&an#Cmouse&HRP&
conjugated&
1:15,000&
Rap1a& 12& Goat&polyclonal&an#body&
1:200&
Rabbit&an#Cgoat&HRP&
conjugated&
1:30,000&&
&
PhosphoCSmad2&
(Ser&245/250/255)&
12& Rabbit&polyclonal&an#body&
1:1000&
Goat&an#Crabbit&HRP&
conjugated&
1:8000&
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• Human/Mouse/Rat Activin A; Activin A is a paracrine protein involved in cell 
proliferation, apoptosis and differentiation and is a member of the TGFβ 
superfamily of signaling proteins.  The activin A ELISA was carried out as 
follows.  The activin A kit was carried out according to manufacturers instructions.  
200µl of activin A biotinylated antibody was added to all wells and the plate 
incubated on an orbital shaker set at 500rpms for 15mintes. Standards were 
formed from dilutions of the activin A standard with levels ranging from 
1000pg/ml to zero. 100µl of assay diluent RD1-98 was added to each well.  100µl 
standard or sample was added to each well in duplicate.  The plate was incubated 
at ambient temperature on the orbital shaker for 3 hours.  Following this the plate 
was washed x6 using wash buffer and a squirt bottle.  200µl of activin A 
conjugate was added to each well.  The plate was incubated at ambient 
temperature for 1 hour on the shaker.  Wash steps were repeated x6.  200µl of 
substrate solution was added to each well and incubated for 30 minutes at ambient 
temperature in darkness.  Final steps involved addition of stop solution to each 
well and the plate was read on a microplate reader at 450nm.  Activin 
concentrations were extrapolated from the standard curve.  Mean minimum 
detection limit was 3.67pg/ml (0.75-7.85pg/ml) and intra-assay CVs were <15%. 
 
• Human TGFβ1; TGFβ1 is a paracrine protein of the TGFβ superfamily of 
proteins involved in cell differentiation, proliferation and apoptosis.  The TGFβ1 
ELISA was carried out as follows. Latent TGFβ1 was activated by adding 20µl of 
1N HCL to 100µl of cell culture supernatant.  Following mixing and incubation 
for 10 minutes at ambient temperature 20µl of 1.2N NaOH/0.5M HEPES was 
added and the sample processed for ELISA.  Standards were formed by diluting 
the 2000pg/ml standard with dilutions ranging from 2000pg/ml to zero.  50µl of 
assay diluent RD1-1 was added to each well that was coated with a monoclonal 
antibody specific for TGFβ1.  50µl of standard or activated sample was added to 
each well in duplicate.  The plate was incubated at ambient temperature for 2 
hours.  The plate was then washed x4 with wash buffer using a squirt bottle.  
100µl of TGFβ1 conjugate was added to each well and followed by a further 
incubation for 2 hours at ambient temperature.  Washing was repeated x4 and 
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100µl of substrate solution was added to each well and incubated in darkness for 
30 minutes at ambient temperature.  Final steps involved addition of 100µl of stop 
solution to each well and the plate was read on a microplate reader at 450nm.  
TGFβ1 levels were extrapolated from the standard curve.  Mean minimum 
detection limits were 4.61pg/ml (1.7-15.4pg/ml) and intra-assay CVs were <15%. 
 
2.2.2.4	  Cell	  titre	  Aqueous	  One	  solution	  cell	  proliferation	  (MTS)	  assay	  for	  assessing	  viable	  
cell	  number	  in	  cell	  culture.	  
The MTS proliferation assay is a colorimetric assay for determining the number of viable 
cells.  The active compound is [3-(4,5-dimethylthiazol-2-yl)5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt:MTS]noon and an 
electron coupling reagent (phenazine ethosulfate;PES).  The MTS compound is 
bioreduced by cells into a coloured formazan product via NADH produced by 
mitochondrial dehydrogenase enzyme in metabolically active cells.  The coloured 
compound is soluble in medium and is directly proportional to the number of viable cells 
and can be quantified by recording absorbance at 490nm on a plate reader.  1.5x103 
MDA-MB-231 or 3x103 MCF7 cells were seeded per well of a 96 well plate in RPMI 
+10%FCS, leaving 2 columns blank for medium+10%FCS only controls. Background 
absorbance from medium+10%FCS with or without protein was within quoted range for 
assay (0.2-0.3 absorbance units). Plates were incubated overnight and the following day 
medium discarded and replaced by serum free RPMI to ensure synchronization of cell 
cycle for 24 hours.  Recombinant proteins; human activin and human follistatin or the 
ALK 4/5 inhibitor SB-431542 were then added to the wells at differing concentrations in 
RPMI+10%FCS and medium+protein was replaced every 24 hours.  The plates were 
incubated for the required time-points, and at the end of the experiment 20µl of 
CellTitre96Aqueous One solution was added to control, treatment and media only wells.  
The plate was incubated in the darkness for 3 hours and then analysed using a plate reader 
with absorbance at 490nm (Fig 2.1) 
 
2.2.2.5	   Immunofluorescence	   to	  quantify	   levels,	  and	  visualise	   localisation,	  of	  proteins	   in	  
cell	  culture.	  
Cell based fluorescent ELISA; This assay uses fluorogenic substrates to quantify 
levels of human/mouse/rat phospho-Smad2/3 in whole cells. Smad2/3 are 
membrane bound intracellular proteins that are phosphorylated in response to  
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Figure 2.1.  Representative photograph of an MTS assay.   
 
96 well plates were seeded with tumour cells and treated with increasing doses of 
recombinant protein.  MTS solution was added at the end of the experiment and broken 
down to a coloured product that can be quantified by use of a plate reader. 
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activin binding to its ACRII cell surface receptor.  The principles of the assay are 
detailed in Figure 2.2 and are summarised as follows: MDA-MB-231 cells were 
seeded at a density of 1.5x103 cells per well of a 96 well plate in RPMI+10%FCS.  
Cell were left for 48 hours at 37oC in a cell incubator.  After 48 hours media was 
replaced by serum free medium for a further 24 hours incubation.  Following this 
cells were treated for 1 hour with drug/protein/conditioned medium of interest 
followed by fixation with 100µl of 4% formaldehyde in 1XPBS for 20 minutes.  3 
wash cycles followed this and then cells were incubated in quenching buffer for 
20 minutes at ambient temperature.  After further wash cycles cells were blocked 
with blocking buffer for 1 hour.  Cells were then washed x3 and incubated with 
100µl of primary antibody overnight at 4oC.  Following further washing, primary 
antibody was removed and 100µl of secondary antibody was added for 2 hours.  
The last step involved addition of 2 fluorescent substrates for 60 and 40 minutes 
each, and the plate was read using a fluorescent plate reader with excitation at 
540nm and emission at 600nm to identify levels of phosphorylated Smad2/3, and 
excitation at 360nm and emission at 450nm to represent the levels of total 
Smad2/3. 
 
• To visualise localisation of phospho-Smad2/3 in whole cells, chamber slides were 
used to grow MCF7 and MDA-MB-231s in cell culture.  4x104 MCF7 cells and 
2x104 MDA-MB-231 cells were seeded per chamber well in RPMI+10%FCS for 
24 hours, then medium was replaced by serum free RPMI for 24 hours.  Each well 
was then treated with recombinant protein or drug in RPMI+10%FCS, and 
chambers maintained in incubators for required duration.  Medium was then 
discarded and 4% paraformaldehyde (PFA) added to chambers for 4 hours at 4oC. 
Following fixation, chambers were washed x2 in PBS and blocking solution 
added (5% goat serum in PBS) for 1 hour at ambient temperature.  Chambers were 
then incubated overnight at 4oC with primary antibody (phosphorylated Smad2 
1:100) in 5% BSA, ensuring one chamber was maintained as a negative control.  
After 24 hours, x4 washes preceded addition of secondary antibody (goat anti-
rabbit 1:100) in antibody solution (5% goat serum in PBS) for 1 hour at ambient 
temperature.  Washes were then repeated and fluorescine avidin in 10mM 
HEPES+0.15NaCl was added for 30 minutes at ambient temperature.  Chambers 
were then dismantled, and the slide mounted with mounting medium containing 
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Figure 2.2 Principles of a cell based ELISA for quantification of phospho-Smad2/3 
and total Smad2/3 levels in whole cells. 
 
MDA-MB-231 cells were seeded in 96 well plates in RPMI+10%FCS.  After 48 hours 
medium was replaced by serum free RPMI.  After 24 hours cells were treated for 1 hour 
with protein/drug/supernatant followed by fixation and detection of Smad2/3 as per 
protocol. 
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######Fix,#permeabilise#and#block#cells#
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DAPI and cover slips attached.  Slides were imaged using an inverted fluorescent Leica 
microscope to evaluate localisation of pSmad2 protein.  Localisation was determined by 
imaging a minimum of 100 cells per chamber, and counting number of cells with 
fluorescent protein in the nucleus (identified by DAPI), and expressing the result as a 
percentage of total number of cells counted (see chapter 4 for further details). 
	  
2.2.3	  In	  Vivo	  methodology.	  
2.2.3.1	  Ethics	  and	  home	  office	  licensing.	  
All experiments were carried out at the University of Sheffield Biological Service, under 
the Home Office Project License number 40/3531. Individual study plans were reviewed 
by the project license holder, prior to commencement, to ensure adherence to the 
guidelines set out in the license.  Female balb/c nude mice were obtained from Leeds 
University breeding program and Charles River.  Animals were 12-weeks old at 
commencement of experiments.  
2.2.3.2	  Anaesthetic.	  
Where recovery of the animal was planned, isofluorane was the gaseous anesthetic of 
choice.  Individual mice were placed in an induction chamber with oxygen flow set to 
4L/min and isofluorane flow set to 5%.  Once mice were sedated they were removed from 
the induction chamber, isofluorane flow turned down to 3% and delivered by a nose cone.  
50µl of vetergesic was administered sub-cutaneously, and once pedal reflex was lost the 
procedure was commenced.  Animals were placed in an incubator post procedure, and 
observed until alert and mobile before returning to cages. 
Where terminal sedation of the animal was planned, 100µl pentobarbitone was injected 
intraperitoneal.  Once pedal reflex was lost the terminal procedure was commenced. 
2.2.3.3	  Insertion	  and	  loading	  of	  sub-­‐cutaneous	  ALZET	  osmotic	  pumps.	  
ALZET 2006 osmotic pumps were used to deliver recombinant human inhibin A protein 
in 1x PBS or 1xPBS alone. The pumps were provided sterile, and all handling and 
loading of the pumps was performed under sterile conditions in a cell hood according to 
manufacturers instructions.  Figure 2.3 demonstrates the structure of the ALZET pumps.  
To calculate the concentration of recombinant inhibin A to add the following formula was 
used: 
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Figure 2.3. Schematic of an ALZET pump.  
 
The 2006 model delivered a continuous solution of PBS+/- recombinant human inhibin 
protein for a maximum of 42 days in the mice, negating the need for multiple injections. 
  
!!!!!!!!!!!PBS!±!inhibin !Osmo.c!sec.on!!!!!!!!!Semipermeable!!!!!!!!!Impermeable!!!!!!!!!!!!!!!!!Flow!moderator!
! ! ! ! ! !!membrane!!!!!!!!!!!!!!!!reservoir!!!!!!!!!!!!
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Cd = K0                    
                        Q 
Cd = concentration of drug required (µg/µl), K0 = mass delivery rate (µg/hr), Q = volume delivery rate (set 
at 0.15µl/hr in the 2006 model). 
 
To deliver 120ng/day inhibin A (5ng/hr), 33.4ng/µl of inhibin A was required per pump.   
To deliver 60ng/day inhibin A (2.5ng/hr), 16.7ng/µl of inhibin A was required per pump,  
To deliver 10ng/day inhibin A, 2.8ng/µl was required per pump. Pumps were primed so 
that they were immediately active on the day of surgery by placing the loaded pumps in 
sterile 0.9% saline at 37oC for 60 hours prior to surgery. 
To insert the pumps, mice were anaesthetised as per recovery method, the operating field 
was maintained under sterile conditions using chlorhexidine, and the mouse positioned in 
a prone position.  A small skin incision was made using a scalpel in the ventral mid line, 
overlying the lumbar vertebrae.  The skin was freed from underling connective tissue by 
blunt dissection, and the ALZET pumps inserted sub-cutaneously.  The wound was 
closed with surgical clips or non-absorbable 6-0 surgical sutures, which remained in place 
for 7 days prior to removal (Figure 2.4).  Mice were weighed post pump insertion to 
record a baseline weight, and placed in an incubator until recovery. 
2.2.3.4	  Ovariectomy	  of	  mice.	  
Mice were anaesthetised as per recovery method and placed in prone position in a sterile 
operating field.  A sub-cutaneous incision was made in the same area as for the pump 
insertion.  Entry to the right side of the posterior peritoneal cavity was obtained by blunt 
dissection.  Following this the right ovary was identified from surrounding peri-renal fat 
and fallopian tube, and externalised (Figure 2.5).  The ovary was then removed from the 
fallopian tube by gentle shearing, which prevents haemorrhage.  The same procedure was 
carried out on the left side via the same incision point.  A sham procedure involved 
externalisation of both right and left ovaries, followed by return to the peritoneal cavity.  
The sub-cutaneous incision was closed using prolene 6.0 non absorbable sutures.  Septrin 
paediatric suspension was added to a litre of water and divided among the cages to 
prevent infection.  Mrs Anne Fowles assisted with training for the ovariectomy (OVX) 
and sham procedures. 
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Figure 2.4. Representative image of an ALZET pump in vivo.   
 
ALZET pumps were placed sub-cutaneous under isofluorane anaesthetic with insertion 
point sutures for wound closure.  Black arrows highlighting side and front view of the 
pumps. 
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Reproduced from The Anatomy of the laboratory mouse.  Margaret J Cook. Elsevier Academic Press 1965. Adapted for 
web by Mouse Genome Informatics, The Jackson Laboratory, Bar Harbour, Miane, 2008. 
 
 
 
Figure 2.5.  Murine anatomical position of the ovary. 
 
 Mice were anaethetised and placed in the prone position.  An incision was made at the level 
of the iliac crests in the mid line, and following blunt dissection into peritoneal cavity, peri-
renal fat was used to localise ovaries.  Ovaries were removed by gentle shearing and 
peritoneal cavity closed. 
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2.2.3.5	   Exsanguination	   from	   the	   heart	   at	   termination	   of	   experiment,	   and	   terminal	  
sample	  collection.	  
Following administration of pentobarbitone for terminal sedation, pedal reflex was 
checked to ensure deep sedation. With the mouse in the supine position, using a 1ml 
syringe and 25-gauge needle, the xiphisternum was identified and the needle introduced 
towards the direction of the left shoulder.  Cardiac blood was collected slowly to prevent 
collapse of the heart, with an average volume of 800µl.  Blood was left at ambient 
temperature to clot, then spun at 4000rpm for 15 minutes.  Serum layer was removed and 
placed in a 1.5ml tube for storage at -20oC until processing.  Following cervical spine 
dislocation, tissues of interest were dissected free and processed as follows:  
• Hind limbs were placed in 4% PFA at 4oC, and changed to 10% EDTA after 48 
hours.  This solution was changed every 2 days for 2 weeks to ensure adequate 
decalcification of the bone prior to processing.   
 
• Calvaria were dissected free of soft tissue and the edges cut to remove debris.  
They were individually crushed in 3mls of 1x PBS. The cell suspension was then 
filtered using a cell strainer, to remove bone debris, and a cell count performed 
using trypan blue. The cell suspension was centifuged at 1500rpm for 5 minutes 
and 300µl of resultant supernatant taken for processing to ELISA or frozen at -
20oC.  
 
• Liver was divided and either placed in 4% PFA for 48 hours at 4oC, then changed 
to 70% ethanol until processing for histology, or was weighed and homogenised 
to allow quantification of protein via ELISA.  Homogenisation of liver was 
performed using a cell dissociation program (M_spleen_01_04) on the 
GentleMacs tissue homogeniser.  Briefly, liver was placed in a C tube with 9mls 
PBS.  The C tube was attached to the homogeniser and run for 45 seconds. 
Following this, the suspension was centrifuged at 7000rpm for 5 minutes and 
supernatant transferred to an eppendorf.  2 further centrifuge steps were carried 
out at 7000rpm for 5 minutes to ensure clear supernatant and all debris removed.  
Supernatant was frozen at -80oC for processing to ELISA. 
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2.2.4.	  In	  vivo	  sample	  processing	  
2.2.4.1	  Blood	  analysis	  
Enzyme linked immune absorbance assay (ELSIA) for quantification of protein levels in 
serum: 
• Mouse Follicle stimulating hormone  (FSH); FSH is a pituitary secreted hormone, 
which is under negative feedback from the ovarian secreted hormone inhibin A. 
The ELISA kit was carried out according to manufacturers instructions. Serum 
was defrosted and agitated, no dilution of samples was required.  Standards were 
mixed by diluting 180ng/ml FSH stock with standard diluent to form serial 
dilutions ranging from 180ng/ml to zero.  100µl of standards or sample were 
added to each well in duplicate and incubated for 2 hours at 37oC.  Liquid was 
removed from wells and 100µl of detection reagent A was added followed by a 1 
hour incubation at 37oC.  Liquid was removed from wells and x4 wash steps 
performed using a squirt bottle.  100µl of detection reagent B was added to wells 
and incubated for 30 minutes at 37oC followed by x5 wash steps.  Following this 
90µl of substrate solution was added for 20 minutes at 37oC in the dark, followed 
by the final step of addition of 50µl of stop solution to the wells. The optical 
density was read at 450nm using a microplate reader, and FSH levels were 
determined from the standard curve.  Mean minimum detection limit was 
0.95ng/ml.  All intra-assay CV’s were below 15%. 
 
• Mouse Tartrate Resistant Acid Phosphatase (TRAP); TRAP is produced by bone 
resorbing osteoclasts and can be detected in serum.  EIA was carried out as 
follows and according to manufacturers instructions. Serum was defrosted and 
agitated.  100µl of anti-mouse TRAP antibody was added to each well of the 
microplate and incubated for 60 minutes at ambient temperature on a microplate 
shaker set to 950rpm.  Wells were washed x3.  100µl of calibrator or control was 
added to appropriate wells in duplicate and 75µl of 0.9% NaCL followed by 25µl 
of sample was added to wells in duplicate.  25µl of releasing agent was added to 
all wells and the plate incubated at ambient temperature for 60 minutes shaking at 
950rpm.  The plate was washed x3 and 100µl of substrate solution added to all 
wells.  An incubation step followed for 2 hours at 37oC followed by addition of 
25µl stop solution to all wells.  The plate was read at 405nm using a microplate 
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reader. Mean minimum detection limit was 0.1U/L.  All intra-assay CV’s were 
below 15%. 
 
• Mouse/rat P1NP; P1NP is a marker of bone formation and can be detected in 
serum.  The P1NP EIA was carried out according to manufacturers instructions. 
Serum was defrosted and agitated, 50µl of calibrator or control was added to 
appropriate wells in duplicate to an antibody coated plate. 5µl of sample and 45µl 
sample diluent was added to each well.  Following this 50µl of P1NP biotin was 
added to each well and the plate was incubated at ambient temperature on a 
microplate shaker at 500rpm for 1 hour.  Following this x3 wash steps were 
performed, and 150µl of enzyme conjugate added to wells, followed by a 30 
minute incubation at ambient temperature.  After a further x3 wash steps, 150µl of 
TMB substrate was added to all wells and incubated at ambient temperature for 30 
minutes.  50µl of stop solution was then added and the absorbance read at 450nm 
using a microplate reader. The optical density was read at 450nm using a 
microplate reader, and P1NP levels were determined from the standard curve.  
Mean minimum detection limit was 0.7ng/ml.  All intra-assay CV’s were below 
15%. 
 
• Mouse Inhibin A; Inhibin A is secreted by ovaries throughout reproductive life 
span.  The ELISA kit was already optimised and was therefore carried out 
according to the manufacturers instructions.  Serum was defrosted and agitated, 
100µl of standard or sample was added to each well in duplicate and incubated for 
2 hours at 37oC. 100µl of detection reagent A was added to each well and 
incubated at 37oC for 1 hour.  x3 wash cycles were followed by addition of 100µl 
of detection reagent B for 30 minutes at 37oC.  A further 5 wash cycles preceded 
addition of 90µl of substrate solution for 20 minutes with the final step being 
addition of 50µl of stop solution and the plate was read at 450nm. Mean minimum 
detection limit was 6.1pg/ml.  Intra- assay CV’s were below 15%. 
 
• Human Inhibin A ELISA; to detect recombinant human inhibin A protein in 
mouse serum a human specific ELISA was used.  The ELISA was carried out 
according to manufacturers instructions.  100µl of sample or standard was added 
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to each well in duplicate.  Liquid was removed and 100µl of detection reagent A 
was added immediately and incubated at 37oC for 1 hour.  Wells were washed 3 
times and 100µl of detection reagent B followed by an incubation period of 1 hour 
at 37oC.  5 further washes were then performed, and 90µl of substrate solution 
added for 20 minutes at 37oC. 50µl of stop solution was added and the plate was 
read at 450nm. Mean minimum detection limit was 39pg/ml. Intra-assay CV’s 
were below 15%.  
2.2.4.2	  Analysis	  of	  tibia.	  
Microcomputed tomography (µCT). 
Microtomography uses X-rays to create a 3D image that can be used to analyse tissue 
architecture. The proximal right tibia was used for evaluation of bone architecture. 
Activation of the X-ray source was performed using the Skyscan 1172 program.  The 
tibia was placed proximal end down in a secure container sealed with cling film, and 
camera set to medium resolution of 2000x1024.  The height of the sample was adjusted to 
include the region of interest (ROI).  The x-ray source was sealed and each bone scanned 
individually.  Images were then reconstructed using NRecon software to form a series of 
JPG cross sectional images for each bone, 4.4µm apart over a distance of 1.0mm.  To 
analyse the images, a reference point was defined to ensure the same section of each bone 
was analysed.  The reference point is shown in figure 2.6 and bone was analysed from 
this point over a distance of 1.0mm.  The ROI of each cross sectional image was selected 
by drawing around the inside of the cortical bone, to encompass the trabeculae (Figure 
2.7).  This process was repeated several times over the length of the tibia to maintain the 
ROI within the cortex of bone.  Using analysis software (CTAN) the ROIs for each bone 
were reconfigured to give a value of bone volume to tissue volume percentage (BV:TV) 
which could be compared between groups.  
 
Immunohistochemistry: 
TRAP stain; TRAP is an enzyme expressed by osteoclasts and can be used to identify 
bone cells on tissue sections.  To perform the stain acetate buffer was made by dissolving 
5.44g sodium acetate in 200ml distilled water and adding 50ml 1.2% acetic acid (494ml 
H2O+6ml  
acetic acid) and 4.6g sodium tartrate.  This solution was incubated at 37°C for 2-4 hours.  
Sections were dewaxed by placing in xylene and rehydrated with alcohols.  This was  
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Figure 2.6 Representative image of cross sectional images of bone at increasing 
distances from the growth plate. 
 
A) µCT image of tibia with corresponding reference points highlighted on cross sectional 
imaging in B). 
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Figure 2.7. Region of interest (ROI) for analysis of trabecular bone volume 
 
ROI was defined by identifying the bridge break in the growth pate and analysing 
trabecular bone volume over a distance of 1.0mm above bridge break.  ROI is represented 
by blue shading. 
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followed by placing sections in warmed acetate buffer for 5min at 37°C.  Sections were 
then incubated in solution A; 0.02g napthol phosphate plus 1ml dimethyl formaldehyde 
and 50ml of acetate buffer, for 30 minutes at 37oC. Sections were then incubated 
insolution B; 0.08g sodium nitrite in 2ml distilled H2O, plus 2ml pararosaniline.  2.5ml of 
this solution was added to 50ml acetate buffer and sections were incubated for 15 minutes 
at 37oC.  Sections were rinsed and counterstained with haematoxylin for 20 seconds, then 
subsequently dehydrated and mounted with cover slips. 
 
Osteomeasure scoring of slides: 
Osteomeasure software allows quantification of bone cells from TRAP stained tissue 
sections.  Osteoclasts were identified by the pink stain visable after TRAP staining.  
Osteoblasts were identified according to morphology and location.  To be identified as an 
osteoblast the cell was characterised as being cuboidal in shape with a nucleus orientated 
to one end of the cell.  It also had to be in contact with the trabecular surface of the bone, 
and with another cell of similar appearance.  See figure 2.8.  The microscope was set at 
10x objective and analysis options selected to include total surface measurement, 
osteoclast number and surface and osteoblast number and surface.  The growth plate was 
identified and analysis started 125µm below this reference point.  The entire trabecular 
surface was analysed, and summary data recorded at the end of each analysis.  Results 
were expressed as number of each bone cell per mm trabecular surface. 
2.2.4.3	  Analysis	  of	  Calvaria	  	  
Enzyme linked immune absorbance assay (ELISA) for quantification of protein levels in 
calvaria; 
• Mouse activin ELISA were carried out as previously described in sections 2.2.2.3 
 
• Mouse follistatin ELISA; The follistatin ELISA was performed according to the 
manufacturers instructions.  Briefly 50µl of standard or sample was added to each 
well in duplicate followed by immediate addition of 50µl of detection reagent A.  
The  
plate was incubated for 1 hour at 37oC. x3 wash cycles were then performed 
followed by addition of 100µl of detection reagent B.  A further incubation for 30 
minutes at 37oC followed and then a further 5 wash cycles.  90µl of 
substratesolution was then added for 20 minutes at 37oC, and 50µl of stop solution  
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Figure 2.8.  Identification of osteoblasts and osteoclasts using TRAP stain. 
 
Osteoblasts were identified by their cuboidal shape and location on the surface of the 
bone and in association with another cell of the same type (black arrows).  Osteoclasts 
were identified by their pink TRAP +ve staining and on the surface of the bone (blue 
arrows) (x20 magnification) 
  
BONE%
Bone%marrow%
	  	  	  	  
	   73	  
was added prior to reading the plate at 450nm.  Mean minimum detection limits were 
0.94ng/ml 
	  2.2.4.4	  Analysis	  of	  Liver	  
Enzyme linked immune absorbance assay (ELISA) for quantification of protein levels in 
liver; 
• Mouse activin ELISA were carried out as previously described in sections 2.2.2.3 
• Mouse follistatin ELISA were carried out as previously described in section 
2.2.4.3 
 
Immunohistochemistry: 
Haematoxylin and eosin stain (H&E); H&E is a common stain used to evaluate 
morphology of various tissues.  The haematoxylin stains nuclei blue and the eosin stains 
eosinophilc structures such as cytoplasm pink.  To perform the stain samples were 
dewaxed in xylene and rehydrated with alcohols, followed by a rinse step in water for 10 
seconds.  Sections were then submerged in Gill’s haematoxylin for 2 minutes and rinsed 
until clear.  They were then submerged in 1% eosin for 5 minutes before being rinsed, 
dehydrated, mounted and visualized with a light microscope. 
2.2.4.5	  Sub-­‐cutaneous	  tumours	  
Immunohistochemistry: 
• Phospho-Smad2 (serine 245,250,255); Slides were dewaxed in xylene and 
rehydrated with alcohols.  Blocking was performed with 3% H2O2 in methanol for 
10 minutes at ambient temperature followed by a rinsing step in PBS-T twice for 
5 minutes.  PBS-T was removed and preheated trypsin added for 15 minutes at 
37oC. A wash step followed and then sections were blocked using 5% 
serum/1%BSA/PBS for 30 minutes at ambient temperature.  The primary linker 
pSMAD2 antibody was then incubated overnight in 1%BSA/PBS at 4oC at a 
concentration of 1:100, excluding negative control.  Sections were washed in 
PBS-T and slides were incubated in biotinylated rabbit secondary antibody 1:200 
in 1%BSA/PBS for 30 minutes at ambient temperature.  Sections were then 
washed and incubated in signal enhancer for 30 minutes prior to further washing 
and incubation with DAB for 3-6 minutes.  Sections were then counterstained 
with haematoxylin, washed and dehydrated with alcohols and xylene before 
mounting and viewing via light microscopy 
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• Follistatin; Slides were processed as for phospho-Smad2. The primary follistatin 
antibody was used at a concentration of 1:200 with biotinylated rabbit secondary 
antibody at a concentration of 1:200.  
 
2.2.5	  Statistical	  analysis	  of	  in	  vitro	  and	  in	  vivo	  data.	  
All analysis of in vitro and in vivo data was performed using Graph pad PRISM version 
5.0d.  Tests chosen for comparisons of groups were based on normality of data, with 
parametric tests used when data was normally distributed, and non-parametric when 
normality was not achieved. 
2.2.6	  Clinical	  serum	  samples	  from	  the	  ANZAC	  and	  AZURE	  clinical	  trials.	  
2.2.6.1	  Ethics	  and	  consent	  
Ethical approval for research on clinical samples, and consent from participants from the 
ANZAC and AZURE clinical trials is detailed in the relevant chapters (chapters 3 and 4). 
2.2.6.2	  Trial	  protocol	  
ANZAC and AZURE trial protocols are detailed in the relevant chapters (chapters 3 and 
4). 
2.2.6.3	  Clinical	  serum	  sample	  processing	  
Enzyme linked immune absorbance assay (ELISA) for quantification of protein levels in 
ANZAC serum samples: 
• Human activin, follistatin and TGFβ1 were performed as previously described in 
section 2.2.2.2 
• Human Inhibin A; Inhibin A is an ovarian secreted hormone produced throughout 
reproductive life, declining to undetectable levels at menopause.  It is a member of 
the TGFβ superfamily of proteins.  The inhibin A ELISA was carried out 
according to manufacturers instructions. Cell culture supernatant was centrifuged 
at 10,000 rpm for 5 minutes; no dilution of samples was required.  Standards were 
provided ready to use, and ranged from 1000pg/ml to zero. In duplicate, 50µl of 
standards, control and samples were added to each well that was pre-coated in 
anti-inhibin A antibody.  50µl of sample buffer A and B was added to each well.  
The wells were incubated for 3 hours at ambient temperature on an orbital shaker 
at 500rpms.  Wells were washed x6 with wash solution using a squirt bottle, and 
then 100µl antibody enzyme conjugate was added to each well. The plate was 
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incubated on the orbital shaker at 500rpm for 1 hour at ambient temperature.  
Washing steps were repeated and 10µl of TMB chromogen solution added to each 
well in darkness for 15 minutes on the orbital shaker.  Final steps involved 
addition of 100µl of stopping solution to each well and absorbance read at 450nm 
using a microplate reader. Inhibin A levels were extrapolated from the standard 
curve. Minimum detection limits were <5pg/ml, and inra-assay CV’s were below 
15%. 
 
Hormone radioimmunoassay (RIA’s) and electrochemiluminescent immunoassay (ECLs) 
for AZURE serum samples: 
• Human Inhibin A; The Access RIA was used to detect inhibin A (Beckman 
Coulter).  This was a two-step immunoenzymatic assay.  Thawed 
sample/calibrator/quality control was added to a vessel containing paramagnetic 
particles coupled with anti-inhibin A monoclonal antibody.  A wash step removed 
excess sample and reagents. Anti-inhibin A monoclonal antibody-alkaline 
phosphatase conjugate was then added to the vessel to detect inhibin A which was 
bound in the previous reaction.  Following incubation, materials bound were held 
in a magnetic field while unbound substrate was washed away.  
Chemiluminescent substrate was then added and the quantity of light generated 
was detected by a luminometer.  The amount of light was proportional to the 
quantity of inhibin A in the sample. The lowest detectable inhibin A level was 
1pg/ml.  Internal quality control and intra-assay precision data is provided in 
chapter 3. 
• Oestradiol and Follicle Stimulating hormone; ECL was used to detect oestradiol 
and FSH using the Roche Cobas E602 autoanalyser. Standards or samples are 
incubated with a biotinylated antibody and a ruthinuim labeled antibody complex 
to the hormone of interest.  Following incubation, streptavidin coated 
paramagnetic micro particles are added which binds the biotinylated antibody.  
The subsequent mixtures of immune complexes are magnetically trapped whilst 
unbound reagent is washed away.  The ruthenium conjugate is stimulated with 
electricity to produce light, the amount of which is proportional to oestradiol or 
FSH in the sample. Oestradiol detection limit was 18.4 pmol/l, FSH detection 
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limit was 0.1IU/l.  Internal quality control and intra-assay precision is detailed in 
chapter 3. Excess serum that was not processed was re-frozen for future studies. 
	  
2.2.6.4	  Statistical	  analysis	  of	  clinical	  serum	  data. 
Details of the programs used, and analyses performed are detailed in the relevant chapters 
(chapters 3 and 4). 	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3. Baseline evaluation of reproductive 
hormones assists in the selection of 
postmenopausal patients for adjuvant 
zoledronic acid. 
An AZURE translational study. 
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3.1	  Summary	  	  
Several large adjuvant clinical trials, involving thousands of breast cancer patients, have 
shown that zoledronic acid decreases disease recurrence and increases survival when 
added to standard therapy in patients who are naturally or chemically postmenopausal. 
The reproductive hormonal changes occurring in the transition from premenopausal to 
postmenopausal involve a fall in circulating oestradiol and inhibin A with a concomitant 
rise in follicle stimulating hormone (FSH).   
 
In early breast cancer, disseminated tumour cells (DTCs) can be detected in the bone 
marrow, in patients without clinically apparent metastatic disease.  The fate of these cells 
may be affected by reproductive hormones and zoledronic acid, resulting in different 
outcomes for pre- and postmenopausal women treated with these drugs. Accurately 
selecting patients for zoledronic acid is important to ensure the population treated derives 
the most benefit. Baseline serum levels of oestradiol, inhibin A and FSH from 806 
patients randomised in the AZURE trial were measured to evaluate if serum hormone 
levels could be used to predict which patients would benefit from the addition of 
zoledronic acid to standard adjuvant therapy.   
 
Here we show the baseline characteristics and invasive disease free survival (IDFS) 
outcomes in the serum population were reflective of the main AZURE population. 
Clinical and biochemical menopausal status were not concordant in all patients, but in a 
heterogenous breast cancer population, serum FSH, oestradiol and inhibin A in 
postmenopausal ranges continued to select patients with improved IDFS outcomes with 
zoledronic acid. No individual hormone level was driving the interaction with zoledronic 
acid, indicating the overall activity of the HPG axis influences outcomes with the drug. A 
low pretreatment FSH (<26IU/l) predicted for a shorter time to skeletal recurrence and a 
low pretreatment oestradiol (<50pmol/l) predicted for a shorter time to distant recurrence.  
These results indicate that premenopausal patients may be at increased risk for bone 
metastases, however postmenopausal patients may have an increased tumor burden in 
non-skeletal sites.  This may reflect the differing effect of reproductive hormones on the 
bone premetastatic niche, influencing DTC survival in bone or spread to distant sites in 
early breast cancer. 
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3.2	  Introduction 
Bone is a common site for breast cancer metastases (Coleman 2005) and the bone 
targeted agents, bisphosphonates, have an established role in the prevention of skeletal 
related events in metastatic disease and management of bone loss associated with cancer 
therapies (Coleman 2004; Wilson and Coleman 2011).  However data are now emerging 
to show that bisphosphonates improve outcomes in early breast cancer, by modification 
of the bone microenvironment and reduction in the number of disseminated tumour cells 
using the bone as a sanctuary for survival (Aft, Perez et al. 2012).  Three large adjuvant 
trials have shown improved disease free survival outcomes (DFS) with addition of 
zoledronic acid in patients with a natural or chemically induced menopause (Coleman, 
Marshall et al. 2011; Gnant, Mlineritsch et al. 2011; Coleman, de Boer et al. 2013). The 
largest of these trials was the AZURE trial (does Adjuvant Zoledronic acid redUce 
REcurrence in patients with high-risk, localized breast cancer? ISCRCTN 79831382, 
BIG01/04) and results following 752 DFS events have been published (Coleman, 
Marshall et al. 2011), moreover, an updated report was recently presented after 84 
months follow up and 966 DFS events (R. Coleman, R. Burkinshaw et al. 2013) showing 
bone metastases free survival was improved with addition of zoledronic acid in a 
heterogenous population of pre- and postmenopausal patients (HR 0.81; 95%CI 0.68-0.97, 
p=0.022). Pre-specified sub-group analyses according to menopausal status continued to 
show an improvement in invasive DFS (IDFS) (HR 0.77; 95%CI 0.63-0.96) and overall 
survival (OS) (HR 0.81; 95%CI 0.63-1.04) in postmenopausal patients >5 years since 
menopause who received zoledronic acid but not any other group (pre-, 1-5 years 
postmenopausal and unknown). This differential effect of treatment according to 
menopausal status was driven by a decrease in loco-regional recurrence and extra-skeletal 
recurrence in patients >5 years postmenopausal receiving zoledronic acid compared to an 
increase in all other menopausal groups. 
The molecular explanation for the differential anti-tumour effect of zoledronic acid 
according to menopausal status is yet to be identified, but the different reproductive 
hormone influences in the bone microenvironment could potentially interact with 
bisphosphonates and affect dormant cancer cells taking sanctuary at this site.  The 
concept of bone acting as a sanctuary for disseminated tumour cells (DTCs) in early 
breast cancer requires consideration.  The presence of DTCs at diagnosis is an 
independent poor prognostic factor and 50% of patient with detectable DTCs will relapse 
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within 10 years (Braun, Vogl et al. 2005).  This relapse may be within the bone or at 
extraosseous sites and can occur decades after the primary tumour diagnosis, suggesting 
these DTCs may be held in a state of dormancy. Upon activation from unknown triggers, 
these DTCs develop autonomous growth becoming overt metastases within the bone, or 
spread via the blood stream to distant sites.  These DTCs may have ‘stem cell’ like 
properties conferring a resistance to standard chemotherapy, with evidence that primary 
systemic therapy does not eradicate DTCs, even in patients who have a complete 
pathological response in the primary tumour (Becker, Solomayer et al. 2007).  This 
persistence of DTCs after primary systemic therapy is an independent poor prognostic 
factor for DFS and OS in the first 5 years following diagnosis (Janni, Vogl et al. 2011).   
The reproductive hormonal influences in bone will be determined by the relative activity 
of the hypothalamic pituitary gonadal (HPG) axis.  The changes in this axis with 
increasing age have been defined by the Stages of Reproductive Ageing Workshop 
(STRAW+10) (Harlow, Gass et al. 2012).  The female reproductive lifespan was divided 
into 3 phases; reproductive, menopausal transition and postmenopausal with defined 
clinical changes in menstrual cycles and measurable changes in reproductive hormones 
before and after final menstrual period (FMP) (Fig 3.1). With increasing age, FSH 
demonstrated an increase and stabilized at >25IU/l 3-6 years post FMP, inhibins declined 
with undetectable levels at the time of FMP, and oestradiol declined but did not stabilize 
at low levels until up to 8 years post FMP. Clinical menstrual cycle criteria were the 
principle defining parameters for stage definition in healthy women and biochemical 
classification was supportive, due to the lack of international standardisation of hormone 
assays. The impact of these reproductive changes on bone turnover has been investigated. 
Perrien et al, in a cross sectional study of 188 pre- and postmenopausal women aged 21-
85 years, correlated oestradiol, FSH, inhibin A and B with bone turnover markers; serum 
bone alkaline phosphatase (BALP) as a marker of bone formation and C-terminal 
collagen I cross-link (CTx), urine pyrindinoline and deoxypyrindinoline as markers of 
bone resorption (Perrien, Achenbach et al. 2006). Multivariate analysis of pre- and 
postmenopausal women showed inhibin A to be a good predictor of markers of bone 
formation and resorption in premenopausal women, and the best predictor of bone 
formation markers in postmenopausal women.  Oestradiol levels were a better predictor 
of bone resorption markers in postmenopausal women.  FSH was not a significant 
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Reproduced	  from	  National	  Institute	  of	  Health	  Public	  Access	  from	  Climacteric,	  2012	  15(2):105-­‐114.	  	  	  
 
 
 
 
Figure 3.1.  The STRAW+10 Staging system for reproductive ageing in women.  
 
Principle defining criteria are based on menstrual cycle changes either side of final 
menstrual period (FMP).  Supportive criteria include endocrine analysis of reproductive 
hormones before and after FMP.  
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predictor of any bone turnover markers. Data from in vitro and in vivo studies have 
shown that administration of recombinant inhibin A increased bone forming osteoblast 
activity (Perrien, Akel et al. 2007), and blocking the activity of FSH using an antibody to 
the β subunit increased bone formation parameters and inhibited bone resorption 
parameters (Zhu, Blair et al. 2012). In addition, oestradiol decreases the lifespan of bone 
resorbing osteoclasts by promoting apoptosis and increases the lifespan of osteoblasts by 
exerting antiapoptotic effects (Manolagas 2000).  Therefore a premenopausal woman will 
have higher bone mass than a postmenopausal woman in part due to the anabolic effects 
of high oestradiol, inhibin and concurrently low FSH on osteoblasts, in addition to the 
suppressive effect of the reproductive hormones on osteoclast function. Expansion of the 
osteoblastic niche in vivo has been shown to increase tumor cell survival (Shiozawa, 
Pedersen et al. 2011), therefore levels of reproductive hormones may affect the ability of 
this niche to support tumour cell survival in bone. 
Based on this evidence, and advice from experts in the field of reproductive research 
(personal communication from Professor David Robertson, Prince Henry’s Institute of 
Medical Research, Victoria, Australia, and Professor Dana Gaddy, University of 
Arkansas, Texas), FSH, oestradiol and inhibin A were identified as being of importance 
in biochemically defining menopausal status and having relevant effects on the bone 
microenvironment which potentially may interact with zoledronic acid in breast cancer. 
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3.3	  Aims	  
The overall purpose of this chapter was to assess if baseline serum FSH, oestradiol and 
inhibin A from patients recruited to the AZURE trial could be used to select patients for 
adjuvant zoledronic acid, and if baseline hormones were either prognostic for breast 
cancer outcomes or were predictive of a treatment benefit with zoledronic acid.  The 
primary endpoint of the AZURE trial was disease-free survival (DFS) with secondary 
endpoints including overall survival and invasive disease free survival (IDFS). For this 
analysis the focus was IDFS of the following types; all IDFS, skeletal only IDFS and 
non-skeletal distant IDFS.  
 
The following aims were set; 
 
1. Compare baseline demographics of the AZURE serum population (n=872) to the 
overall AZURE population (n=3360). 
 
2. Evaluate if biochemical classification of menopausal status using FSH, oestradiol 
and inhibin A concurs with patient reported clinical classification. 
 
3. Assess if biochemical classification of menopause using FSH, oestradiol and 
inhibin A predicts IDFS outcomes with zoledronic acid. 
 
4. Assess if baseline individual hormone levels can predict IDFS outcomes with 
zoledronic acid. 
 
5. Evaluate the prognostic value of baseline hormones levels for bone only distant 
recurrence and any distant recurrence as first event. 
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3.4	  Patients	  and	  Methods	  
 
3.4.1	  Patient	  inclusion	  and	  exclusion	  criteria.	  
The AZURE trial was an academic, multi-centre, international phase III trial that 
recruited 3360 women with node positive Stage II/III breast cancer.  Patients were 
randomized 1:1 to receive standard adjuvant therapy (chemotherapy and/or endocrine 
therapy) +/- the bone-targeted drug, zoledronic acid, 4mg IV for 5 years, initially q3-4 wk, 
then with increasing intervals between doses (Chapter 1, Fig 1.7).  Patients were 
randomized using a computer generated system which included the following 
minimization criteria; number of involved lymph nodes, clinical tumour stage, oestrogen 
receptor status, menopausal status, type and timing of systemic therapy, study center and 
statin use.  The primary endpoint was DFS with pre-specified subgroup analyses planned 
for the minimization criteria; secondary endpoints included OS and IDFS. Investigations 
for confirmation of recurrence events were as deemed appropriate by the treating 
physician. The date of recurrence defined as the date on which relapse was first suspected 
to minimize ascertainment bias and validated by either on site or telephone based 
monitoring. All data were recorded on the central database at Leeds CTRU. 
Eligibility criteria for the AZURE trial included patients aged >18 years with 
histologically confirmed breast cancer with N1 disease or T3-4 primary tumour.  Patients 
were excluded if there was clinical or imaging evidence of metastases or if the primary 
tumour could not be fully surgically excised. Baseline serum samples were available from 
872 patients recruited into the AZURE trial.  The serum was stored at -80oC at Cancer 
Clinical Trials Unit, Sheffield, UK and was collected according to the AZURE laboratory 
manual, version 1, 30th April 2004 (see appendix 1).  For inclusion in the serum hormone 
analyses, patients had to have confirmed written consent to storage and future analysis of 
serum.  If the above criteria were not fulfilled then patients were excluded.  In addition, 
60 patients were excluded because they were taking medication (hormone replacement 
therapy, tibilone and tamoxifen) at the time of serum collection that may alter levels of 
reproductive hormones. Initially, neo-adjuvant patients were also excluded from the 
analysis over concerns that tumour secretion of inhibin A may affect results.  However, 
after review of the inhibin A levels, the decision was made to include these patients since 
the levels were reflective of the patients clinical menopausal status and generally within 
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the expected range.  In total, 806 patients were eligible for inclusion in the hormone 
analysis. 
3.4.2	  Biochemical	  definition	  of	  postmenopausal.	  
Using assay specific reference ranges for pre- and postmenopausal, criteria were set for 
fulfillment of an established biochemical postmenopausal status.  These criteria were 
stringent and chosen to minimize the cross over with premenopausal nadir serum levels 
during the menstrual cycle. To fulfill a definition of biochemically ‘postmenopausal’ the 
following had to be met; 
1. FSH ≥ 26IU/l 
2. Oestradiol ≤ 50pmol/l 
3. Inhibin A ≤ 3.6pg/ml  
If any one or more of these criteria were not fulfilled the patient was classified as non-
postmenopausal.. 
3.4.3	  Hormone	  evaluation. 
Inhibin A analysis was performed on the automated ACCESS chemiluminescence 
immunoassay system from Beckman Coulter Ref A36097. Oestradiol and FSH analysis 
were performed on the automated Roche 602 Elecsys electrochemiluminescence 
immunoassay.  FSH levels were standardized to the second International Reference 
Preparation 78/549. Lower limit of detection for the assays were as follows; inhibin A 
<1pg/ml, oestradiol 18.4pmol/l, FSH 0.1 IU/L. Internal quality control materials were run 
every 24 hours covering 3 levels of analyte (low, medium and high), and reference ranges 
for pre- and postmenopausal women were assay specific, determined by the manufacturer 
and validated in-house (Table 3.1).  All laboratories used for analysis were Clinical 
Pathology Accredited, ensuring strict operational guidelines and standards within 
Sheffield Teaching Hospitals (STH) NHS Trust, UK. The planned analyses were 
registered with the STH Research Co-ordinator, with agreement from lab managers 
regarding movement of samples across the city to minimize freeze thaw cycles. 
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Table 3.1 Internal quality control data for inhibin A, oestradiol and FSH including 
assay dependent reference ranges for postmenopausal and premenopausal. 	  
	  
 
 
 
 
 
Internal quality control material was run every 24 hours covering 3 levels of analyte (low, 
medium and high).  All laboratories were CPA accredited.  The definitions of 
‘biochemically postmenopausal’ were based on the assay specific cut points for FSH and 
inhibin A.  An oestradiol of <50pmol/l was chosen to define ‘biochemically 
postmenopausal’ to avoid the nadirs in cycling serum oestradiol in premenopausal women  
Hormone' Average'monthly'internal'
QC'data'
Reference'ranges'
Inhibin'A'(pg/ml)'
!
Mean!
SD!
CV%!
Low''''''''''Med''''''''''''High''
!
159.1!!!!!!438.8!!!!!!!!!!!869.2!
7.5!!!!!!!!!!!!20.4!!!!!!!!!!!!!39.8!!!!!!!!!
4.7!!!!!!!!!!!!!4.6!!!!!!!!!!!!!!!!4.6!
!
Premenopausal!(cycle!dependent)!
5D160!pg/ml!
Postmenopausal!0D3.6pg/ml!
Oestradiol'(pmol/l)'
!
Mean!
SD!
CV%!
'
Low''''''''''Med''''''''''''High''
!
170 !!!!!!!!!!!!1059!!!!!!!!!!2576!
11.4!!!!!!!!!!!25.2!!!!!!!!!!!!54.5!
6.7!!!!!!!!!!!!!!2.3!!!!!!!!!!!!!!!2.1!
!
Premenopausal!(cycle!dependent)!
46D1828pmol/l)!
!
Postmenopausal!18.4D201pmol/l!
FSH'(IU/l)'
!
Mean!
SD!
CV%!
'
Low''''''''''Med''''''''''''High''
!
5.5!!!!!!!!!!!!18.1!!!!!!!!!!!39.08!
0.09!!!!!!!!!!0.23!!!!!!!!!!!!!0.53!
1.7!!!!!!!!!!!!1.29!!!!!!!!!!!!1.36!
!
Premenopausal!(cycle!dependent)!
1.7D22!IU/l)!
!
Postmenopausal!26D135IU/l!
	  	  	  	  
	   87	  
3.4.4	  Data	  collection	  from	  central	  database.	  
Demographic, treatment and outcome data for all patients recruited to AZURE were held 
on a password protected ‘Makro’ database at the Clinical Trials Research Unit (CTRU), 
Leeds.  Access to this database was limited to the senior AZURE trial statistician, Helen 
Marshall and medical statistician Samantha Hinsley.  The following data were extracted; 
1. Patient characteristics at randomisation; 
• Trial number 
• Age  
• Date of randomisation 
• Menopausal status;  Premenopausal, <5 years since menopause, unknown 
menopausal status, >5 years since menopause. 
2. Disease characteristics at randomisation 
• ER status; Positive, negative, unknown. 
 
• Tumour stage at diagnosis; T1-4. 
 
• Number of lymph nodes involved; 0, 1-3, >4, unknown. 
3. Treatment characteristics: 
• Randomised to; Interventional arm (zoledronic acid) or control arm (no zoledronic 
acid) 
 
• Systemic therapy; Chemotherapy, endocrine, chemotherapy+endocrine. 
 
• Timing of chemotherapy; Adjuvant/neo-adjuvant 
4. Disease outcomes 
• Invasive disease free survival (IDFS); subdivided into skeletal distant recurrence, 
non-skeletal distant recurrence, loco-regional recurrence, second malignancy, 
IDFS minus skeletal recurrence, all IDFS. 
3.4.5	  Study	  approval	  for	  translational	  serum	  analysis	  
This translational study was approved by the AZURE Trial Steering Committee (TSC) 
and Data Monitoring Committee (DMEC) in August 2011.  
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3.4.6	  Statistical	  methodology	  
Statistical analysis was carried out by Helen Marshall and Samantha Hinsey at the 
Clinical Trials Unit, Leeds.  966 disease free survival events were observed in the 
AZURE trial. Statistical analysis was carried out after a median follow-up of 
approximately 84 (IQR 71-92) months for patients included in the endocrine analyses. 
Cut points used for analyses of hormones (high versus low) were as previously described 
for non-postmenopausal versus postmenopausal categorization. Kaplan-Meier survival 
curves were used to evaluate rates of invasive disease free survival with differences 
between groups assessed using the log-rank test and Cox’s proportional hazards model to 
adjust for tumour stage, ER status, lymph node involvement and neo-adjuvant therapy as 
per the main AZURE subgroup analyses. Time to first distant recurrence analyses were 
adjusted for tumour stage, ER status and lymph node status. Time to bone as first 
recurrence was adjusted for randomised treatment allocation, tumour stage and lymph 
node involvement as per the main AZURE subgroup analyses. Analyses were also 
adjusted for randomised treatment allocation when assessing the interaction of individual 
hormone levels with treatment.  P-values were considered significant at α <0.05. All 
analyses were performed with the use of SAS software version 9.2. 
3.4.7	  Funding	  and	  publication	  
The cost of collection of the serum samples was provided by the research infrastructure 
support at participating sites in the UK by the National Cancer Research Network.  The 
cost of shipping and analyses of FSH, oestradiol and inhibin A were provided by a grant 
award from Novartis Pharmaceuticals. Part of these data were presented as an oral 
presentation at San Antonio Breast Cancer Symposium, Texas, December 2012 based on 
the 2010 data lock used for the interim analysis. These analyses have been subsequently 
updated and use the 2013 datalock. 
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3.5	  Results	  
3.5.1	  Demographics	  and	  baseline	  characteristics	  of	  serum	  population	  compared	  
to	  overall	  study	  population.	  
Baseline data were available for the 872 patients with stored serum. The serum 
population was reflective of the overall AZURE study population with respect to lymph 
node involvement, T stage, ER status and menopausal status (Table 3.2).  Within the 872 
patient serum population, the treatment groups (zoledronic acid and control) were well 
matched (Table 3.3). 60 patients at baseline were established on hormone replacement 
therapy, endocrine therapy or tibilone and excluded from further hormone analysis.   
IDFS outcomes in the serum population were comparable to the main AZURE outcomes 
and showed a similar heterogeneity of treatment effect according to menopausal status, 
with postmenopausal patients having improved IDFS with zoledronic acid, an effect not 
seen in non-postmenopausal patients (postmenopausal HR for zoledronic acid vs control; 
main AZURE population 0.77; 95%CI 0.63-0.96 and serum population 0.728; 95% CI 
0.470-1.129) (Fig 3.2).  The differing effect of zoledronic acid between menopausal 
subgroups, although significant in the overall AZURE population (p=0.030), was not 
significant in the serum population (p=0.3148), which may be due to the smaller sample 
size. 
These data confirmed the serum population was a true representation of the overall 
population. 
3.5.2	   Biochemical	   classification	   of	   menopausal	   status	   versus	   clinical	  
classification.	  
Median hormone levels (range) in the clinically pre- and postmenopausal patients showed 
the expected fall in oestradiol from 392pmol/l (19-4278) in premenopausal patients to 
55.8 pmol/l (19-934) in postmenopausal patients, a fall in inhibin A from 22.7pg/ml (0.2-
170) in premenopausal patients to 1.6pg/ml (0.1-38.9) in postmenopausal patients and a 
rise in FSH from 18.5IU/l (1.1-133) in premenopausal patients to 71 IU/l (3.5-194) in 
postmenopausal patients.  There was not complete agreement between clinical  
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Table 3.2 Baseline characteristics of the overall AZURE population and the serum 
AZURE population  
 
 
 
 
The serum population was similar to the overall main study population in terms of lymph 
nodes, T stage, ER status and menopausal status 
Overall'Study''(n'='3360) Serum''samples'(n'='872) 
Lymph'nodes 
0 
1#3% 
>4 
Unknown%
 
%
61%(1.8%) 
2073%(61.7%) 
1212%(36.0%) 
13%(0.4%) 
%
16%(1.8%) 
534%(61.0%) 
320%(36.6%) 
2%(0.4%) 
T'stage 
T1 
T2 
T3 
T4 
%
1065%(31.7%) 
1718%(51.1%) 
455%(13.6%) 
117%(3.5%) 
%
285%(32.6%) 
427%(48.8%) 
131%(15.0%) 
29%(3.4%) 
ER'status 
Posi;ve 
Nega;ve 
Unknown 
%
2635%(78.4%) 
704%(21.0%) 
20%(0.6%) 
%
676%(77.2%) 
192%(22.0%) 
4%(0.5%) 
Menopausal'status 
Premenopausal 
≤%5%years%post 
>%5%years%post 
Status%unknown 
%
1503%(44.8%) 
491%(14.6%) 
1041%(31.0%) 
324%(9.6%) 
%
409%(46.8%) 
123%(14.2%) 
266%(30.5%) 
74%(8.6%) 
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Table 3.3.  Baseline characteristics for the serum AZURE population according to 
treatment received.  
Standard'therapy'
(n=434)'
N'(%)'
Standard'therapy+Zoledronic'acid'
(n=431)'
N'(%)'
Tumour'stage'
T1#
T2#
T3#
T4#
#
136#(31.3)#
225#(51.8)#
57#(13.1)#
16#(3.7)#
#
147#(34.1)#
200#(46.4)#
71#(16.5)#
13#(3.0)#
Neo?adjuvant'therapy'
Yes#
No#
#
23#(5.3)#
411#(94.7)#
#
28#(6.5)#
403#(93.5)#
Systemic'therapy'
Endocrine#alone#
Chemotherapy#alone#
Endocrine#and#chemotherapy#
#
20#(4.6)#
93#(21.4)#
321#(74)#
#
13#(3.0)#
95#(22.0)#
323#(74.9)#
Anthracycline'
Yes#
No#
#
402#(92.6)#
32#(7.4)#
#
410#(95.1)#
21#(4.9)#
Taxane'
Yes#
No#
#
85#(19.6)#
349#(80.4)#
#
91#(21.1)#
340#(78.9)#
Menopausal'status'
Premenopausal#
<5#years#since#menopause#
>5#years#since#menopause#
Unknown#menopausal#status#
#
205#(47.2)#
63#(14.5)#
131#(30.2)#
35#(8.1)#
#
199#(46.2)#
61#(14.2)#
132#(30.6)#
39#(9.0)#
ER'status'
PosiJve#
NegaJve#
Unknown#
#
333(76.7)#
99#(22.8)#
2#(0.5)#
#
338#(78.4)#
91#(21.1)#
2#(0.5)#
#
Lymph'node'involvement'
0#
1M3#nodes#
≥4#
Unknown#
#
7#(1.6)#
271#(62.4)#
156#(35.9)#
0#(0)#
#
9#(2.1)#
258#(59.9)#
162#(37.6)#
2#(0.5)#
Histological'grade'
1#
2#
3#
#
34#(7.8)#
175#(40.3)#
219#(50.5)#
#
32#(7.4)#
184#(42.7)#
204#(47.3)#
Hormone'replacement'therapy'at'baseline'
Yes#
No#
#
#
5#(1.2)#
429#(98.8)#
#
#
4#(0.9)#
426#(98.8)#
Tibilone'at'baseline'
Yes#
No#
#
0#(0)#
434#(100)#
#
1#(0.2)#
430(99.8)#
Endocrine'therapy'at'baseline'
Yes#
No#
#
29#(6.7)#
405#(93.3)#
#
21#(4.9)#
410#(95.1)#
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Figure 3.2 Invasive disease free survival (IDFS) outcomes in the main AZURE 
population and the serum AZURE population.   
 
Data represents adjusted hazard ratios (HR) and 95% confidence interval (CI) for the 
main AZURE population and the serum AZURE population according to menopausal 
sub-groups; postmenopausal (PM) and non-postmenopausal (non-PM).  The 
heterogeneity of treatment effect according to menopausal status was significant in the 
main AZURE population (p=0.030) but not in the serum AZURE population (p=0.315). 
 
0.4 0.6 0.8 1.0 1.2 1.4 1.6
Non-PM serum population(n=606)
Non-PM Main AZURE(n=2318)
PM serum population(n=266)
PM Main AZURE(n=1041)
Zol Better Control Better
HR = 0.77 (95%CI 0.63-0.96)
HR = 0.78 (95%CI 0.51-1.2)
HR = 1.03 (95%CI 0.89-1.2)
HR = 1.0 (95%CI 0.7 - 1.43)
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menopausal status and biochemical menopausal status (defined in section 3.4.2). Thirty 
one (7.4%) clinically premenopausal women were biochemically classified as 
postmenopausal, of these 1 woman was aged 29 and the remainder were aged ≥44 years.  
Forty three (15.9%) clinically > 5 years postmenopausal women were biochemically 
classified as non-postmenopausal.  Of these 43 women, the biochemical classification of 
postmenopausal was not attained due to an oestradiol >50pmol/l in 31 women (72%), an 
FSH <26IU/l in 11 women (25%) and an inhibin A >3.6pg/ml in 11 women (25%).  
These data show that a biochemical definition of postmenopausal status is not 100% 
concordant with clinical menopausal status.  In clinically > 5 years postmenopausal 
patients this appears to be driven by oestradiol levels that remain higher than the 
postmenopausal cut point in over half of the discordant patients.  In clinically 
premenopausal patients, only 1 patient was aged <44 years, suggesting that older 
premenopausal patients may have reproductive profiles that are within biochemically 
postmenopausal ranges despite regular menses. 
 
3.5.3	  Invasive	  disease	  free	  survival	  according	  to	  treatment	  allocation	  in	  patients	  
with	  a	  biochemically	  defined	  menopausal	  status.	  	  
Among the patients biochemically classified as postmenopausal using FSH, oestradiol 
and inhibin A, IDFS was improved with addition of zoledronic acid compared to standard 
therapy (HR 0.809; 95% CI 0.537-1.220), although the confidence intervals overlap unity 
due to relatively small number of events.  However, biochemically non-postmenopausal 
women had similar IDFS irrespective of treatment allocation (HR 0.987; 95% CI 0.699-
1.394) (Fig 3.3).  Unlike in the main analysis of all patients, this interaction between 
treatment and biochemical menopausal status was not statistically significant (p=0.4699), 
likely due to smaller numbers in the serum population. Considering skeletal IDFS, a trend 
for benefit of treatment with zoledronic acid was seen in both biochemically 
postmenopausal and non-postmenopausal patients (postmenopausal HR;0.813, 95%CI 
0.367-1.799, non-postmenopausal HR; 0.822, 95%CI 0.463-1.460), however, non-
skeletal distant IDFS showed differing affects with addition of zoledronic acid according 
to menopausal status with a trend to benefit in biochemically postmenopausal patients  
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Figure 3.3 Invasive disease free survival according to biochemical definition of 
menopausal status in the serum AZURE population. 
 
IDFS in biochemically non-postmenopausal patients (top) and biochemically 
postmenopausal patients (bottom). Menopause: treatment interaction p value 0.469 
  
Zol vs no Zol
HR 0.987 (95%CI 0.699 - 1.394)
Zol vs no Zol
HR 0.809 (95%CI 0.537 - 1.220)
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(postmenopausal HR 0.905; 95%CI 0.494-1.655), and potential increase in non-skeletal 
distant recurrence in non-postmenopausal patients (HR 1.558;95%CI 0.895-2.713).  
These treatment menopause interactions were not statistically significant due to wide 
confidence intervals, but the hazard ratios mirrored the results of the overall AZURE 
population.  Among the patients clinically classified as <5 years post menopause (n=124), 
70 (56.4%) were biochemically non-postmenopausal and 54 (43.5%) were biochemically 
postmenopausal.  Of the patients with unknown menopausal patients (n=74), 27 (36.5%) 
were biochemically non-postmenopausal and 47 (63.5%) were biochemically 
postmenopausal. The clinical classification of menopause in these patients is less 
discernable than in menstruating premenopausal women and women many years post 
menopausal, and therefore IDFS outcomes were evaluated using biochemical menopausal 
status in these patients in addition to clinical menopausal status for all other patients.  
IDFS was improved in postmenopausal patients (HR 0.806; 95%CI 0.657-0.990) with 
addition of zoledronic acid, but not in non-postmenopausal patients (HR 1.043; 95%CI 
0.873-1.246) interaction p value 0.064 (Fig 3.4).  This heterogeneity of treatment effect 
according to menopausal status was again driven by a decrease in non-skeletal distant 
recurrence in postmenopausal women with an increase in non-postmenopausal women 
(HR postmenopausal 0.878;95%CI 0.644-1.195 vs HR non-postmenopausal 1.271;95% 
CI 0.966-1.673 p=0.0795), rather than differences in skeletal recurrence. 
 
These data suggest that biochemical classification of a heterogeneous population of breast 
cancer patients into postmenopausal and non-postmenopausal groups using FSH, 
oestradiol and inhibin A continues to predicts a trend to improved IDFS in biochemically 
postmenopausal patients with addition of zoledronic acid, driven by a decrease in non-
skeletal distant recurrences. Moreover, using biochemical classification of menopause for 
women in whom clinical self reporting may be inaccurate (i.e <5 years since menopause 
or unknown menopausal status) in conjunction with clinical classification for 
premenopausal and established (>5 years) postmenopausal continues to show a trend for 
improved IDFS in postmenopausal patients. 
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Figure 3.4 Invasive disease free survival using a biochemical definition of 
postmenopausal or non postmenopausal for women <5 years postmenopausal or 
unknown and a clinical definition for all others. 
 
IDFS in non-postmenopausal patients (top) and postmenopausal patients (bottom). 
Menopause: treatment interaction p value 0.064. 
Zol vs no zol
HR 1.043 (95% CI 0.873-1.246)
Zol vs no zol
HR 0.806 (95% CI 0.657-0.990)
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3.5.4	  Predictive	  value	  of	  non-­‐postmenopausal	  versus	  postmenopausal	  levels	  of	  
FSH,	  oestradiol	  or	  inhibin	  A	  for	  IDFS	  outcomes	  with	  zoledronic	  acid. 
IDFS was similar with addition of zoledronic acid in patients with a high or low FSH 
(>26IU/l; HR 0.932 95%CI 0.657-1.321, ≤26IU/l; HR 0.872 95%CI 0.538-1.305).  
However in patients with baseline FSH ≤26IU/l, there was a trend to a decreased skeletal  
distant recurrence with zoledronic acid (HR 0.713 95%CI 0.381-1.334) but an increased 
non-skeletal distant recurrence (HR 1.314 95%CI 0.62-2.493).  This was mirrored in the 
IDFS outcomes with inhibin A and oestradiol, which negatively regulate FSH secretion; 
inhibin ≥3.6pg/ml showed a trend for an improved skeletal IDFS with zoledronic acid 
(HR 0.596 95%CI 0.3-1.185) but a worse non-skeletal IDFS (HR 1.504 95%CI 0.787-
2.874), oestradiol ≥50pmol/l showed a trend for an improved skeletal IDFS with 
zoledronic acid (HR 0.78 95%CI 0.430-1.416) but a worse non-skeletal IDFS (1.505 
95%CI 0.85-2.664)(Table 3.4). 
These data suggest no single hormone is predictive of an improvement in IDFS in bone or 
outside of bone with addition of zoledronic acid, but reproductive hormone levels in the 
non-postmenopausal range (low FSH, high inhibin and high oestradiol) continue to 
predict a worse extraskeletal IDFS with zoledronic acid as per the results of the main 
AZURE trial. 
3.5.5	   Prognostic	   value	   of	   pre-­‐	   versus	   postmenopausal	   levels	   of	   FSH,	   oestradiol	   or	  
inhibin	  A	  on	  bone	  recurrence	  and	  distant	  recurrence.	  	  	  
An FSH ≤26IU/l (non-postmenopausal) was borderline significant for a shorter time to 
bone as first recurrence compared to an FSH >26IU/l (HR 0.66 95%CI 0.41-1.04 
p=0.0721)(Fig 3.5). Inhibin A or oestradiol were not significantly associated with time to 
bone recurrence. An oestradiol <50pmol/l (postmenopausal) was borderline significant 
for a shorter time to distant recurrence (bone+non bone) compared to an oestradiol 
≥50pmol/l (HR 1.33 95%CI 0.98-1.82 p=0.0646) (Fig 3.6). Considering there was no 
significant difference in time to bone as first recurrence according to oestradiol levels, 
this effect of low oestradiol on a shorter time to distant recurrence may be driven by an 
increase in metastatic disease recurring outside of bone. Inhibin A or FSH were not 
significantly associated with time to distant recurrence.  
	  	  	  	  
	   98	  
 
 
 
 
 
Table 3.4 IDFS outcomes for zoledronic acid vs control in patients with high versus 
low serum levels of reproductive hormones. 
 
Outcomes are separated in to all IDFS events, skeletal distant recurrence and non-skeletal 
distant recurrence.  Hazard ratio (HR) >1 indicates risk of experiencing an event is greater 
in the zoledronic acid arm, HR <1 indicated risk of experiencing an event is greater in the 
control arm. 
 	  	  
	  	  
 
Hormone' All'IDFS'
HR'(95%CI)'
Skeletal'distant'
recurrence'
HR'(95%CI)'
Non>skeletal'distant'
recurrence'
HR'(95%CI)'
FSH$IU/l$
>26'
≤26'
'
0.932'(0.657>1.321)'
0.872'(0.583>1.305)'
'
1.008'(0.501>2.030)'
0.713'(0.381>1.334)'
'
1.170'(0.695>1.971)'
1.314'(0.62>2.493)'
Inhibin$A$pg/ml$
<3.6'
≥3.6'
'
0.943'(0.671>1.326)'
0.862'(0.571>1.302)'
'
1.086'(0.573>2.058)'
0.596'(0.3>1.185)'
'
1.080'(0.643>1.815)'
1.504'(0.787>2.874)'
Oestradiol$pmol/l$
<50'
≥50'
'
0.801'(0.542>1.184)'
0.993'(0.694>1.421)'
'
0.881'(0.416>1.866)'
0.781'(0.430>1.416)'
'
0.976'(0.548>1.738)'
1.505'(0.850>2.664)'
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Figure 3.5 Baseline FSH as a prognostic marker for bone recurrence.  
 
Time to bone as first recurrence in patients with serum FSH <26IU/l (blue line) vs 
>26IU/l (red line).  	  	   	  
FSH >26 vs≤26
Unadjusted HR 0.61 (95%CI 0.39-0.97) p=0.0355
Adjusted HR 0.66 (95%CI 0.41-1.04) p=0.0721
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Figure 3.6 Baseline oestradiol as a prognostic marker for distant recurrence.  
 
Time to distant recurrence as first event in patients with serum oestradiol <50pmol/l 
(red line) vs ≥50pmol/l (blue line)
Oestradiol <50 vs ≥ 50
Unadjusted HR1.25 (95%CI 0.93 -1.69) p=0.1447
Adjusted HR 1.33 (95%CI 0.98-1.81) p=0.0646
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3.5	  Discussion	  
 
 
These data show that clinical and biochemical classification of menopause do not always 
concur. However, in a heterogenous population of breast cancer patients biochemically 
classifying patients as postmenopausal using FSH, oestradiol and inhibin A, predicted the 
same trend of an improved IDFS with zoledronic acid as was shown in the main AZURE 
trial in patients who were clinically >5 years postmenopausal. No single hormone was 
predictive of a response to zoledronic acid, suggesting that either a combination of 
hormones or the overall ‘activity’ of the HPG axis influences the anti-tumour efficacy of 
zoledronic acid.  In addition, low pretreatment FSH and oestradiol may provide 
prognostic information on the risk of both bone and distant recurrence respectively.  
 
The disparity between clinical and biochemical classification of menopause in the 
AZURE breast cancer population was not unique to this population and has been 
demonstrated in healthy populations. Although longitudinal studies in healthy populations 
have characterized age specific mean hormone levels, the extrapolation of this to an 
individual is more challenging.  It is generally accepted that a single measurement of FSH 
or oestradiol in an individual may not a reliable way to stage menopause (Burger, Hale et 
al. 2008), given that ovarian function can fluctuate over time. This is especially of 
relevance in women in the years around final menstrual period (FMP), when hormonal 
measurements of FSH and oestradiol are unpredictable and variable (Burger 2011).  
AZURE did not collect serial serum samples and therefore only the baseline sample could 
be used to evaluate levels of FSH, oestradiol and inhibin A.  In the clinically 
premenopausal patients who appeared to be biochemically postmenopausal (n=31), only 1 
patient was > 44 years old.  Older premenopausal women have been shown to have an 
increasing frequency of anovulatory menstrual cycles compared to younger menstruating 
women (Hale, Zhao et al. 2007; Burger, Hale et al. 2008).  These anovulatory cycles have 
differing hormone profiles compared to ovulatory cycles and were biochemically 
characterized in a longitudinal study of menstruating women aged 45-47 (n=13) over 4-9 
years. As the women approached their FMP the menstrual cycles showed an increase in 
FSH and concurrently low inhibin and oestradiol (Landgren, Collins et al. 2004), a 
biochemical profile which is more consistent with a postmenopausal status. These data 
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therefore suggest that the older menstruating patients in the AZURE trial may have had 
biochemical hormone profiles that were more in keeping with a postmenopausal status.   
 
In the patients who were clinically >5 years postmenopausal, 43 (15.9%) had a 
biochemical profile that appeared non-postmenopausal due to any one of FSH, oestradiol 
or inhibin A not being within postmenopausal ranges. The majority of this group of 
patients failed to attain a biochemical classification of postmenopausal due to an 
oestradiol level >50 pmol/l (70%), rather than an inhibin A or FSH out of 
postmenopausal ranges.  This persistently elevated serum oestradiol in women many 
years postmenopausal has several potential explanations.  Firstly, the reproducibility of 
self reported age at natural menopause has been shown to diminish with increasing time 
since menopause (Colditz, Stampfer et al. 1987), and therefore inaccurate patient recall of 
the date of natural menopause may have resulted in some women <5 years since 
menopause self reporting a natural menopause >5 years previous. Secondly, the rate of 
change in individual serum hormone levels during the years around FMP are not 
analogous. Data from a longitudinal study (n=150) showed FSH increased 2 years prior to 
FMP with mean serum levels being within postmenopausal range at the time of FMP.  
Inhibins begun to decline several years prior to FMP and were undetectable in 50% of 
women at the time of FMP. However, oestradiol begun to fall at 1 year prior to FMP, but 
serum levels did not reach low stable nadirs until +2 to +5 years post FMP (Burger, 
Dudley et al. 1999), thus women up to +5 years post FMP may still have oestradiol levels 
that are higher than the cut point used in the AZURE trial for defining postmenopausal 
(<50pmol/l).  Thirdly, a raised body mass index (BMI) in postmenopausal women is 
associated with increased serum oestrogen (Folkerd and Dowsett 2013), due to elevated 
fat conversion of androgens to oestone via the enzyme aromatase (Nelson and Bulun 
2001).  The median (range) BMI in the AZURE patients >5 years postmenopausal with 
oestradiol levels ≥50pmol/l was higher (32.32; 22.76-53.58) than those with levels 
<50pmol/l (26.92; 19.22-47.8), indicating that a raised BMI in the patients >5 years 
postmenopausal may have contributed to an elevated oestradiol resulting in inaccurate 
biochemical classification of non-postmenopausal. 
 
These data suggest that a single biochemical evaluation of FSH, oestradiol and inhibin A 
should not solely be used to select postmenopausal patients for adjuvant zoledronic acid, 
but should be interpreted with consideration of patient reported clinical menopausal status. 
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However, despite the discrepancies between clinical and biochemical classification of 
menopausal status, when the serum AZURE population were solely biochemically 
classified as postmenopausal or non-postmenopausal irrespective of clinical classification, 
patients with a biochemical postmenopausal status continued to derive benefit from 
zoledronic acid.  The hazard ratios indicated a trend to an improved IDFS driven by a 
reduction in non-skeletal disease recurrence in biochemically postmenopausal patients, 
with the opposite trend in IDFS outcomes in biochemically non-postmenopausal patients. 
Therefore selecting patients for adjuvant zoledronic acid may be assisted by baseline 
evaluation of reproductive hormones to ensure that the population receiving the drug 
gains benefit, and patients who may experience a detrimental effect in terms of increased 
extra-skeletal recurrence are not exposed.   
 
The selection of patients for adjuvant zoledronic acid using a combination of both self 
reported clinical menopausal status and complementary biochemical evaluation of 
baseline reproductive hormones is not possible in patients with unknown clinical 
menopausal status for reasons such as a previous hysterectomy.  Using only biochemical 
serum levels of reproductive hormones to select premenopausal breast cancer patients 
with an unknown menopausal status for adjuvant goserelin+/- zoledronic acid has already 
been undertaken in the prospective randomized ABCSG-12 trial.  Eligibility criteria for 
trial entry included a menstrual bleed within the previous 12 months, and in patients who 
were of an unknown reproductive status, FSH and oestradiol at baseline were measured to 
confirm premenopausal ranges prior to initiation of goserelin + endocrine therapy+/- 
zoledronic acid (Gnant, Mlineritsch et al. 2011).  As discussed previously (section 1.3.1), 
zoledronic acid improved DFS in this trial.  In the AZURE serum population, a 
biochemical classification of patients with unknown menopausal status or <5 years since 
menopause, in conjunction with self reported clinical menopausal status for all other 
patients continued to show the same trend for a reduction in invasive disease recurrence 
with addition of zoledronic acid in postmenopausal patients.  These data suggested that 
biochemical evaluation alone may be able to select patients for adjuvant zoledronic acid 
with a clinically unknown menopausal status or within 5 years since menopause.  
However the number of IDFS events in this group was small (n=44) and therefore the 
overall results were dominated by the IDFS outcomes from the clinically classified 
patients. Longitudinal data evaluating the dynamic changes in serum hormones in the 
years either side of the final menstrual period have shown that it is not until +5 years post 
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FMP that hormone levels stabilise (Burger, Dudley et al. 2002), suggesting that serial 
measurements of reproductive hormones would likely be needed when using biochemical 
classification alone in selecting this subgroup of patients for adjuvant zoledronic acid.  
 
The results presented so far suggested that a reproductive hormone profile consisting of 
FSH, oestradiol and inhibin A could select patients with improved IDFS outcomes with 
zoledronic acid.  Further evaluation of high versus low levels of each individual hormone 
as a predictor of response to zoledronic acid showed that no single hormone was affecting 
the anti-tumour efficacy of zoledronic acid. Therefore, it appears to be the overall activity 
of the HPG axis that is influencing the efficacy of zoledronic acid. Consideration of the 
different reproductive profiles from the AZURE trial compared to the ABCSG-12 trial 
indicate that oestradiol and/or inhibin A may be more important in influencing outcomes 
with adjuvant zoledronic acid than FSH. In the ABCSG-12 trial all patients received 
goserelin, with chemically induced low levels of FSH, oestradiol and inhibins, and 
demonstrated an improvement in DFS both in bone and outside of bone with zoledronic 
acid (Gnant, Mlineritsch et al. 2011).  In AZURE, the patient population that derived 
improvements in DFS and OS were >5 years postmenopausal and therefore had high FSH 
levels in addition to low oestradiol and inhibins. These data suggest that the ovarian 
hormones oestradiol and/or inhibin A may be more important in affecting the anti-tumour 
efficacy of zoledronic acid.  This is in part supported by a pre planned subset analysis of 
ABCSG-12 by patient age at study entry. Zoledronic acid did not significantly reduce the 
relative risk of DFS events in women aged <40 years (n=413) (HR 0.94, 95% CI 0.57-
1.56), but did in women aged >40 years (n=1390) (HR 0.58, 95% CI 0.40-0.84) (Gnant, 
Mlineritsch et al. 2011), possibly due to inadequate suppression of ovarian function with 
goseralin in a younger cohort of patients. 
 
The beneficial effect of zoledronic acid in a low oestradiol environment is also supported 
by the ZO-FAST trial (n=1065) that recruited postmenopausal women and randomized to 
early zoledronic acid+letrozole started at diagnosis, or delayed zoledronic acid started at 
the time of significant bone loss (median 12.8 months).  Early zoledronic acid was 
associated with a 34% reduction in the risk of disease recurrence (local and distant) or 
death at 60 months, and the reduction in distant disease recurrence was primarily in bone, 
but also showed a trend to fewer recurrences outside bone (Coleman, de Boer et al. 2013).   
Moreover, the beneficial effect of early zoledronic acid versus delayed on overall survival 
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in this postmenopausal population was driven by women who were >5 years since 
menopause or aged >60 years compared to recently postmenopausal women (HR 0.5 
p=0.0224), supporting the theory that women with stable very low levels of oestradiol 
may be deriving the most benefit from adjuvant bisphosphonates both in bone and outside 
of bone. 
 
Although baseline levels of individual hormones were not predictive of a response to 
zoledronic acid, they did appear to have a prognostic role in identifying patients at 
increased risk of bone and distant recurrence.  Premenopausal pretreatment levels of FSH 
(<26IU/l) were borderline prognostic for a shorter time to bone recurrence.  This finding 
is supported by clinical studies evaluating the presence of DTCs from breast cancer in the 
bone marrow at diagnosis. A large meta-analysis (n=4700) of the prevalance of bone 
marrow DTCs demonstrated that premenopausal patients had a significantly higher 
prevalence compared to postmenopausal women (premenopausal 32.7%, post 
menopausal 29.5% p=0.02)(Braun, Vogl et al. 2005), suggesting premenopausal bone 
may be more attractive to tumour cells. In addition, data on recurrence patterns of 6792 
breast cancer patients entered into trials conducted by the International Breast Cancer 
Study Group showed that younger patients (<35 years) had significantly higher 
incidences of bone metastases occurring during the course of their disease, however when 
patients were categorized according to pre- or postmenopausal status there was no 
significant difference in rates of bone metastases (Colleoni, O'Neill et al. 2000).  These 
data suggest that very young women, who would be expected to have low FSH levels, 
have a higher incidence of bone metastases.  However, categorizing patients as 
premenopausal would include both young and older menstruating women and it is likely 
that average FSH levels in this group would be higher than women <35 years, with 
subsequent loss of a significant effect on bone recurrence rates.  Smaller studies have 
both supported and refuted these results.  Eskelinen et al correlated baseline FSH levels to 
DFS and OS in premenopausal (n=182) and postmenopausal (n=570) women treated for 
primary invasive breast cancer.  There was a trend to a lower probability of survival with 
lower FSH levels in premenopausal women (Eskelinen, Norden et al. 2004).  Pujol et al 
reported a prospective evaluation of baseline FSH in premenopausal (n=360) breast 
cancer patients and showed a trend for worse outcomes with higher FSH levels (Pujol, 
Daures et al. 2001).  It is therefore not clear from existing evidence whether FSH is a true 
prognostic marker for DFS in breast cancer, however our data suggest that a low FSH 
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may be more important as a prognostic marker specifically for bone recurrence.  This 
requires further investigation, especially considering the data supporting the anti-tumour 
efficacy of adjuvant zoledronic in conjunction with goseralin in premenopausal (low 
FSH) patients (Gnant, Mlineritsch et al. 2011). 
   
Postmenopausal levels of oestradiol (<50pmol/l) were borderline prognostic for a shorter 
time to distant (bone + non bone) recurrence which may be driven by increased non bone 
recurrence, suggesting that postmenopausal bone may be less attractive for DTCs and 
they may preferentially spread to non-skeletal sites. These data are supported by a large 
(n=9766) retrospective analysis of recurrence rates in postmenopausal ER+ve breast 
cancer patients treated with adjuvant endocrine therapy. An increased risk of distant but 
not locoregional recurrence with increasing age at diagnosis was found (van de Water, 
Seynaeve et al. 2013).  Although baseline oestradiol was not measured in this study, 
serum levels would be expected to progressively fall with increasing age and may have 
contributed to the increase in distant recurrence. This study also showed less use of 
systemic chemotherapy with increasing age (van de Water, Seynaeve et al. 2013).  The 
percentage of AZURE patients receiving chemotherapy+/- endocrine therapy was similar 
according to baseline oestradiol levels (Table 3.6), suggesting that time to distant 
recurrence was not influenced by differential administration of systemic therapy. These 
data imply that reproductive hormones may influence the survival of DTCs in the bone 
microenvironment.  These DTCs, under hormonal influences, could subsequently form 
established bone metastases, or move to other distant sites. The effects of reproductive 
hormones on the bone microenvironment may be direct via modification of the size of the 
osteoblastic niche (Shiozawa, Havens et al. 2008), or indirect via interactions with 
paracrine tumour suppressors such as activin and TGFβ (Wilson, Holen et al. 2012).  This 
requires further investigation in order to identify the cellular and molecular mechanisms.  	  
In conclusion, biochemical menopausal categorisation should not replace, but may 
complement, clinical categorisation in a mixed heterogenous breast cancer population 
considered for adjuvant zoledronic acid. Selecting biochemically postmenopausal patients 
from women with a clinically unknown menopausal status or within 5 years of 
menopause, for adjuvant treatment with zoledronic acid may be possible, but is likely to 
require serial measurements rather than a single evaluation. The anti-tumour efficacy of 
zoledronic acid is more likely to be affected by ovarian hormones rather than pituitary 
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Table 3.5 Baseline characteristics according to oestradiol levels in the AZURE 
serum population 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Oestradiol+<50pmol/l+
N(%)+
Oestradiol+≥+50pmol/l+
N(%)+
Tumour+stage+
T1#
T2#
T3#
T4#
#
109#(33.9)#
163#(50.6)#
42#(13)#
8#(2.5)#
#
141#(29.3)#
237#(49.2)#
83#(17.2)#
21#(4.4)#
Systemic+therapy+
Endocrine#therapy#
Chemotherapy#
Endocrine+chemotherapy#
#
10#(3.1)#
77#(23.9)#
235#(73)#
#
#
2#(0.4)#
104#(21.6)#
376#(78)#
ER+status+
PosiBve#
NegaBve#
#
243#(75.5)#
78#(24.2)#
#
376#(78)#
104#(21.6)#
Lymph+node+involvement+
0#
1F3#nodes#involved#
≥#4#nodes#involved#
#
3#(0.9)#
202#(62.7)#
117#(36.3)#
#
13#(2.7)#
282#(58.5)#
185#(38.4)#
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hormones, but in our analysis no single level of individual hormone was predictive of a 
response to zoledronic acid.  The concept of pretreatment levels of FSH and oestradiol 
having prognostic value in identifying patients at increased risk of bone or distant 
recurrence requires further investigation before this could be used to tailor adjuvant 
treatment.  
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Chapter	  4.	  Neo-­‐adjuvant	  zoledronic	  
acid	  alters	  serum	  levels	  of	  activin,	  
follistatin	  and	  TGFβ 	  when	  added	  to	  
standard	  chemotherapy	  for	  breast	  
cancer.	  
An	  ANZAC	  sub-­‐study.	  	   	  
	  	  	  	  
	   110	  
4.1	  Summary	  	  
 As previously described in chapter 1, neo-adjuvant breast cancer clinical trials have 
suggested that zoledronic acid may have an anti-tumour effect, and can improve 
pathological response in breast tumours, when combined with chemotherapy.  The 
efficacy of zoledronic acid in early breast cancer appears to be enhanced in certain 
subgroups including postmenopausal women and women with oestrogen receptor (ER) 
negative breast cancer.  
 
Inhibin A is an ovarian hormone that declines to undetectable levels at the time of the 
final menstrual period.  Inhibin A is a member of the TGFβ superfamily of signaling 
peptides, which includes activin and TGFβ.  Activin and TGFβ are secreted by breast 
cancer cells, with the former peptide being a tumour suppressor, and the latter having 
both tumour suppressive and promoter actions depending on the stage of tumourigenesis.  
Activin is bound to follistatin, which neutralizes its biological activity, therefore to 
evaluate levels of ‘biologically active’ activin, follistatin levels must be concurrently 
assessed. 
 
The ANZAC study randomised 40 women to receive zoledronic acid 4mg IV, 24 hours 
after the first cycle of FEC100 neo-adjuvant chemotherapy versus chemotherapy alone, to 
evaluate change in tumour apoptosis from baseline to day 5 in serial breast biopsies. 
Serum was collected at baseline, day 5 and 21 post administration of zoledronic acid.  
The effects of zoledronic acid on serum levels of activin, follistatin and TGFβ were 
evaluated in the overall population and in subgroups according to menopausal status and 
ER status of primary tumour. 
 
 Serum follistatin significantly fell in the overall study population from baseline to day 21 
with the addition of zoledronic acid to chemotherapy.  This change was driven by 
postmenopausal women, since premenopausal women showed no significant change in 
follistatin at day 21 with addition of zoledronic acid. Patients with ER-ve tumours had a 
significant fall in serum follistatin from baseline to day 5 with addition of zoledronic acid 
to chemotherapy, an effect not seen in patients with ER+ve tumours.  
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These novel data suggest that zoledronic acid can reduce serum follistatin, which 
antagonizes the anti-proliferative effects of activin, and this may lead to an enhanced anti-
tumour effect in postmenopausal and ER-ve patients.   
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4.2	  Introduction	  	  
There is a wealth of preclinical data demonstrating that zoledronic acid has direct anti-
tumour effects both in vitro and in vivo, as discussed in chapter 1. Zoledronic acid has 
demonstrated a synergistic anti-tumour effect when used in combination with 
anthracycline chemotherapy.  Maximal tumour cell apoptosis was achieved in ER+ve 
(MCF7) and ER-ve (MDA-MB-436) cell lines when zoledronic acid was given 
immediately after treatment with doxorubicin. (Neville-Webbe, Rostami-Hodjegan et al. 
2005).  This sequence dependent effect was confirmed in vivo in a sub-cutaneous 
xenograft model of ER-ve MDA-MB-436 tumours.  Treatment with doxorubicin and 
clinically relevant doses of zoledronic acid (100µg/kg) simultaneously decreased tumour 
volumes compared to doxorubicin alone or zoledronic acid alone, However, doxorubicin 
followed 24 hours later by zoledronic acid resulted in almost total tumour regression 
(Ottewell, Monkkonen et al. 2008).  
  
Zoledronic acid, when administered clinically at 4mg IV, results in a peak plasma 
concentration of ~2µM, which subsequently falls to ~0.1µM at 4 hours and <0.05µM at 8 
hours (Spencer, Roberts et al. 2008).  In situ primary breast tumours, will therefore be 
exposed to a low concentration of zoledronic acid at the time of administration.  Despite 
this there is emerging clinical evidence that, when combined with anti-cancer therapy, 
these low doses of zoledronic acid can exert an anti-tumour effect outside of bone.  
 
Neo-AZURE was a retrospective evaluation of a subgroup of 205 women in the AZURE 
trial that received neo-adjuvant chemotherapy (CT) +/- zoledronic acid (zol).  The 
primary endpoint was residual invasive tumour size (RITS).  Zoledronic acid significantly 
reduced RITS when added to chemotherapy (RITS; ZOL+CT 15.5mm, CT 27.4mm 
p=0.006).  Multivariate analysis demonstrated a trend for a higher efficacy of zoledronic 
acid in reducing RITS in ER-ve tumours vs ER+ve tumours (p=0.0609) (Coleman, 
Winter et al. 2010).  These data have been supported by Aft et al, who randomized 119 
patients to perioperative CT +/- ZOL q3/52 for 1 year.  Disease free survival (DFS) and 
overall survival (OS) were not different between groups in the overall population, 
however, patients with ER-ve tumours had a significant reduction in disease recurrence 
and death with addition of zoledronic acid (DFS; HR=0.361, 95% CI 0.148 to 0.88: OS; 
HR= 0.375, 95% CI 0.143 to 0.985)(Aft, Naughton et al. 2012). 
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The reasons for the differential effect of zoledronic acid according to menopausal status 
and ER status demonstrated in (neo)adjuvant clinical trials have not been defined.  The 
differences between a premenopausal woman and a postmenopausal woman have been 
extensively discussed previously (chapter 3), and for the remainder of my research I 
chose to focus on the role of inhibin A as a potential endocrine modifier of the anti-
tumour efficacy of zoledronic acid.  Inhibins are members of the TGFβ super-family of 
signaling peptides, are secreted by functioning ovaries, and are detectable in serum of 
premenopausal women but decline to undetectable levels in postmenopausal women as 
previously discussed in chapter 3.  Inhibins are heterodimeric proteins consisting of a 
dimer of 2 subunits; an α subunit and either a βA or βB subunit to form the respective 
inhibin A or B. There is no known downstream intracellular signaling pathway for the 
inhibins (Bilandzic and Stenvers 2011), and thus the molecular mechanism of action is 
via inhibition of receptor binding of other TGFβ superfamily ligands including activin 
and TGFβ, which are abundant in many tissues, including bone (Ogawa, Schmidt et al. 
1992; Iqbal, Sun et al. 2009).  
Both activin and TGFβ1 have paracrine tumour modifying effects in breast cancer.  
Activin is secreted by breast cancer cell lines in vitro and inhibits proliferation 
(Kalkhoven, Roelen et al. 1995; Cocolakis, Lemay et al. 2001).  In addition, in clinical 
breast tumour samples, as grade of tumour increases, there is loss of functioning activin 
pathways (Jeruss, Sturgis et al. 2003). Activin is bound to follistatin, a single chain 
glycosylated polypeptide, which neutralizes the biological activity of activin thus 
preventing its tumour suppressive activity (Shimonaka, Inouye et al. 1991).  TGFβ1 is 
secreted by breast cancer cell lines in vitro, and has been shown to have both an 
inhibitory and promoting effect on breast tumour development in mouse models (Yang, 
Dukhanina et al. 2002; Forrester, Chytil et al. 2005).   
Inhibin therefore has relevant effects in breast cancer via its modification of these 
associated paracrine factors, However, it is not known if zoledronic acid can directly 
affect activin, follistatin or TGFβ1 in breast cancer, or if the effects of zoledronic acid on 
these factors may be different in an inhibin rich (premenopausal) vs inhibin poor 
(postmenopausal) endocrine environment. 
 
ANZAC (A Randomised phase II feasibility study investigating the biological effects of 
the AdditioN of Zoledronic Acid to neo-adjuvant combination Chemotherapy on invasive 
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breast cancer) was a prospective randomized phase II feasibility study designed and run 
by Dr Matthew Winter at Sheffield University 2009-2011.  ANZAC was designed to 
evaluate the synergistic anti-tumour effects of chemotherapy and zoledronic acid in 40 
breast cancer patients (pre- and postmenopausal) receiving zoledronic acid 4mg IV 24 
hours after receiving first cycle of neo-adjuvant FEC100 chemotherapy.  The primary 
objectives of this study were to evaluate change in apoptosis between the diagnostic core 
biopsy and an additional biopsy at day 5-post treatment.  Secondary objectives included 
the evaluation of ki67 on repeat core biopsies and serum angiogenesis biomarkers at 
baseline, day 5 and day 21. Stored serum allowed evaluation of serum activin A, TGFβ1 
and follistatin at baseline, and subsequent time points after administration of CT+/- 
zoledronic acid, in premenopausal/high inhibin (n=18) and postmenopausal/low inhibin 
(n=22) patients.  Further evaluation of serum levels, according to ER status of the primary 
breast tumour, was also possible since this information was collected at baseline as part of 
the main study. 
 
To my knowledge, there have been no clinical studies evaluating changes in serum levels 
of activin, TGFβ1 or follistatin with addition of zoledronic acid to neo-adjuvant 
chemotherapy in early breast cancer.  The new information in this chapter shows that 
zoledronic acid can affect serum levels of follistatin, activin and TGFβ1 when added to 
standard neo-adjuvant chemotherapy.  The fall in follistatin at day 21 was driven by 
postmenopausal women, who also have a concurrent increase in serum activin, thus 
increasing the bioavailability of this tumour suppressor in serum in this subgroup.  There 
was also an early fall in follistatin at day 5 in patients with ER-ve tumours, However, the 
numbers in these analyses are small and require further investigation in a larger cohort of 
patients.
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4.3	  Aims  
 
The overall purpose of this chapter was to assess serum samples from the ANZAC study 
to evaluate whether zoledronic acid, whan added to standard chemotherapy, can alter 
serum levels of activin, follistatin and TGFβ1, and if menopausal status or oestrogen 
receptor (ER) status can modify this.  The following aims were set; 
 
 
1. Evaluate if zoledronic acid alters levels of activin, follistatin or TGFβ1 in the 
overall study population. 
 
2. Evaluate if zoledronic acid alters serum levels of activin, follistatin or TGFβ1 
differentially, according to menopausal status of patients. 
 
3. Assess if zoledronic acid alters serum levels of activin, follistatin or TGFβ1 
differentially, according to ER status of primary tumours 
 
4. Determine if serum levels of activin, follistatin or TGFβ1 correlate with growth 
index (ki67/apoptosis) of primary breast tumours. 
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4.4	  Patients	  and	  Methods	  	  
4.4.1	  Ethical	  approval	  
This study was approved by the South Yorkshire National Research Ethics committee, 
with a favorable outcome obtained on the 4th August 2011 (REC ref no; 11/YH/0259). 
4.4.2	  Study	  population	  
This study was a retrospective analysis of serum from patients recruited into the ANZAC 
trial.  ANZAC was a single centre open label randomized phase II feasibility study.  
Patients had a histological diagnosis of invasive breast cancer and were recommended for 
neo-adjuvant chemotherapy.  Standard neo-adjuvant chemotherapy was FEC100 
(Fluorouracil 500mg/m2, Epirubicin 100mg/m2 and Cyclophosphamide 500mg/m2 all 
administered day 1 of a 3 week cycle) x3 followed by Docetaxel  (100mg/m2 day 1 of a 3 
week cycle) x3.  Patients were randomized on a 1:1 basis to addition of zoledronic acid 
4mg IV to be administered 24 hours after the first cycle of FEC100 (Fig 4.1).  Repeat core 
biopsies were scheduled for day 5 and 21 and serum was collected at baseline, and at the 
time of repeat core biopsies.  For this retrospective analysis, serum was evaluated for the 
proteins of interest, and any correlations to tumour proliferation characteristics were done 
using previously scored immunohistochemistry results from tumour sections from the 
original ANZAC study, sections were not re-scored for the purpose of this sub-study  
4.4.3	  Inclusion	  and	  exclusion	  criteria	  
Inclusion and exclusion criteria for the main ANZAC trial have been previously 
published, but are summarized in table 4.1 (Winter, Wilson et al. 2013). 
Inclusion criteria for retrospective study;  
• Recruited into the ANZAC trial (A randomized phase II feasibility study 
investigating the biological effects of the AdditioN of Zoledronic Acid to neo-
adjuvant combination Chemotherapy on invasive breast cancer). EudraCT 
number; 2007-001526-27. 
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Figure 4.1 ANZAC trial schematic.   
 
40 patients with histologically confirmed breast cancer and recommended for neo-
adjuvant therapy were randomised to receive first cycle of FEC100 chemotherapy +/- 
addition of zoledronic acid 24 hours post chemotherapy.  Serum was collected at baseline, 
day 5 and day 21 and was available from the majority of patients for this sub-study. 	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Table 4.1 Inclusion and exclusion criteria for the ANZAC study 
	  
	  
	  
  
  
Inclusion)criteria) Exclusion)criteria)
Histological*diagnosis*of*invasive*
breast*cancer*
T0*T1*tumours*
T2*tumour*or*above* Previous*chemotherapy*or*radiotherapy*to*treated*breast*
Recommended*for*neo=adjuvant*
chemotherapy*
Previous*diagnosis*of*malignancy*unless*contralateral*breast*cancer*oﬀ*all*treatment*for*>6*
months,*disease*free*for*5*years,*non*melanomatous*skin*cancer*or*carcinoma*of*the*uterine*
cervix*treated*curaFvely*
Any*hormone*or*HER2*status* Serum*creaFnine*>1.5*x*upper*limit*of*normal*reference*range*or*calculated*creaFnine*clearance*
<40mls/min*
Age*>18* Prior*treatment*with*bisphosphonates*in*the*last*year*
Reliable*method*of*contracepFon*
if*appropriate*
Concurrent*tamoxifen*or*aromatase*inhibitors*
WHO*PS*0=2* On*anFcoagulaFon*including*warfarin*or*coumarin*derivaFves*
Conﬁrmed*core*biopsy*at*baseline*
and*consent*to*addiFonal*core*
biopsy*
Known*hypersensiFvity*to*bisphosphonates*
WriUen*informed*consent* Current*acFve*dental*problems*
Recent*or*planned*dental*surgery*
Pregnant*or*lactaFng*women*
Cardiac*dysfuncFon*that*precludes*anthracycline*chemotherapy*
Males*
Unwilling*to*have*repeat*breast*biopsies*
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• Serum stored at Cancer Clinical Trials Unit, Sheffield, UK and collected 
according to the ANZAC study laboratory protocol. 
• Confirmed written consent to storage and analysis of serum. 
Exclusion criteria for retrospective study; 
• No written consent to storage and analysis of serum 
• Inadequate volume of serum for analysis 
4.4.4	  Storage	  and	  transport	  of	  ANZAC	  serum	  
All serum samples were stored at the Cancer Clinical Trials Unit, Weston Park Hospital, 
Sheffield, UK.  Samples were stored at -80oC.  All samples sent for analysis had 
undergone ≤1 freeze thaw cycle.  Transport of samples between the trials unit and the 
medical school laboratory was on dry ice to prevent numerous freeze thaw cycles prior to 
analysis. 
4.4.5	  Analyses	  of	  proteins.	  
All protein analyses were performed by myself, with supervision from Mrs Alyson Evans, 
a senior technician in the laboratory team.  Inhibin A, activin A, follistatin and TGFβ1 
were analysed on manual ELISA plates purchased from R&D (see section 2.2.6 for 
minimum detection limits).  Serum was fully defrosted prior to use and aliquoted into 
quantities specific for each ELISA to reduce freeze thaw cycles.   All samples from 
individual patients were analysed in the same run.  Standard curves were included on 
each plate; samples were analysed in duplicate with CVs <15%. 
FSH analysis was performed on the automated Roche 602 Elecsys 
electrochemiluminescence immunoassay at the Clinical Chemistry Laboratory Sheffield 
Teaching Hospitals.  FSH levels were standardized to the second International Reference 
Preparation 78/549. For assay precision and quality control data see chapter 3, table 3.1. 
4.4.6	   Data	   collection	   from	   ANZAC	   database,	   and	   correlation	   with	   serum	  
measurements.	  
Demographic, treatment and outcome data for all patients recruited to ANZAC was held 
on a password protected database by the Chief Investigator, Dr Matthew Winter.  
Permission for access to this database was given.  The following data was extracted for 
	  	  	  	  
	   120	  
the analyses; 
1. Patient characteristics at randomisation; 
• Trial number 
• Age  
• Clinical menopausal status; premenopausal vs. postmenopausal 
2. Disease characteristics at randomization; 
• ER status; Positive vs. negative 
3. Treatment characteristics; 
• Randomised to: Interventional arm (zoledronic acid) or control arm (no zoledronic 
acid) 
4. Disease outcomes; 
• Growth index of tumours at baseline, day 5 and day 21. Growth index was a ratio 
of Ki67/apoptosis (%) measured on the biopsy samples as part of the ANZAC trial, 
methodology described in the published paper (Winter, Wilson et al. 2013) 
The data collected on the serum analysis was entered in an Excel spreadsheet and 
combined with the data extracted from the main ANZAC database. 
4.4.7	  Statistical	  methodology	  
All statistical analysis was performed by myself using Graphpad PRISM v6.0 software.  
For comparison of treatment groups, the nonparametric Mann Whitney U test was 
performed.  For correlation analysis, Spearmen’s nonparametric correlation coefficient 
was performed. 
4.4.8	  Funding	  and	  publication	  
The cost of the serum analyses were funded by a grant from Weston Park Cancer Charity 
awarded to myself, as main applicant, on the 27th March 2012.  The results of this 
analysis have been published in Clinical Cancer Research in 2013 (Winter, Wilson et al. 
2013). 
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4.5	  Results 	  
4.5.1	  Patient	  samples	  available	  for	  analysis.	  
Baseline demographic data according to treatment received has previously been published 
(table 4.2).  For these analyses, >95% of patients had sufficient stored serum for 
evaluation of activin, follistatin and TGFβ at baseline, day 5 and day 21. All serum levels 
were within assay detection ranges.   
Baseline levels of activin, follistatin, TGFβ and inhibin A were not significantly different 
according to treatment group or ER status.  Baseline activin, follistatin and TGFβ were 
not significantly different according to menopausal status, However, as expected, inhibin 
A was significantly different. Baseline median (range) inhibin A levels in pre- and 
postmenopausal patients were 27.9pg/ml (5.1-171.3) and 5.8pg/ml (0.7-17.6) respectively, 
with a persistent lower level in postmenopausal women at all other timepoints (Pre- vs. 
postmenopausal, Day 5; 21.90 pg/ml (4.78-70.5) vs. 7.6 pg/ml (0.9-29.8), Day 21; 11.95 
pg/ml (1.4-61.4) vs. 5.4 pg/ml (0.1-14.9). This was statistically significant with mean 
difference in AUC (pre-post): 16.9 pg/ml, 95% CI: 9.1, 24.6, P<0.001.   
Median inhibin A levels significantly declined in premenopausal patients from baseline to 
day 21 (p=0.0016), suggesting that chemotherapy may decrease serum inhibin A levels in 
premenopausal patients (Fig 4.2) 
 
4.5.2	  Effect	  of	  zoledronic	  acid	  in	  the	  overall	  study	  population.	  
4.5.2.1	  Serum	  activin	  	  
Figure 4.3 shows the change in serum activin levels over time for each individual patient 
treated with CT alone or CT+ZOL. There was a consistent fall in serum activin from 
baseline to day 5 in 98% of all patients.  By day 21, 45% (9/20) and 65% (13/20) of 
patients treated with CT alone or CT+ZOL had recovered activin levels to higher than 
baseline (Fig 4.4).  Addition of zoledronic acid to chemotherapy did not significantly 
affect the changes in activin from baseline to day 5 or baseline to day 21 (Median change 
from baseline pg/ml; Day 5, CT -116 (IQR -166 to -85) CT+ZOL -98 (IQR -142 to -69) p 
value 0.2853.  Day 21, CT -2.5 (IQR -50 to +38) CT+ZOL +44.6 (IQR -9 to +87) p value 
0.0764) suggesting chemotherapy may be driving the changes in serum activin (Table 
4.4). 
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Table 4.2.  Baseline clinico-pathological characteristics of patients enrolled in the 
ANZAC study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table reproduced with permission from Dr Matthew Winter. MD thesis August 2011; Translational and 
clinical evaluation of chemotherapy and zoledronic acid in early invasive breast cancer, Sheffield 
University 
 
 
ER status was defined as positive based on a McCarthy’s H score ≥50 
 
   
 
 
 
 
 
 
 
 
 
 
        
 
Chemotherapy alone 
 
n=20 (%) 
Chemotherapy + 
Zoledronic acid 
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Figure 4.2 Effect of menopausal status on serum inhibin A levels.   
 
Data represents median +IQR serum inhibin A levels at baseline, day 5 and day 21 in pre- 
and postmenopausal women treated with chemotherapy (CT) alone or CT+ Zoledronic 
acid (ZOL).  Mean difference in area under the curve analysis for pre and postmenopausal 
women p value<0.001. 
  
Premenopausal
Ba
se
lin
e
Da
y 5
Da
y 2
1
0
20
40
60
M
ed
ia
n 
in
hi
bi
n 
+I
Q
R
 (p
g/
m
l)
 CT alone
 CT +ZOL
Postmenopausal
Ba
se
lin
e
Da
y 5
Da
y 2
1
0
20
40
60
M
ed
ia
n 
in
hi
bi
n 
+I
Q
R
 (p
g/
m
l)
CT alone
 CT + ZOL
	  	  	  	  
	   124	  
	  
 
Figure 4.3 Changes in serum activin levels over time according to treatment received. 
 
Data represents serum levels per patient to demonstrate change in serum level over time 
in patients receiving chemotherapy (CT) alone (top) and chemotherapy plus zoledronic 
acid (CT+ZOL) (bottom). 
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Figure 4.4. Percentage change in serum activin from baseline for individual patients.   
 
Data represent individual percentage change for individual patients from baseline to day 5 
(top) and baseline to day 21 (bottom). Inset represents median percentage change +IQR 
per treatment group.  
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Table 4.4 Changes in serum activin from baseline to day 5 and baseline to day 21 
according to treatment received in the overall study population.  
 
Data represent median (IQR) change from baseline, Mann Whitney U test to compare CT 
with CT+ZOL for each time-point measurement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	   	  
Time-point 
measurement of 
Activin 
Treatment 
group 
Median 
change 
IQR P value 
Baseline to day 5 
pg/ml 
CT 
CT+ZOL 
-116 
-98 
-166 to -85 
-142 to -69 
0.2853 
Baseline to day 5 
%  
CT 
CT+ZOL 
-38.1 
-39.2 
-54 to -31 
-45 to -21 
0.3793 
Baseline to day 21 
pg/ml 
CT 
CT+ZOL 
-2.5 
+44.6 
-50 to +38 
-9 to + 87 
0.0764 
Baseline to day 21 
%  
CT 
CT+ZOL 
-0.07 
14.26 
-16 to 15.9 
-3 to +29 
0.081 
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4.5.2.2	  Serum	  follistatin	  
Figure 4.5 shows the change in serum follistatin over time for each individual patient 
treated with CT alone and CT +ZOL.  The changes in serum follistatin from baseline to 
day 5 were similar in both treatment groups with 45% (9/20) and 60% (12/20) in the CT 
and CT+ZOL groups showing a decrease in follistatin, and the remainder of patients 
showing either no change or an increase in follistatin.  At day 21 however, zoledronic 
acid appeared to be having an effect on serum follistatin, with more patients treated with 
CT+ZOL (80%) showing a decrease in follistatin compared to baseline than CT alone 
(40%)(Fig 4.6).  Median change in follistatin from baseline to day 21 was significantly 
different between the two treatment groups (Median change pg/ml; CT alone 94.8 (IQR -
173 to 432), CT+ZOL group -348 (IQR -886 to +3.5, p value 0.004) (Table 4.5).  These 
data suggest that zoledronic acid, rather than chemotherapy, may be affecting serum 
follistatin at day 21. 
 
4.5.2.3	  Serum	  TGFβ1	  
Figure 4.7 shows the change in serum TGFβ1 over time for each individual patient 
treated with CT alone and CT+ZOL.  Changes in TGFβ1 from baseline to day 5 showed a 
similar pattern to follistatin in that changes were similar between both treatment groups, 
with 60% (12/20) and 50% (10/20) in the CT and CT+ZOL groups having a decrease in 
TGFβ.  At day 21 however, zoledronic acid appeared to be affecting serum TGFβ1 with 
more patients treated with CT+ZOL (85%) showing an increase in serum TGFβ1 
compared to baseline than CT alone  (60%) (Fig 4.8). Median change in TGFβ1 from 
baseline at day 21 was significantly different between the two treatment groups (Median 
change pg/ml; CT alone 5025 (IQR -891 to 9293), CT+ZOL 12259 (IQR +5346 to 
+17934) p value 0.0294)(Table 4.6). These data suggest that zoledronic acid may be 
affecting TGFβ1 levels at day 21. 
 
All together, these data suggest that chemotherapy drives changes in serum activin 
however, zoledronic acid may be directly affecting serum levels of follistatin and TGFβ1 
21 days post administration.  
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Figure 4.5 Changes in serum follistatin over time according to treatment received. 	  
 
Data represents serum levels per patient to demonstrate change in serum level over time 
in patients receiving chemotherapy alone (top) and chemotherapy plus zoledronic acid 
(bottom). 
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Figure 4.6. Percentage change in serum follistatin from baseline for individual 
patients. 
 
Data represents individual percentage change for each patient from baseline to day 5 (top) 
and baseline to day 21 (bottom). Inset represents median percentage change +IQR per 
treatment group.  
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Table 4.5 Changes in serum follistatin from baseline to day 5 and baseline to day 21 
according to treatment received for the overall study population.  
 
 
 
 
 
Data represents median (IQR) change from baseline.  Mann Whitney U test to compare CT 
with CT+ZOL for each time-point measurement. * p value <0.05 
 
 
 
Time-point 
measurement of 
Follistatin 
Treatment 
group 
Median 
change 
IQR P value 
Baseline to day 5 
pg/ml 
CT 
CT+ZOL 
+133 
-242 
-193 to 423 
-591 to 418 
0.0962 
Baseline to day 5 
% change 
CT 
CT+ZOL 
+8.2 
-15.61 
-11 to 30 
-27 to 38 
0.1914 
Baseline to day 21 
pg/ml 
CT 
CT+ZOL 
94.8 
-348.2 
-173 to 432 
-886 to 3.5 
0.004* 
Baseline to day 21 
% change 
CT 
CT+ZOL 
3.68 
-23.71 
-11 to 40.2 
-50 to 0.73 
0.0205* 
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Figure 4.7 Changes in serum TGFβ1 time accoding to treatment received. 	  
 
Data represents serum levels per patient to demonstrate change in serum level over time 
in patients receiving chemotherapy alone (top) and chemotherapy plus zoledronic acid 
(bottom). 
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Figure 4.8. Percentage change in serum TGFβ1 from baseline for individual patients 
  
Data represents individual percentage change for each patient from baseline to day 5 (top) 
and baseline to day 21 (bottom). Inset represents median percentage change +IQR per 
treatment group. 
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Table 4.6 Changes in serum TGFβ1 from baseline to day 5 and baseline to day 21 
according to treatment received in the overall study population.  
 
 
 
 
Data represents median (IQR) change from baseline.  Mann Whitney U test to compare 
CT with CT+ZOL for each time-point measurement. * p value<0.05.	   	  
Time-point 
measurement of 
TGFb1 
Treatment 
group 
Median 
change 
IQR P value 
Baseline to day 5 
pg/ml 
CT 
CT+ZOL 
-1716 
727 
-5815 to 2729 
-6187 to 10900 
0.3369 
Baseline to day 5 
% change 
CT 
CT+ZOL 
-6.1 
1.9 
-27.2 to 10.6 
-26.1 to 53.3 
0.3104 
Baseline to day 21 
pg/ml 
CT 
CT+ZOL 
5025 
12259 
-891 to 9293 
5346 to 17934 
0.0294* 
Baseline to day 21 
% change 
CT 
CT+ZOL 
17.3 
45.7 
-3.1 to 42.3 
21.8 to 88.56 
0.0205* 
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4.5.3	   Exploratory	   analysis	   of	   the	   effect	   of	   zoledronic	   acid	   on	   serum	   protein	   levels	  
according	  to	  menopausal	  status	  and	  ER	  status.	  
4.5.3.1	  Menopausal	  status	  
22 patients were classified as clinically premenopausal and 18 patients were 
postmenopausal.  Clinical menopausal status was confirmed biochemically by 
measurement of baseline FSH. Median (range) FSH in clinically pre- and postmenopausal 
patients was 6.8 IU/l (1.8-30.7) and 68.4 IU/l (28-103.2) respectively (Fig 4.9). Only 1 
premenopausal patient had an FSH above the assay specific cut point for postmenopausal 
(26.7 IU/l), However, baseline inhibin A in this patient was 15.5 pg/ml and therefore 
consistent with a premenopausal status. 
 
Figure 4.10 shows the serum levels of activin, follistatin and TGFβ1 in pre- and 
postmenopausal patients according to treatment received.  At day 5 there was no 
significant difference in the serum levels of any of the proteins of interest according to 
treatment received in pre- or postmenopausal patients.  However, zoledronic acid 
appeared to differentially alter serum levels of both activin and follistatin from baseline to 
day 21 according to menopausal status of the patient.   
 
Postmenopausal women showed an increase in serum activin at day 21 compared to 
baseline with addition of zoledronic acid to chemotherapy, an effect not seen in 
premenopausal women (median change from baseline to day 21 pg/ml; premenopausal 
women CT alone -1.8 (IQR -47.6 to +83.1), CT+ZOL group -0.6 (IQR -20.3 to 85.9) 
p=0.07, postmenopausal women CT alone -6.7 (-128.3 to 10.65), CT+ZOL 70.9 (IQR 
27.1 to 100.2) p=0.004) (Table 4.7).  
Postmenopausal women also showed a decrease in serum follistatin at day 21 compared 
to baseline with addition of zoledronic acid to chemotherapy, an effect not seen in 
premenopausal women (median change from baseline to day 21pg/ml; Premenopausal 
women CT alone -85 (IQR -238 to +182), CT+ZOL -384 (IQR -1186 to +167) p=0.18, 
postmenopausal women CT alone 321 (IQR -39 to +925), CT+ZOL -312 (IQR -793 to -
86) p=0.004) (Table 4.7).  
 
These data show that the addition of zoledronic acid to chemotherapy causes significant 
changes from baseline to 21 in activin (↑) and follistatin (↓) compared to chemotherapy 
alone, in postmenopausal women only. This suggests the significant fall in serum 
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Figure 4.9 Serum follicle stimulating hormone according to menopausal status 
 
Data represent serum values of FSH for all patients classifies as clinically pre- or 
postmenopausal. Red dotted line represents cut point for assay to define 
postmenopausal i.e. serum levels above red line defines patients biochemically as 
postmenopausal (FSH >26IU/l). 
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Figure 4.10 Changes in serum activin, follistatin and TGFβ1 according to 
menopausal status and treatment received. 
 
Data represents the median +IQR at each time-point in premenopausal women (left) and 
postmenopausal women (right). 
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Table 4.7 Changes in serum activin, follistatin and TGFβ1 according to menopausal 
status. 
 
 
 
 
Data represents median (IQR) change from baseline to day 5 (D5) and day 21 (D21).  
Mann Whitney test for significance between CT and CT+ZOL. *p value <0.05 
  
Menopausal 
status + 
measured factor 
Time-point Treatment Median 
Change 
pg/ml 
IQR P 
value 
Premenopausal 
Activin 
Baseline to D5 CT 
CT+ZOL 
-108.9 
-113.7 
-157.7 to -77.4 
-189.4 to -85.9 
0.84 
Baseline to D21 CT 
CT+ZOL 
-1.8 
-0.6 
-47.6 to +83.1 
-20.3 to 85.9 
0.07 
Postmenopausal 
Activin 
Baseline to D5 CT 
CT+ZOL 
-141.5 
-89.1 
-202.6 to -92.3 
-125.6 to -61.9 
1.0 
Baseline to D21 CT 
CT+ZOL 
-6.7 
70.9 
-128.3 to 10.65 
27.1 to 100.2 
0.004* 
Premenopausal 
Follistatin 
Baseline to D5 CT 
CT+ZOL 
404.6 
-291 
-89 to +432 
-709 to +586 
0.23 
Baseline to D21 CT 
CT+ZOL 
-85 
-384 
-238 to +182 
-1186 to +167 
0.18 
Postmenopausal 
Follistatin 
Baseline to D5 CT 
CT+ZOL 
133.4  
-239 
-317 to +961 
-466 to +273 
0.43 
Baseline to D21 CT 
CT+ZOL 
321 
-312 
-39 to +925 
-793 to -86 
0.004* 
Premenopausal 
TGFβ1 
Baseline to D5 CT 
CT+ZOL 
-2352 
-4761   
-10206 to +2594 
-7070 to +6853 
0.69 
Baseline to D21 CT 
CT+ZOL 
+2627 
+12256 
-1697 to +8608 
+4580 to +15567 
0.11 
Postmenopausal 
TGFβ1 
Baseline to D5 CT 
CT+ZOL 
-1155 
+5006 
-4918 to +9537 
-3600 to +15200 
0.34 
Baseline to D21 CT 
CT+ZOL 
6066 
12309 
1269 to 10333 
3786 to 23494 
0.16 
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follistatin seen in the overall population, with addition of zoledronic acid, is being driven 
by the postmenopausal patients 
	  
4.5.3.2	  Oestrogen	  receptor	  (ER)	  status	  
30 patients had ER+ve primary breast tumours and 10 patients had ER –ve primary breast 
tumours at diagnosis. 
Figure 4.11 shows the serum levels of activin, follistatin and TGFβ1 in ER+ve and ER-ve 
patients according to treatment received.  At day 5 there was a significant difference in 
serum follistatin in ER-ve patients treated with CT or CT+ZOL, with follistatin being 
lower in the latter.  This effect was not seen in patients with ER+ve tumours (median 
change baseline to day 5, pg/ml; ER-ve patients CT alone 156 (IQR -123 to -440), 
CT+ZOL -528 (IQR -1787 to -257) p=0.0095; ER+ve patients CT alone group -161 (IQR 
-210 to -455), CT+ZOL -13 (IQR -484 to +548) p=0.44).   
At day 21 there was a significant difference in serum activin from baseline in ER-ve 
patients treated with CT compared to CT+ZOL.  Activin significantly increased from 
baseline levels with the addition of zoledronic acid to chemotherapy in ER-ve patients 
(median change from baseline to day 21 pg/ml; CT alone 10.6 (IQR -38.3 to 53.9), 
CT+ZOL 80.9(IQR 60.8 to 106.7) p=0.0381), an effect not seen in patients with ER+ve 
tumours. This significant fall in serum follistatin with zoledronic acid at day 5 in ER-ve 
patients, was lost by day 21 (median change baseline to day 21 pg/ml; CT alone -62 (IQR 
-803 to 593), CT+ZOL -796 (IQR -1955 to -177) p=0.1714 (Table 4.8). 
TGFβ1 was also differentially altered at day 21 compared to baseline according to ER 
status, with addition of zoledronic acid to chemotherapy in ER+ve patients increasing 
TGFβ1 at day 21, an effect not seen in ER-ve patients (median change baseline to day 21 
pg/ml; CT alone 1828 (IQR -2710 to 7008), CT+ZOL 12259 (IQR 5346 to 17934) 
p=0.0057 (Table 4.8).  
 
These results suggest that zoledronic acid may be altering levels of follistatin, activin and 
TGFβ1 differentially according to ER status of the primary tumour.  Changes in the 
primary tumour secretion of these factors would be expected to occur early after 
administration of zoledronic acid +/- chemotherapy i.e. day 5, rather than at the day 21 
time-point, suggesting that the changes seen in follistatin at day 5 may be linked to 
differential primary tumour secretion of follistatin according to ER status.  However, the 
numbers per group are small and these results are exploratory.
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Figure 4.11 Changes in serum activin, follistatin and TGFβ1 according to oestrogen 
receptor (ER) status and treatment received. 
 
Data represents median +IQR at each time-point in ER +ve patients (left) and ER-ve 
patients (right). 
  
M
ed
ia
n 
ac
tiv
in
 +
 IQ
R
 (p
g/
m
l)
Baseline D5 D21
0
100
200
300
400
500
CT alone
CT+ZOL
1 2 3
0
1000
2000
3000
4000
M
ed
ia
n 
fo
lli
st
at
in
 +
 IQ
R
 (p
g/
m
l)
CT alone
CT+ZOL
Baseline D5 D21
1 2 3
0
10000
20000
30000
40000
50000
M
ed
ia
n 
TG
Fb
1 
+ 
IQ
R
 (p
g/
m
l) CT alone
CT +ZOL
Baseline D5 D21
M
ed
ia
n 
ac
tiv
in
 +
 IQ
R
 (p
g/
m
l)
Baseline D5 D21
0
100
200
300
400
500
CT alone
CT+ZOL
M
ed
ia
n 
fo
lli
st
at
in
 +
 IQ
R
 (p
g/
m
l)
Baseline D5 D21
0
1000
2000
3000
4000
CT alone
CT+ZOL
M
ed
ia
n 
TG
Fb
1 
+ 
IQ
R
 (p
g/
m
l)
Baseline D5 D21
0
10000
20000
30000
40000
50000
CT alone
CT+ZOL
ER+ve
n=30
ER-ve
n=10
	  	  	  	  
	   140	  
 
 
 
Table 4.8 Changes in activin, follistatin and TGFβ1 according to oestrogen receptor 
(ER) status of primary tumour.  
 
Data represents median (IQR) change from baseline to day 5 (D5) and day 21 (D21).  
Mann Whitney test for significance between treatment groups. * p value <0.05 
 
 
 
  
ER status and 
measured factor 
Time-point Treatment Median 
Change 
pg/ml 
IQR P 
value 
ER+ve 
Activin 
Baseline to D5 CT 
CT+ZOL 
-135 
-101 
-213 to -88 
-142 to -69 
0.23 
Baseline to D21 CT 
CT+ZOL 
-4.9 
10.1 
-67.8 to 30.3 
-14.9 to 82.1 
0.23 
ER-ve 
 Activin 
Baseline to D5 CT 
CT+ZOL 
-110 
-98 
-143 to -59 
-149 to 43 
0.91 
Baseline to D21 CT 
CT+ZOL 
10.6 
80.9 
-38.3 to 53.9 
60.8 to 106.7 
0.038* 
ER+ve 
Follistatin 
Baseline to D5 CT 
CT+ZOL 
161 
-13 
-210 to -455 
-484 to +584 
0.44 
Baseline to D21 CT 
CT+ZOL 
137 
222 
-134 to 421 
-484 to 201 
0.065 
ER-ve 
Follistatin 
Baseline to D5 CT 
CT+ZOL 
156 
-528 
-123 to 440 
-1787 to -257 
0.009* 
Baseline to D21 CT 
CT+ZOL 
-62 
-796 
-803 to 593 
-1955 to -177 
0.171 
ER+ve 
 TGFβ1 
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4.5.4	   Correlation	   of	   serum	   levels	   of	   activin,	   follistatin	   and	   TGFβ 	   to	   growth	   index	   of	  
primary	  breast	  tumour	  biopsies.	  
These data have shown that zoledronic acid, when added to standard chemotherapy, has 
biological effects on serum levels of TGFβ1, follistatin and activin and this can be further 
influenced by menopausal status and ER status of the primary tumour.  Serum 
measurements however, are unable to identify the source of secretion of these paracrine 
proteins.  As part of the ANZAC trial, growth index (ki67/apoptosis) from repeat breast 
biopsies was measured by methods previously reported (Winter, Wilson et al. 2013).  
Growth index results were available in 100% of patients at baseline, 88% (35/40) at day 5 
and 55% (22/40) at day 21.  Serum activin levels correlated with growth index at baseline 
(p=0.0374) and day 21 (p=0.0198) (Fig 4.12), and serum TGFβ1 levels correlated with 
growth index at baseline only (p=0.0029) (Fig 4.13).  Serum follistatin levels did not 
correlate with growth index at any timepoint.  Serum follistatin in ER-ve patients did not 
significantly correlate with growth index at day 5 either, however, growth index was only 
available in 9 patients at this time-point. 
These data suggest, at baseline, activin and TGFβ1 may be secreted by the tumour cells, 
since higher serum levels correlate significantly with a higher growth index.  After 
treatment only activin remains significantly correlated with growth index at day 21 
suggesting that activin is secreted primarily by tumour cells compared to TGFβ1, which 
may be secreted from other sources.  The source of follistatin may not be the primary 
tumour as there was no correlation with growth index, however, numbers in each group 
are small and these analyses are exploratory only. 
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Figure 4.12.  Correlation of growth index with serum activin levels. 
 
Data represents individual serum levels plotted against corresponding growth index from 
the overall population for baseline (top), day 5 (middle) and day 21 (bottom).  Coloured 
dots identify different treatment groups. Spearman’s non parametric correlation 
coefficient for significance, * p value <0.05	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Figure 4.13.  Correlation of growth index with serum TGFβ1 levels. 
 
Data represents individual serum levels plotted against corresponding growth index from 
the overall population for baseline (top), day 5 (middle) and day 21 (bottom).  Coloured 
dots identify different treatment groups. Spearman’s non parametric correlation 
coefficient for significance,* p value <0.05 
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4.6	  Discussion	  	  
These data are the first to show that neo-adjuvant zoledronic acid significantly affects 
serum levels of the TGFβ superfamily of proteins, and their inhibitors, in both a 
heterogeneous breast cancer population, and in specific subgroups according to 
menopausal status and ER status.  At baseline, serum activin, follistatin and TGFβ are not 
affected by menopausal or ER status.  However, baseline inhibin is significantly higher in 
premenopausal patients and declines significantly over time suggesting an effect of 
chemotherapy on ovarian function. After treatment with zoledronic acid, serum follistatin 
decreases at day 21 compared to baseline, with a concurrent increase in TGFβ in the 
overall study population.  Evaluation of serum changes induced by zoledronic acid 
according to menopausal status and ER status showed a significant decrease in serum 
follistatin at day 21, and a concurrent increase in serum activin in postmenopausal women 
treated with zoledronic acid.  This effect was not seen in premenopausal women.  
Postmenopausal women treated with neo-adjuvant zoledronic acid, would therefore be 
expected to have a higher bioavailability of the tumour suppressor activin, due to both an 
increase in activin and a decrease in the activin inhibitor follistatin, compared to 
premenopausal women treated with zoledronic acid.  In addition, patients with ER-ve 
tumours showed a significant early fall in follistatin levels at day 5 with addition of 
zoledronic acid that is not seen in ER+ve patients.  These novel effects of zoledronic acid 
on serum levels of the TGFβ superfamily may be relevant, since both postmenopausal 
and ER-ve patients have been shown in clinical trials to derive an increased anti-tumour 
effect from zoledronic acid.  
 
Recent clinical evidence further supporting the neo-adjuvant anti-tumour efficacy of 
zoledronic acid in postmenopausal patients and patients with ER-ve tumours was 
presented by Horiguchi et al this year at the American Society of Clinical Oncology 
(ASCO) conference; 188 breast cancer patients aged 20-70 were randomised to receive 
zoledronic acid 4mg q3-4/52 for 7 treatments during neo-adjuvant FEC100 + weekly 
paclitaxel.  There was a trend towards an improved pathological complete response in the 
ZOL+CT group vs CT (18.4% vs 7.8% p=0.16), and the difference between pCR rates 
was higher in postmenopausal patients (ZOL+CT 18.4%, CT 5.4%) and patients with 
receptor negative tumours (ZOL+CT 35.3%, CT 11.8%)(Horiguchi J 2013).  This was 
further supported by the Neozotac study randomizing 250 patients to neo-adjuvant CT 
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alone or CT+ZOL 4mg IV q3/52 during chemotherapy. Pathological results from 228 
patients were presented this year at ASCO and showed no difference in the overall 
population in pCR rates, but a trend was observed to improved pCR in postmenopausal 
women (CT alone 18% va CT+ZOL 11%)(Charehbili A 2013).   
 
The increased anti-tumour efficacy of zoledronic acid in these two subgroups of patients 
may be contributed to by the effects of zoledronic acid on the serum levels of TGFβ 
superfamily ligands, however, there are limitations in the ANZAC data which must be 
considered.  The date of the last menstrual period (LMP) was not recorded for the pre 
menopausal patients, which made the interpretation of changes in inhibin over time 
difficult.  However, the significant difference in serum inhibin between premenopausal 
women and postmenopausal women is in keeping with previously published data as 
discussed in chapter 3.  The significant decline in inhibin in premenopausal women from 
baseline to day 21 may be due to a chemotherapy effect on ovarian function, or it may 
represent sampling of blood from premenopausal women at different time points in the 
menstrual cycle.  During the menstrual cycle small antral follicles are recruited from the 
primordial follicle pool and progressively develop until only one is selected as the 
dominant follicle for ovulation.  Inhibin A is highest in the late follicular phase of the 
menstrual cycle, reaching a peak at ovulation and then declining until a later surge 4-6 
days post ovulation followed by a subsequent decline (de Kretser, Hedger et al. 2002). 
Inhibin is secreted by larger pre-ovulatory follicles in the follicular phase, and by the 
corpus luteum in the post ovulation surge (Hohmann, Laven et al. 2005).  If, by chance, 
the majority of premenopausal patients at baseline were in the late follicular phase or 4-6 
days post ovulation, then the inhibin A levels would have been higher at baseline, and 21 
days later, there would be an expected cyclical decline in inhibin A.  Alternatively, 
chemotherapy targets cycling cells and could therefore affect larger follicles that have 
been recruited into a phase of cell division and maturation. In a prospective study, inhibin 
A was measured in 30 breast cancer patient before chemotherapy, 4 weeks after 
completion of chemotherapy and at 2 years post chemotherapy.  There was a significant 
decline in inhibin A at the completion of chemotherapy and 2 year time-point, compared 
to baseline (Burkhardt, Juckstock et al. 2010). There are no clinical studies in breast 
cancer to my knowledge that have evaluated the fall in inhibin A earlier than 6 months 
post initiation of chemotherapy. However, it has previously been shown that a single dose 
of CMF (cyclophosphamide 400mg/m2, methotrexate 40mg/m2, 5-fluorouracil 600mg/m2 
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day 1 and 8) chemotherapy can increase the rate of amenorrhoea (defined as no menstrual 
bleeding for 3 consecutive months within 9 months of primary breast surgery) from 21% 
in women receiving no adjuvant chemotherapy to 31% in women receiving only 1 cycle 
of peri-operative CMF (Goldhirsch, Gelber et al. 1990).  Therefore it would be 
conceivable that ovarian function could decline and serum inhibin may fall within 21 
days of a single dose of FEC100.   
 
Whilst the major source of circulating inhibin is derived from ovarian secretion, it is less 
clear which sources contribute to circulating activin, follistatin and TGFβ1. ANZAC did 
not recruit non-tumour controls, and therefore interpretation of the changes in these 
paracrine proteins with zoledronic acid is challenging, as the serum alterations may be 
due to alterations in release of these proteins from tumour, bone or other sites. 
Activin is abundant in bone matrix, and in the non-cancer setting has been shown to be 
elevated in the serum of postmenopausal patients (n=47) with a BMD T score <-2.0 
lumbar spine, compared to postmenopausal controls (n=27) with normal bone density 
(BMD T score >-1.0 lumbar spine), suggesting activin A may have a negative role on the 
bone by increasing osteoclastogenesis (Anastasilakis, Polyzos et al. 2013).  However, 
serum activin may increase as a consequence of increased bone turnover rather than the 
cause.  In a cancer population, serum activin A was significantly higher in patients with 
breast cancer or prostate cancer (n=72) compared to sex and age matched controls (n-48), 
and was higher in breast and prostate patients with bone metastases compared to those 
without. In addition, in the breast cancer patients, the level of activin in serum correlated 
with the number of bone metastases (Leto, Incorvaia et al. 2006). Again it is unclear if 
this increase in serum activin with bone metastases compared to non-bone metastases is a 
cause or consequence of increased lytic bone destruction or increased tumour burden and 
thus secretion of activin.  Interestingly, in the breast and prostate cancer patients without 
bone metastases, serum activin was elevated compared to healthy controls.  This may 
imply the tumour cells are secreting enough activin in the local tumour environment to 
increase serum levels. This is supported by data from Reis et al (2002), who showed that 
activin levels were twice as high in breast tumour homogenates compared to non 
neoplastic tissue. In addition, in postmenopausal breast cancer patients undergoing 
surgery for removal of breast tumour, a significant decrease in serum activin A was seen 
at day 1 and 2 post-surgery compared to pre-surgery.  A similar effect was not seen in 
women undergoing breast reduction surgery for non-malignant causes.  Serum activin 
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levels in the breast cancer patients, however, did not correlate with the presence of lymph 
nodes, tumour grade or tumour size (Reis, Cobellis et al. 2002). These data may suggest 
that activin secretion from tumour cells is a consequence rather than a cause of 
tumourigenesis since increased levels do not correlate with adverse prognostic factors.  
These data would support the correlation demonstrated between serum activin and growth 
index of the primary breast tumours at baseline and day 21 in the ANZAC study, 
suggesting that as the proliferation of breast tumours increases, a concurrent increase in 
serum activin occurs as a consequence of an increased number and activity of tumour 
cells. 
 
Follistatin levels in serum are detectable in healthy subjects and are elevated in pregnancy 
and various pathological states such as liver disease and kidney disease (Sakamoto, 
Shintani et al. 1996).  The main isoform of follistatin in the circulation is FS315, and 
follistatin binds activin in an almost irreversible complex that prevents activin interacting 
with its receptors (Sepporta, Tumminello et al. 2013).  There is a paucity of data on 
follistatin levels in serum of breast cancer patients, but in prostate cancer patients (n=35), 
serum follistatin is significantly higher than patients with benign prostatic hypertrophy 
(n=20). In addition, serum follistatin correlated with the presence of bone metastases in 
the prostate cancer cohort (Tumminello, Badalamenti et al. 2010). These data suggest 
follistatin may be secreted by prostate cancer cells, or that follistatin may be either 
liberated from bone in the presence of bone metastases, or there is increased secretion 
from the prostate cancer cells when localized in bone.  In the ANZAC serum cohort, 
follistatin did not correlate with growth index of primary tumour at any time-point, 
suggesting the source of follistatin may not be the primary breast cancer cells, but other 
sources such as bone. 
 
TGFβ is abundantly stored in bone, and serum levels demonstrate a significant positive 
correlation with bone mineral density T score at lumbar vertebrae, radius and ulnar (Wu, 
Peng et al. 2013).  In the breast cancer setting, TGFβ1 has been shown to be elevated in 
conditioned medium of breast cancer tumour explants compared to matched normal 
breast tissue (Toomey, Condron et al. 2001), and Dave et al found preoperative TGFβ1 to 
be elevated in the serum of patients with invasive breast cancer (n=117) compared to 
controls. These data suggest TGFβ1 is produced and released from the tumour in 
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sufficient levels that can be detected in the circulation.  In patients with advanced disease 
serum levels were significantly higher than early stage disease, suggesting levels may 
also correlate with tumour burden (Dave, Shah et al. 2012).  Serum levels of TGFβ1 have 
also been shown to correlate with stages of early breast cancer. Sheen-Chen et al 
evaluated serum TGFβ1 from 60 patients with invasive breast cancer pre surgery, and 
compared them to 14 patients with benign breast tumours. They found that, although 
there was no significant difference between patients and controls, levels of TGFβ1 were 
significantly higher in patients with more advanced lymph node status, poorer 
histological grade and more advanced TNM (tumour, nodes, metastases) stage (Sheen-
Chen, Chen et al. 2001).  Similar positive correlation between serum TGFβ1 and lymph 
node involvement has also been reported in a cohort of 36 preoperative early breast 
cancer patients (Chod, Zavadova et al. 2008), again suggesting that serum TGFβ1 may be 
reflective of tumour burden.  However, in a larger cohort of patients with invasive breast 
cancer (n=135) compared to DCIS (n=67), fibroadenoma (n=35) or healthy women 9 
(n=40), no significant difference was found in serum levels between the groups, and in 
the invasive breast cancer patients TGFβ1 levels did not correlate with tumour stage, 
lymph node involvement or histological grade (Lebrecht, Grimm et al. 2004). Similar 
lack of difference in serum levels of 90 early stage breast cancer patients compared to 75 
health controls was reported by Duranyildiz et al (Duranyildiz, Camlica et al. 2009).  
Taken together these data suggest that tumours do secrete TGFβ1, but it is not reliably 
differentially secreted in the circulation according to tumour characteristics or tumour 
burden to make it a good predictive or prognostic marker for breast cancer severity. The 
ANZAC data would support the correlation between baseline serum TGFβ1 and growth 
index of the primary tumours, suggesting that higher cell turnover secretes more TGFβ1 
that can be detected in serum.  However, in the ANZAC study, at day 21, serum TGFβ1 
no longer correlated with growth index, implying that another source other than the 
primary tumour may be responsible for TGFβ1 secretion. 
 
Considering these data it would seem plausible that the addition of zoledronic acid to 
standard chemotherapy could alter serum levels of these paracrine factors, since 
zoledronic acid has been demonstrated to affect both primary breast tumours (Clezardin, 
Ebetino et al. 2005) and bone resorption (Clezardin, Fournier et al. 2003). To my 
knowledge there are no other data from a breast cancer population that have evaluated 
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changes in these factors with zoledronic acid treatment.  The overall study population 
showed a decrease in serum follistatin and an increase in serum TGFβ1 with addition of 
zoledronic acid at day 21. Zoledronic acid has been shown to increase secretion of 
TGFβ1 from primary rat osteoblasts in vitro (Naidu, Dechow et al. 2008), suggesting that 
the effect of zoledronic acid on bone may potentially alter serum levels of TGFβ1.  
Osteoblastic in vitro cultures have shown that inhibitors of osteoblastic function i.e. 
dexamethasone, do so via an increase in follistatin mRNA expression, but pretreatment 
with the bisphosphonate alendronate can prevent this by reducing follistatin mRNA 
expression (Hayashi, Yamaguchi et al. 2009), indicating that bisphosphonates may effect 
follistatin expression in bone. 
 
In the exploratory analyses of effects of zoledronic acid according to menopausal status 
and ER status, the decrease in follistatin at day 21 in postmenopausal patients was 
complemented by an increase in activin.  In the non-cancer setting, a single infusion of 
zoledronic acid 5mg IV in postmenopausal women with low BMD does not alter serum 
activin at 3 months post infusion (Anastasilakis, Polyzos et al. 2013).  This may indicate 
that the effect of zoledronic acid on serum activin in the ANZAC study was primarily due 
to direct tumour secretion of activin rather than from other sources such as bone, or may 
represent a different timing of serum collection (day 21 vs. 3 months). 
 
The potential impact of these changes in serum levels of activin, follistatin and TGFβ1 
can be hypothesized considering the known effects of these paracrine factors on breast 
cancer cell proliferation.  As discussed earlier, preclinical data has show activin to be a 
suppressor of breast cancer cell proliferation, with follistatin inhibiting activin and its 
tumour suppressive effect.  TGFβ1 can be both a tumor suppressor and a tumor promoter 
depending upon the stage of tumorigenesis.  In the overall ANZAC population the 
significant decline in follistatin at day 21 with addition of zoledronic acid may represent a 
new and novel anti-tumor mechanism of zoledronic acid.  By decreasing serum follistatin, 
zoledronic acid increases the bioavailability of the tumour suppressor activin.  The 
significant increase in TGFβ1 at day 21 in the zoledronic acid group may have a tumour 
suppressive or promoter action on the primary breast tumor. It is interesting that the 
significant decline in serum follistatin with zoledronic acid at day 21 is driven by the 
postmenopausal cohort, which also demonstrate a significant increase in serum activin at 
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day 21.  Thus zoledronic acid may be having an even greater anti-tumour effect in 
postmenopausal women by both increasing activin and concurrently decreasing follistatin 
levels in serum. In patients with ER-ve tumours, an early significant fall in follistatin with 
zoledronic acid at day 5 with a significant increase in activin at day 21, may be 
contributing to the enhanced anti-tumour activity of zoledronic acid seen in neoadjuvant 
clinical trials in these patients.  
 
It is not possible however, to extrapolate serum levels of these proteins to levels found 
within primary tumours, and therefore these conclusions and hypotheses are theoretical 
only.  The possible enhanced anti-tumour activity of zoledronic acid via manipulation of 
the activin: follistatin system in postmenopausal women and patients with ER-ve tumours 
is novel and requires further investigation. 	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Chapter 5. Effects of zoledronic acid 
on the activin-signaling pathway in 
human breast cancer cell lines. 
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5.1	  Summary	  	  
Neo-adjuvant breast cancer clinical trials have demonstrated that the anti-tumour efficacy 
of zoledronic acid is influenced by oestrogen receptor (ER) status, with ER-ve tumours 
being more responsive to the beneficial effects of zoledronic acid on disease free, overall 
survival and pathological complete response.  The mechanism behind this differential 
effect remains to be identified. I have previously shown that zoledronic acid, when added 
to first cycle of neo-adjuvant chemotherapy, decreased serum levels of follistatin, which 
neutralizes the tumour suppressor activin, in patients with ER-ve tumours at day 5-post 
treatment, an effect not seen in patients with ER+ve tumours.  It is unknown if zoledronic 
acid can directly affect the activin pathway in breast cancer cells, either at cell surface 
receptor level, or by influencing downstream signaling pathways. The aims of the work in 
this chapter was therefore to evaluate the effect of zoledronic acid on activin and 
follistatin in ER-ve and ER+ve breast cancer cell lines in vitro.  
 
Zoledronic acid decreased the paracrine secretion of the activin neutraliser, follistatin, in 
ER-ve breast cancer cell lines only (MDA-MB-231 and MDA-MB-436).   The functional 
implication of this was investigated using cell proliferation assays in ER-ve and ER+ve 
cell lines to assess the effect of recombinant activin, +/- follistatin. Follistatin negated the 
anti-proliferative effect of activin in MDA-MB-231 and MCF7 cells. In addition if the 
activin type I receptor (ALK4/5) was blocked using the inhibitor SB-431542, the anti-
proliferative effect of activin was decreased in MDA-MB-231 cells, indicating blocking 
activin either at receptor level or outside the tumour cells, prevents it acting as a tumour 
supressor. The effects of zoledronic acid on the signaling pathways downstream of the 
ALK4 receptor were assessed by focusing on Smad2, and its two main phosphorylation 
sites using immunofluorescence.  Zoledronic acid prevented nuclear localisation of the 
tumour promoting linker-phosphorylated Smad2 in MDA-MB-231 cells, and increased 
the levels of the tumour suppressor c terminus-phosphorylated Smad2.  
 
These in vitro findings were confirmed in a sub-cutaneous xenograft model of ER-ve 
MDA-MB-436 tumours treated with zoledronic acid, which showed a decrease in the area 
of tumour stained +ve for follistatin, and a decrease in the number of cells stained +ve for 
linker phosphorylated-Smad2 compared to saline control. 
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These data are the first to demonstrate zoledronic acid can affect the activin-signaling 
pathway in ER-ve breast cancer cells both in vitro and in vivo. 	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5.2	  Introduction	  	  
Neo-adjuvant chemotherapy is used in early breast cancer to change inoperable breast 
tumours to operable, or to enable breast-conserving surgery to be performed. The addition 
of zoledronic acid to neo-adjuvant chemotherapy has been shown to significantly reduce 
the residual invasive tumour size compared to chemotherapy alone (Coleman, Winter et 
al. 2010), suggesting a direct anti-tumour effect of zoledronic acid on both ER-ve and 
ER+ve breast tumours. However, not all breast tumours are equally responsive to 
zoledronic acid, and clinical studies have shown that addition of zoledronic acid to neo-
adjuvant chemotherapy reduces disease recurrence and death in patients with ER-ve, but 
not ER+ve, tumours (Aft, Naughton et al. 2012) (Horiguchi J 2013).  The molecular 
mechanism underpinning this differential effect of zoledronic acid according to ER status 
has not yet been identified. In vitro, zoledronic acid inhibits proliferation of the ER-ve 
cell line MDA-MB-231 and induces apoptosis via an increase in the levels of pro-
apoptotic factors.  This effect of zoledronic acid was not seen in the ER+ve cell line 
MCF7 (Rachner, Singh et al. 2010). An ER dependent anti-proliferative effect of the 
bisphosphonate clodronate has also been reported, with a reduction in tumour cell 
survival of the ER-ve MDA-MB-435S cell line, but no effect was shown in MCF7 cells 
(Busch, Rave-Frank et al. 1998).  The in vitro anti-tumour affects of zoledronic acid 
include reduced survival, adhesion, migration and invasion of tumour cells, and are 
thought to be due to the effect on the mevalonate pathway, via inhibition of FPP synthase 
and reduced prenylation of small GTPases (Gnant and Clezardin 2012).  Whether the 
differential anti-tumour affect of zoledronic acid according to ER status is due to an effect 
on the mevalonate pathway is not known. 
 
The neo-adjuvant ANZAC study (n=40) showed a menopause (Winter, Wilson et al. 
2013) and tumour ER status (Wilson C 2013) dependent effect on serum levels of 
follistatin following administration of zoledronic acid.  At day 5 post FEC100 
chemotherapy, in patients with ER-ve tumours, the addition of 4mg IV zoledronic acid 
resulted in a significantly lower serum level of follistatin compared to patients receiving 
chemotherapy alone.  This may represent a fall in the secretion of follistatin from ER-ve 
breast tumours that are not seen in ER+ve tumours.  Follistatin is a paracrine antagonist 
of activin and both proteins modify breast cancer cell proliferation.  Activin is produced 
by breast cancer cells and inhibits their proliferation; follistatin binds to activin and 
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prevents receptor binding with the type II receptor (ActRII), thus promoting proliferation 
(Bloise, Couto et al. 2009).  Once activin binds to ActRII, dimerization occurs with 
ActRIB (ALK4) and the receptor associated intracellular proteins, Smad2 and 3, are 
phosphorylated.  They subsequently translocate to the nucleus with the co-receptor 
Smad4 (Liu and Feng 2010) (Chapter 1 Fig 1.13). Smads undergo phosphorylation at the 
COOH-tail following receptor dimerization, or at a linker region joining the MH1 and 
MH2 domains by intracellular protein kinases primarily RAS and cyclin dependent 
kinases (Matsuzaki 2011).  These different phosphorylation sites have different effector 
functions; the COOH-tail being a tumour suppressor and the linker phosphorylation site 
being a tumour promoter (Matsuzaki 2011).  Previously published in vitro data suggested 
ER-ve cell lines were resistant to the anti-proliferative effects of activin as a result of low 
expression of the activin type II receptor, however, MDA-MB-231 were found to express 
sufficient type II receptors suggesting an alternative mechanism of resistance to activin 
(Kalkhoven, Roelen et al. 1995).  Further in vitro studies found the ER-ve cell line MDA-
MB-436 to have a functional activin-signaling pathway by demonstration of 
phosphorylation of Smad2 in response to exogenous activin, and proliferation was 
inhibited by exogenous activin following removal of follistatin from the medium or 
silencing of the follistatin related gene (FLRG)(Razanajaona, Joguet et al. 2007).  These 
data indicate that exogenous neutralisers of activin, such as follistatin, are responsible for 
the lack of inhibition of proliferation in response to activin in ER-ve cell lines, rather than 
lack of/non functional activin receptors. 
 
To my knowledge there are no in vitro studies evaluating the ability of zoledronic acid to 
affect activin and follistatin in breast cancer cell lines.  The new information in this 
chapter details how zoledronic acid can affect the activin signaling pathway by a dual 
mechanism in ER-ve breast cancer cell lines; decreasing secretion of follistatin and 
altering the localization of linker phosphorylated Smad2.  These data suggest a 
potential novel mechanism to explain the differential tumour effect of zoledronic acid 
according to ER status. 
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5.3	  Aims	  
 
The overall purpose of this chapter was to evaluate the affect of zoledronic acid on the 
activin-signaling pathway in breast cancer cells in vitro and in vivo.  The following aims 
were set; 
 
1. Evaluation of activin, follistatin and TGFβ secretion from ER-ve and ER+ve 
breast cancer cell lines  in vitro. 
 
2. Determine the effect of zoledronic acid on secretion of activin and follistatin from 
ER-ve and ER+ve breast cancer cell lines in vitro.   
 
3. Establish the functional effect of activin and follistatin on proliferation of ER-ve 
and ER+ve cell lines.  
 
4. Evaluate the effect of zoledronic acid on the downstream activin-signaling 
pathways, focusing on COOH-tail phosphorylation and linker phosphorylation of 
Smad2 in vitro. 
 
5. Assess the effect of zoledronic acid on follistatin and linker phosphorylated 
Smad2 levels in a xenograft model of sub-cutaneous ER-ve MDA-MB-436 
tumours. 	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5.4	  Materials	  and	  methods	  	  
The following section contains a brief description of the methods used for the studies 
included in this chapter.  See materials and methods chapter 2 for further information. 
5.4.1	  Secretion	  of	  activin	  and	  follistatin	  from	  ER-­‐ve	  and	  ER+ve	  cell	  lines.	  
Two ER-ve cell lines were used (MDA-MB-231 and MDA-MB-436) and two ER+ve cell 
lines (MCF7 and T47D).  Cells were seeded in 6 well plates at densities chosen to reflect 
specific cell line rate of replication, with an aim to achieve ~80% confluence of cells at the 
end of the experiment.  MDA-MB-231 and MCF7 cells were maintained in 
DMEM+10%FCS for 24hrs and 48 hrs with supernatant removed at each time-point and 
frozen for ELISA.  Live cell count was performed from each well at the end of the 
experiment, to enable normalization of activin/follistatin levels to cell count by expressing 
results as secreted concentration/million cells.  MDA-MB-436 and T47D cells were 
maintained for 48hrs. 
	  
5.4.2	  Effect	  of	  zoledronic	  acid	  on	  the	  secretion	  of	  activin	  and	  follistatin	  from	  ER-­‐ve	  and	  
ER+ve	  breast	  cancer	  cell	  lines,	  and	  effect	  on	  proliferation.	  
MDA-MB-231, MBA-MB-436, MCF7 and T47D cell lines were seeded in 6 well plates at 
densities previously described.  Cells were exposed to 50µM zoledronic acid for 48-hours.  
At the end of the experiment supernatant was collected for ELISA and live cell count 
performed as previously described to enable normalization of activin/follistatin levels to 
cell number. The experiment was repeated in the ER-ve cell lines using a 4-hour pulse of 
zoledronic acid, followed by removal of drug and replacement with medium for a further 
44 hours. 
 
5.4.3	  Effect	  of	  activin	  and	  follistatin	  on	  proliferation	  of	  ER-­‐ve	  and	  ER+ve	  cell	  lines.	  
MDA-MB-231 and MCF7 cells were seeded in 96 well plates at densities detailed in 
chapter 2. Activin dissolved in RPMI+10%FCS was added to each well on day 0 at 
concentrations ranging from 60pg/ml to 6000pg/ml.  The wells were washed and medium 
+/- activin was changed every 24 hours due to the predicted endogenous secretion of the 
activin antagonist follistatin from the cell lines.  Plates were developed at day 1,3 and 5 
by addition of a compound that degrades to a coloured formazan product that can be 
quantified using absorbance on a plate reader.  Based on the results of the activin 
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proliferation assays, the optimal time-point was determined as day 3 for further 
proliferation assays using activin in combination with follistatin and activin in 
combination with an ALK4/5 inhibitor. All proliferation experiments were carried out 
with 8 replicates and 3 repeats. 
 
 
5.4.4	  Effect	  of	  zoledronic	  acid	  on	  downstream	  activin-­‐signaling	  pathways. 
MDA-MB-231 and MCF7 cells were seeded in chamber slides, as described in chapter 2, 
containing RPMI +10%FCS.  A 48-hour endpoint was maintained in these experiments 
based on previous results.  After fixation of cells at the end of the experiment, one 
chamber was maintained as the –ve control with addition of 5%BSA only, and primary 
antibody in 5% BSA was added to the other 7 chambers.  Primary antibodies used were to 
detect phosphorylated COOH-tail Smad2 (serine 465/467) or phosphorylated linker 
Smad2 (serine 245/250/255). Chamber slides were scored using a Leica DMI 400B 
inverted fluorescent microscope.  Nuclear localization was identified using paired images 
of DAPI stained nuclei with fluorescent stained Smad2, and manually quantified from 
saved images taken from 4 quadrants of each chamber and expressed as a percentage of 
total number of cells (Fig 5.1).  To quantify the level of phosphorylated linker Smad2 
(pSmad2L) western blot was used.  To quantify the level of phosphorylated COOH-tail 
Smad2 (pSmad2C) relative to total Smad2 a cell-based immunoassay was used which 
utilized 2 different fluorescent secondary antibodies to determine levels of each protein 
(see Chapter 2 Fig 2.2).  MDA-MB-231 cells were plated and left for 48 hours in 
RPMI+10%FCS.  Medium was removed and exchanged for serum free medium for 24 
hours.  Cell were then treated for 1 hour with supernatant from MDA-MB-231s 
previously treated with medium alone (control) or medium + 50µM zoledronic acid for 
48 hours.  Cell were then fixed and assay completed as per protocol. 
	  
5.4.5	  Effect	  of	  zoledronic	  acid	  on	  follistatin	  and	  linker	  phosphorylated	  Smad2	  in	  a	  sub-­‐
cutaneous	  xenograft	  model	  of	  ER-­‐ve	  MDA-­‐MB-­‐436	  tumours.	  	  
The in vivo component of this work was carried out by Dr Penny Ottewell and has been 
previously published (Ottewell, Monkkonen et al. 2008).  To summarise the experimental   
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Figure 5.1.  Representative immunofluorescent images of tumour cells evaluated for 
cellular localization of phosphorylated Smad2 protein. 
 
Blue DAPI nuclear stain was used with a paired green fluorescent pSmad2 stain to count 
the number of tumour cells with nuclear pSmad2, represented as a percentage of the total 
cells per image.  Arrows indicate corresponding DAPI and pSmad2 images from cells 
counted as pSmad2 not located in the nucleus (top) and cells counted as pSmad2 located 
in the nucleus (bottom) 
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outline, female MF1 nude mice were injected sub-cutaneous with 5x105 MDA-MB-436 
cells, and weekly zoledronic acid 100µg/kg intra peritoneal vs. saline control was given 
from day 7.  Mice were maintained for 6 weeks then culled 24 hours after the last 
zoledronic acid injection (Fig 5.2).  Tumours were isolated and fixed in 4% 
paraformaldehyde in PBS for 24 hours and subsequently paraffin embedded for IHC.  
Sections were cut and stained for follistatin or linker phosphorylated Smad2 using 
methodology described in chapter 2.   Two sections per tumour were stained with each 
primary antibody and 20 x 750µm2 images were scored from each tumour using an Leica 
BMRB upright microscope and Osteomeasure software (OsteoMetrics Inc., Decatur, GA).  
Follistatin was scored according to the intensity of staining graded as 0 no staining, 1 
weak staining, 2 moderate staining and 3 strong staining, and the area of staining as 0 no 
staining, 1 up to 10% of the tumour area, 2 10-50% of the tumor area, 3 >50% of the 
tumour area. pSmad2L was scored by counting the number of positively stained cells per 
tumour area (Fig 5.3).   
 
5.4.6	  Statistical	  analysis	  
Unless stated otherwise, all experiments were carried out with 3 replicates and 3 repeats.   
Prism GraphPad (5.0a) was used for statistical analysis. Data analysis was by non-
parametric Mann-Whitney or Kruskal-Wallis with post hoc Dunns test.  Data represent 
mean and SEM.  Significance is defined as a p value <0.05 and represented graphically 
by * or p value <0.01 ** or P value <0.001 ***. 	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Figure 5.2.  Experimental outline for xenograft model of sub-cutaneous MDA-
MB-436 tumours.   
 
Female MF1 nude mice (n=8-9 per group) were injected with 5x105 MDA-MB-436 
tumour cells in right flank and treatment commenced with weekly zoledronic acid 
at day 7 when tumours were palpable.  Mice were culled 24 hours after the final 
zoledronic acid treatment. 
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Figure 5.3.  Representative image of sub-cutaneous MDA-MB-436 tumour evaluated 
for expression of pSmad2L.   
 
Cells marked with a yellow star were counted as being positive for pSmad2L due to the 
intensity of their positive DAB stain (brown).  20x 750µm2 images were scored to give an 
average score per tumour. 	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5.5	  Results	  
 
5.5.1	  Secretion	  of	  activin	  and	  follistatin	  from	  ER-­‐ve	  and	  ER+ve	  cell	  lines.	  
To determine if breast cancer cell lines secrete activin, follistatin and TGFβ1 in vitro, 
ELISAs specific to human activin, follistatin and TGFβ1 were used to analyse cell culture 
supernatant collected from 4 different breast cancer cell lines.  There was no significant 
secretion of TGFβ1 at 48 hours, however, all cell lines secreted both activin and 
follistatin in cell culture at 48 hours (Fig 5.4).  Both ER-ve cell lines secreted significant 
levels of activin at 48 hours compared to medium alone (MDA-MB-231 p value= 0.0034, 
MDA-MB-436 p value= 0.0436).  The ER-ve cell line MDA-MB 231 secreted significant 
levels of follistatin at 48 hours compared to medium alone (p value=0.0088). In ER+ve 
cell lines follistatin and activin secretion was not significantly increased at 48 hours. This 
time-point was used in subsequent experiments assessing changes in secreted activin and 
follistatin with addition of zoledronic acid. 
	  
5.5.2	  Effect	  of	  zoledronic	  acid	  on	  the	  secretion	  of	  activin	  and	  follistatin	  from	  ER-­‐ve	  and	  
ER+ve	  breast	  cancer	  cell	  lines,	  and	  effect	  on	  proliferation.	  
To determine if zoledronic acid can alter the secretion of either activin or follistatin from 
MDA-MB-231 and MCF7 cells, both cell lines were exposed to medium alone or 
medium containing 25µM or 50µM zol for 48 hours.  Cell supernatant was collected and 
evaluated for levels of activin and follistatin measured by ELISA with values normalized 
to live cell count at the end of the experiment.  This was to ensure an accurate reflection 
of the quantity of soluble protein secreted relative to cell number, because 48 hours of 
continuous exposure to zoledronic acid (50µM) significantly lowered live cell count in 
MDA-MB-231 and MDA-MB-436 cells compared to control (MDA-MB-231 p value 
=0.0009, MDA-MB-436 p value =0.0045) but not MCF7 or T47D cells (Fig 5.5).  25µM 
zoledronic acid did not cause a significant change in secretion of activin or follistatin 
secretion with in any cell lines.  Follistatin secretion from MDA-MB-231 cells was 
significantly decreased after exposure to 50µM zoledronic acid compared to control (p 
value =0.0012) (Fig 5.6).  This effect was not seen in the MCF7 cells.  
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Figure 5.4.  Activin and follistatin secretion from ER- breast cancer cell lines (MDA-
MB-231 and MDA-MB-436) and ER+ve breast cancer cell lines (MCF7 and T47D).   
 
The cell lines were plated in 6 well plates.  Activin (A) and follistatin (B) secretion into 
supernatant was determined by ELISA at 24 and 48 hours. Data represents 3 replicates 
and 3 repeats. Mann Whitney test for significance comparing wells with cells to media 
alone (no cells), *p value <0.05. <MDL = below assay minimum detection limit. 
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Figure 5.5. Effect of 48 hours of treatment with 50µM zoledronic acid on cell 
viability.   
 
ER-ve MDA-MB-231 and MDA-MB-436 cells and ER+ve MCF7 and T47D cells were 
plated in 6 well plates and maintained in medium alone (open bars) +/- 50µM ZOL 
(closed bars).   Data represents 3 replicates and 3 repeats.  Mann-Whitney test for 
comparison of control with ZOL treated, **p value <0.01. 
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Figure 5.6.  Activin and follistatin secretion from MDA-MB-231 (ER-ve) and MCF7 
(ER+ve) cells in response to 48 hours exposure to increasing doses of zoledronic acid.   
 
Cells were plated in 6 well plates and treated with medium alone or with addition of 
25µM or 50µM ZOL.  Data represents 3 replicates and 3 repeats. Mann Whitney test for 
significance comparing each dose to control, * p value <0.05, NS= not significant. 
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Activin secretion was not significantly altered after exposure to 50µM Zoledronic acid in 
either cell line.  Since the ‘biological activity’ of activin will be relative to follistatin 
levels the molar ratio of follistatin:activin was calculated.  The literature reports a 4:1 
ratio of follistatin:activin would neutralize activin (Harrison, Chan et al. 2006). The mean 
concentrations of secreted follistatin and activin from each treatment group were 
converted into pmol/L, by dividing by the relevant molecular weight, and expressed as a 
ratio (Fig 5.7).  Addition of 50 µM zoledronic acid reduces the molar ratio of 
follistatin:activin in MDA-MB-231 cells (control ratio 14:1, ZOL ratio 4:1), compared to 
MCF7 cells which show a rise in the molar ratio of follistatin:activin with addition of 
zoledronic acid (control ratio 3:1, ZOL ratio 4:1). 
 
Continuous treatment of breast cancer cells with zoledronic acid for 48 hours does not 
represent a clinically relevant duration of drug exposure for primary breast cancer cells. 
Zoledronic acid reaches a peak in the circulation at the end of the IV administration and 
declines to 10% of the peak level after 4 hours (Ltd 2013), therefore breast cancer cells 
located outside of bone will only be exposed to a short pulse of drug every 3-4 weeks. To 
evaluate the effects of a short exposure of zoledronic acid on the secretion of follistatin in 
ER-ve cell lines, two ER-ve cell lines (MDA-MB-231 and MDA-MB-436) were treated 
with 50µM zoledronic acid for 4 hours followed by 44 hours of medium alone and 
supernatant was evaluated for follistatin levels. Both cell lines significantly decreased 
their secretion of follistatin in response to a 4-hour pulse of zoledronic acid compared to 
control (MDA-MB-231 p value =0.0015, MDA-MB-436 p value = 0.001) (Fig 5.8).   
 
These data demonstrate that even a relatively brief exposure to zoledronic acid decreased 
the secretion of follistatin from ER-ve cell lines.  The lack of effect of zoledronic acid on 
both cell count and secretion of activin or follistatin in ER+ve cell lines suggested they 
may not take up zoledronic acid.  To evaluate if ER+ve cell lines were able to take up the 
drug, western blot was used to evaluate if zoledronic acid can increase intracellular levels 
of unprenylated Rap1a in MCF7 cells, since zoledronic acid has been shown to increase 
accumulation of unprenylated small GTPases via inhibition of the mevalonate pathway 
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Figure 5.7 Molar ratio of follistatin:activin in MDA-MB-231 and MCF7 cells treated 
with increasing doses of zoledronic acid for 48 hours.   
 
The mean quantity of secreted protein per million cells (pg/ml) was converted into pmol/ml 
for both activin and follistatin by dividing by their molecular weight. The molar ratio was then 
calculated by dividing follistatin by activin. The red horizontal lines represent the molar ratio 
of follistatin: activin that neutralizes activin, bars above the red line represent an excess molar 
ratio of follistatin to activin, bars below the red line represent an excess molar ratio of activin 
to follistatin. 
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Figure 5.8.  Changes in follistatin secretion from ER-ve cell lines in response to a 4 
hour pulse of 50µM zoledronic acid.   
 
Both cell lines were plated in 6 well plates in the presence of medium alone (open bars) 
or medium + 50µM zoledronic acid (closed bars) for 4 hours.  Cells were then washed 
with PBS and medium was added to all cells for a following 44 hours. Data represent 3 
replicates and 3 repeats.  Mann Whitney test for significance comparing ZOL treated cells 
to their respective control, ** p value <0.005, *** p value <0.001. 
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(Russell 2011). In addition, by adding the mevalonate pathway intermediary, 
geranylgeraniol (GGOH), the effects of zoledronic acid on accumulation of unprenylated 
Rap1a should reverse. Both MDA-MB-231 and MCF7 cell lines showed an increase in 
the accumulation of unprenylated Rap1a in response to treatment with zoledronic acid. 
Addition of GGOH partly reversed the effects of zoledronic acid (as shown by a decease 
in unprenylated Rap1a) in MCF7 cells but not in MDA-MB-231 cells (Fig 5.9).   
 
These data have shown that zoledronic acid has a differential effect on follistatin 
secretion dependent upon the ER status of the tumour cell line, with ER-ve cell lines 
decreasing follistatin secretion in response to zoledronic acid, an effect not seen in ER+ve 
cell lines. Both ER-ve and ER+ve cells take up zoledronic acid, as shown by the 
accumulation of unprenylated Rap1a, however, addition of GGOH reduced the levels of 
unprenylated Rap1a in MCF7 cells but not MDA-MB-231 cells, suggesting that uptake of 
the drug may be greater in the MDA-MB-231 cells.  
 
5.5.3	  Effect	  of	  activin	  and	  follistatin	  on	  proliferation	  of	  ER-­‐ve	  and	  ER+ve	  cell	  lines.	  
In order to evaluate the effect of activin and follistatin on proliferation in both ER-ve and 
ER+ve cell lines, a time course and dose response MTS proliferation assay was 
performed. Three doses of activin (60pg/ml, 1800pg/ml and 6000pg/ml) and 3 time-
points were evaluated (day 1, 3 and 5) to compare change in proliferation in control 
medium alone +/- exogenous activin.  Due to the endogenous secretion of follistatin from 
MDA-MB-231 cells, medium +/- activin was replaced every 24 hours, to ensure the 
exogenous added activin would not be neutralized by endogenous secreted follistatin. 
Both the ER-ve cell line MDA-MB-231 and the ER+ve cell line MCF7 showed a 
decrease in proliferation compared to control medium alone with addition of activin.  
This fall also showed a significant dose-dependent effect with increased inhibition of 
proliferation with increasing doses of activin at day 1 and 3 in both cell lines (Fig 5.10).  
These results indicate that both an ER-ve and ER+ve cell lines are responsive to the 
growth inhibitory effect of exogenous activin in vitro, however, these effects are lost at 
day 5.  
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Figure 5.9.  Effect of zoledronic acid on unprenylated Rap1a in MCF7 and MDA-
MB-231 cells. 
 
 Cells were treated with medium alone, GGOH 50µM, ZOL 10µM or GGOH + ZOL for 
48 hours. Rap1a primary antibody 1:200 was used to assess intracellular levels of 
unprenylated protein, with GAPDH 1:20,000 used as a loading control.   
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Figure 5.10.  Effects of increasing doses of activin on tumour cell proliferation over 
time.   
 
MDA-MB-231 and MCF7 cells were plate in 96 well plates and treated with increasing 
doses of activin over 5 days.  Medium +/- activin was replaced every 24 hours with 
addition of MTS solution at the final time-points to allow measurement of absorbance of 
each dose of activin relative to untreated cells. Data represents 8 replicates and 3 repeats. 
Wilcoxon Signed-Rank test was used to detect differences between different doses, * p 
value <0.05, NS = no significant difference. 
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To confirmation the inhibition of cell growth was due to the exogenous activin, cell lines 
were treated with activin 6000pg/ml +/- an ALK4/5 inhibitor SB-431-542 (10µM/l) for 
72 hours.  The ALK4/5 inhibitor will prevent ActRII dimerising with its type I receptor 
ALK4. MDA-MB-231 cells showed less inhibition of proliferation with addition of the 
ALK4/5 inhibitor to activin, although this was not statistically significant, however,  
MCF7 cells showed increased inhibition of proliferation with addition of the ALK4/5 
inhibitor to activin  (Fig 5.11).  The apparent increase in inhibition of proliferation in 
MCF7 cells was unexpected, and therefore direct toxicity of the ALK4/5 inhibitor on 
MCF7 cells was considered.  Exposure of MCF7 cells to the ALK4/5 inhibitor for 3 days 
significantly decreased viable cell count compared to control (p value 0.005) (Fig 5.12).  
These data confirmed the growth inhibitory effects of activin in MDA-MB-231 cells. 
 
To evaluate the effect of the exogenous activin neutralizer, follistatin, on the growth 
inhibitory effect of activin, cells were treated with activin +/- follistatin for 72 hours. The 
dose of follistatin that would be predicted to completely neutralize 6000pg/ml of activin 
is 64,000pg/ml.  There was a reversal of the inhibitory effects of activin on cell 
proliferation when follistatin was added at a neutralizing dose in both MDA-MB-231 and 
MCF7 cells, although the changes were not statistically significant  (Fig 5.13).  These 
data indicated that both ER+ve and ER-ve cell lines are sensitive to the growth inhibitory 
effects of activin, which can be negated by follistatin. 
 
5.5.4	  Effect	  of	  Zoledronic	  acid	  on	  the	  downstream	  activin-­‐signaling	  pathways.	  
Downstream activin-signaling pathways involve the receptor associated and cytoplasmic 
Smads 2 and 3, which translocate to the nucleus after phosphorylation to affect DNA 
transcription.  The function of phosphorylated Smad2 depends upon its phosphorylation 
site, with COOH-tail phosphorylated Smad2 (pSmad2C) being a tumour suppressor and 
linker phosphorylated Smad2 (pSmad2L) promoting tumour growth (Matsuzaki 2011).  
Receptor binding of activin leads to phosphorylation of the membrane bound pSmad2C.  
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Figure 5.11. Effect of activin and the ALK4/5 inhibitor on cell proliferation at 72 
hours.  
 
Cells were plated in 96 well plates and treated with medium alone (control) or 
recombinant activin  (6000pg/ml) +/-ALK4 inhibitor (10µM/l).  The MTS solution was 
added at 72 hours. Data represents 8 replicates and 3 repeats.  Wilcoxon Signed-Rank test 
for significance, NS= not significant. 
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Figure 5.12 Effect of the ALK4/5 inhibitor on cell viability of MCF7 cells treated for 
72 hours.   
 
Cells were plated in 6 well plates and treated with medium alone (control) or medium + 
10µM/l of ALK4/5 inhibitor. Data represents 3 replicates and 3 repeats.  Mann Whitney 
test for significance ** p value <0.01. 
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Figure 5.13. Effect of activin and follistatin on cell proliferation at 72 hours.   
 
Cells were plated in 96 well plates and treated with medium alone (control) or medium 
with addition of exogenous recombinant activin  (6000pg/ml) +/- follistatin 
(64,000pg/ml).  The MTS solution was added after 72 hours. Data represents 8 replicates 
and 3 repeats. Wilcoxon Signed-Rank test for significance, NS= not significant. 
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In contrast, phosphorylation of pSmad2L occurs downstream of cytoplasmic proteins 
such as RAS and nuclear proteins such as cyclin dependent kinases (Matsuzaki 2011).   
Zoledronic acid, as an inhibitor of post-translational prenylation of small GTPases, can 
decrease the activity of RAS in breast tumour cells (Ibrahim, Mercatali et al. 2012), 
therefore may potentially decrease downstream phosphorylation of pSmad2L (Fig 5.14). 
 
In order to evaluate if 50 µM zoledronic acid can modify phosphorylation pSmad2L in 
MDA-MB-231 and MCF7 cells, nuclear localization of the different phosphorylation sites 
was assessed using immunofluorescent staining (chapter 2 section 2.2.2.5) after 48 hours 
of treatment with zoledronic acid compared to medium only control. The percentage of 
MDA-MB-231 cells with nuclear pSmad2L was significantly decreased after 48 hours 
exposure to 50µM zoledronic acid compared to control (p value <0.0001).  No significant 
difference was seen at the 24-hour time-point in MDA-MB-231 cells, or in the MCF7 
cells at 24 or 48 hours (Fig 5.15 a and b).  
 
To assess if the observed effect was an alteration in localization in response to zoledronic 
acid or a decrease in the total cellular quantity, western blots were performed on lysates 
from MDA-MB-231 cells treated with or without zoledronic acid for 48 hours. No 
significant alteration in the total cellular quantity of pSmad2L in response to zoledronic 
acid was seen (Fig 5.16), suggesting that zoledronic acid alters localization of pSmad2L 
but not total cellular quantity. No significant difference was seen in the percentage of 
cells with nuclear pSmad2C in either cell line at 48 hours (Fig 5.17 a and b). However, 
previous data had shown 48 hours of treatment with 50µM zoledronic acid decreased 
MDA-MB-231 secretion of the activin neutralizer, follistatin.  Therefore to evaluate if the 
changes in follistatin secretion from MDA-MB-231 could affect the receptor associated 
phosphorylation of Smad2/3C, a cell based fluorescent immunoassay was used to 
evaluate the percentage of pSmad2/3C compared to total Smad2/3 in MDA-MB-231 cells 
exposed to 1 hour of supernatant from MDA-MB-231 cells that had been previously 
treated for 48 hours with 50µM zoledronic acid or medium alone.  MDA-MB-231 cells 
exposed to supernatant from zoledronic acid treated cells had a significantly higher 
percentage of pSmad2C than cells treated for 48 hours with medium alone (p value 
0.0286). 
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Figure 5.14.  Schematic of the different effector functions of the alternate 
phosphorylation sites of Smad2 in tumour cells, and the potential effect of 
Zoledronic acid.   
 
COOH-tail phosphorylation of Smad2 (C) results from dimerization of the ACRII 
receptor with ALK4, allowing translocation to the nucleus to inhibit tumour cell growth.  
Phosphorylation at the linker region (L) changes the effector function of Smad2, which 
becomes a tumour promoter.  ZOL increases the bioavailability of activin in ER-ve cell 
lines by decreasing the activin neutralizing molecule, follistatin.  ZOL may also be able to 
affect linker phosphorylation via its known effects on small GTPases such as RAS and 
the cyclin dependent kinases (CDKs). 
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Figure 5.15a.  Representative immunofluorescent images of the effect of zoledronic 
acid on cellular localization of pSmad2L in MDA-MB-231 and MCF7 cells.  
 
Corresponding Dapi (blue) and pSmad2L (green) images in (A) MDA-MB-231 cells 
treated with medium alone (control) and 50µM zoledronic acid for 48 hours.  (B) MCF7 
cells treated with medium alone and 50µM zoledronic acid for 48 hours. 
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Figure 5.15b. Effect of zoledronic acid on nuclear localization of pSmad2L in MDA-
MB-231 cells and MCF7 cells.   
 
A minimum of 100 cells per chamber were counted from MDA-MB-231 and MCF7 
treated with medium alone (open bars) or medium + 50µM zoledronic acid (closed bars) 
for 48 hours. Data represents mean + SEM of 3 replicates and 3 repeats.  Mann Whitney 
test for significance ***p value <0.001, NS=not significant 
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Figure 5.16.  Effect of zoledronic acid on the total cellular quantity of pSmad2L in 
MDA-MB-231  
 
Cells were plated in 6 well plates and treated with medium alone (c) or medium + 50µM 
zoledronic acid (z) for 24 or 48 hours. Cells were lysed at each time-point and processed 
to western blot using specific antibodies to Smad2L 1:1000 and gapdh 1:20,000 as a 
loading control. 
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Figure 5.17a.  Representative immunofluorescent images of the effect of zoledronic 
acid on cellular localization of pSmad2C in MDA-MB-231 and MCF7 cells.  
 
Corresponding Dapi (blue) and pSmad2C (green) images in (A) MDA-MB-231 cells 
treated with medium alone (control) and 50µM zoledronic acid for 48 hours.  (B) MCF7 
cells treated with medium alone and 50µM zoledronic acid for 48 hours. 
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Figure 5.17b.  Effect of zoledronic acid on nuclear localization of pSmad2C in MDA-
MB-231 cells and MCF7 cells.   
 
A minimum of 100 cells per chamber were counted from MDA-MB-231 and MCF7 cells 
treated with medium alone (open bars) or medium+50µM zoledronic acid (closed bars). 
Data represents mean + SEM of 3 replicated and 3 repeats.  Mann Whitney test for 
significance NS = not significant. 
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Since the supernatant would have contained zoledronic acid, a further control was added 
of 1-hour treatment of 50µM zoledronic acid which did not show any change in the 
percentage of pSmad2C compared to medium alone (Fig 5.18).  Phosphorylation of 
Smad2C is not solely the result of activin binding to ActRII but can also be increased by 
TGFβ1 binding to TGFβRII.  To assess if a 48-hour treatment with 50µM zoledronic acid 
altered TGFβ1 secretion in MDA-MB-231 cells, TGFβ1 levels from the cell supernatant 
were evaluated and compared to control medium alone using a TGFβ1 ELISA. 
Zoledronic acid did not significantly alter the secretion of TGFβ1 from MDA-MB-231 
cells at 48 hours (Fig 5.19), therefore the effect of the supernatant from zoledronic acid 
treated MDA-MB-231 cells on pSmad2C, is likely to be due to a decrease in follistatin 
levels which increases bioavailability of activin. 
 
These data therefore suggest that zoledronic acid can both decrease nuclear localization 
of pSmad2L and increase cellular quantity of pSmad2C in MDA-MB-231 cells, 
supporting the potential increased anti-tumour effects in ER-ve breast cancer cells. 
 
5.5.5	  Effect	  of	  zoledronic	  acid	  on	  follistatin	  and	  linker	  phosphorylated	  Smad2	  in	  a	  sub-­‐
cutaneous	  xenograft	  model	  of	  ER-­‐ve	  MDA-­‐MB-­‐436	  tumours.	  
To evaluate if the zoledronic acid induced changes in both follistatin levels and pSmad2L 
in ER-ve cells in vitro also occurred in vivo, ER-ve MDA-MB-436 sub-cutaneous tumour 
sections from mice treated with or without zoledronic acid were stained and scored for 
follistatin and pSmad2L. 
Both MDA-MB-231 and MDA-MB-436 sub-cutaneous tumours express follistatin and 
pSmad2L (Fig 5.20a and b). To assess the effects of zoledronic acid on follistatin, MDA-
MB-436 tumour sections from saline  (n=5) and zoledronic acid (n=6) treated mice were 
scored for intensity of staining and area of positive staining.  Follistatin staining was 
primarily cytoplasmic in the tumor sections, with the intensity of stain relating to the 
distance from the centre of the tumour.  Large tumours with central necrotic areas 
demonstrated no staining in the core, whereas the outer cortex of the tumours 
demonstrated more intense staining in both control and zoledronic acid treated tumours 
(Fig 5.21a). No difference was seen in the intensity of follistatin stain, however, there was   
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Figure 5.18.  Effect of supernatant from zoledronic acid treated MDA-MB-231 cells 
on intracellular pSmad2/3 levels in MDA-MB-231 cells. 
 
MDA-MB-231 cells were plated in a 96 well plate and exposed to either supernatant from 
MDA-MB-231 cells previously treated with 50µM zoledronic acid for 48 hours, or fresh 
medium + 50µM zoledronic acid for 1 hour.  Cells were fixed and fluorescent antibodies 
used to detect pSmad2/3C and total Smad2/3C. Data represent the % of pSmad2C to total 
Smad2C +SEM, and represents 3 replicates from 3 repeated cell secretion experiments. 
Mann Whitney test for significance, * p value <0.05, NS= not significant. 
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Figure 5.19 Secretion of TGFβ1 from MDA-MB-231 cells in response to zoledronic 
acid.  
 
MDA-MB-231 cells were plated in 6 well plates and treated with medium alone (control) 
or medium + 50µM zoledronic acid for 48 hours.  Supernatant was removed and 
processed to TGFβ1 ELISA.  Data represents mean +SEM of 3 replicates and 3 repeats.  
Mann Whitney test for significance, NS=not significant. 
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Figure 5.20a Representative images showing follistatin expression in MDA-MB-231 
and MDA-MB-436 sub-cutaneous tumours 
 
The positive follistatin staining was located in the cytoplasm and extracellular space in 
both ER-ve tumours.  Images represent x1.6 magnification (left) and x20 magnification 
(right). 
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Figure 5.20b Representative images showing pSmad2L expression in MDA-MB-231 
and MDA-MB-436 sub-cutaneous tumours 
 
The positive pSmad2L staining was primarily located in mitotic cells in both ER-ve 
tumours (highlighted by black triangles). Images represent x1.6 magnification (left) and 
x20 magnification (right). 
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Figure 5.21a Representative images of follistatin expression in MDA-MB-436 sub-
cutaneous tumours from mice treated with and without zoledronic acid.   
 
 
The positive follistatin staining was localized to the outer cortex of the tumours with no 
positive staining detected in the necrotic core.  For quantification of staining, 20x750µm2 
images were scored from two sections per tumour and scored for intensity of +ve stain 
and area of positive stain on a 0-3 scale.  Images represent tumours from saline treated 
mice (top) and zoledronic acid treated mice (bottom) at x1.6 magnification (right) and 
x20 magnification (left). 
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a significant decrease in the area of staining in tumours from mice treated with zoledronic 
acid compared to saline (Fig 5.21b).  Data was analysed using average scores from 2 
assessors blinded to treatment groups. 
 
For pSmad2L, MDA-MB-436 tumour sections were assessed from saline (n=6) and 
zoledronic acid treated mice (n=8).  The results showed that when there was +ve staining 
for pSmad2L, the cells were in mitosis (Fig 5.22a).  The number of cells with positive 
staining for pSmad2 was significantly lower in zoledronic acid treated mice (Fig 5.22b).  
These tumours had previously been stained and scored for the proliferation marker Ki67, 
with no significant difference in Ki67 seen between saline and zoledronic acid treated 
mice (Ottewell, Monkkonen et al. 2008).  Also further work from the same group 
evaluating the effects of a similar 6-week schedule of zoledronic acid on sub-cutaneous 
MDA-MB-436 tumours using cell cycle specific microarrays, had shown no significant 
change in genes encoding for cyclins and CDKs with single agent zoledronic acid 
(Ottewell, Lefley et al. 2010).  Therefore the number of cells in mitosis would not be 
expected to be different between tumours from the control and zoledronic acid treatment 
groups, indicating the decrease in pSmad2L is not secondary to alterations in mitosis 
levels. 
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Figure 5.21b Effect of zoledronic acid on follistatin expression in sub-cutaneous 
MDA-MB-436 tumours. 
  
Area of +ve staining was scored as 0 no stain, 1 up to 10% +ve cells, 2 10-50% +ve cells 
and 3 >50% +ve cells.  
Intensity of staining was scored as 0 no stain, 1 weak, 2 moderate and 3 strong.   
20 different tumour areas were evaluated per animal and data represents average score 
from 2 persons blinded to treatment.  Mann Whitney test for significance *** p value 
<0.001, NS= not significant.  
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Figure 5.22a.  Representative images of pSmad2L expression in MDA-MB-436 sub-
cutaneous tumours in mice treated +/- zoledronic acid 
 
Sections from sub-cutaneous tumours were stained for follistatin with primary antibody 
1:200. Representative examples from control (saline treated) (left) vs. zoledronic acid 
treated mice (right).  
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Figure 5.22b. Effect of zoledronic acid on pSmad2L expression in MDA-MB-436 sub-
cutaneous tumours  
 
20 images were taken from different areas of each tumour.  The number of positive cells 
was counted per area and averaged per tumour.  A Data in graph represents average score 
per treatment group in control (saline treated) vs. zoledronic acid treated. Mann Whitney 
test for significance *** p value <0.001  
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5.6	  Discussion	  	  
The results presented in this chapter support a potential new novel anti-tumour 
mechanism of action of zoledronic acid in ER-ve breast cancer cells, via effects on the 
activin-signaling pathway.  Zoledronic acid caused an apparent increase in the 
bioavailability of activin by decreasing the activin neutraliser, follistatin, both in vitro and 
in vivo.  Zoledronic acid also appeared to reduced the nuclear localization in vitro, and the 
number of positive cells in vivo, of the tumour promoter pSmad2L.  These data may 
represent a mechanism to explain the differential anti-tumour effect of zoledronic acid 
according to ER receptor status, which has been demonstrated in neo-adjuvant clinical 
trials of zoledronic acid. 
 
Both activin and follistatin were secreted from ER-ve and ER+ve breast cancer cells, but 
in different molar ratios, with ER-ve cells secreting an excess of follistatin:activin 
favouring tumour proliferation, compared to ER+ve cells which secreted an excess of 
activin:follistatin.  Previously published data have demonstrated that activin is secreted 
by benign proliferative fibrocystic disease of the breast (Di Loreto, Reis et al. 1999). The 
activin βA subunit is detected in breast carcinoma, fibroadenoma and normal mammary 
tissue with a 43% increase in mRNA levels in carcinoma compared to normal breast 
tissue, translating into a significantly higher tissue concentration of activin A in breast 
cancer homogenates compared to non-neoplastic breast tissue (Reis, Cobellis et al. 2002). 
Neither of these studies evaluated any concurrent expression of follistatin mRNA or 
follistatin secretion from normal mammary or malignant tissue. 
 
Whilst activin is generally accepted to be a tumour suppressor in breast carcinoma, and 
confirmed by my data, there is controversy in the literature regarding the ability of activin 
to affect ER-ve cell lines, with some reports of insensitivity of ER-ve cell lines to the 
growth inhibitory effects of activin.  Kalkhoven et al evaluated a panel of breast cancer 
cell lines for their growth sensitivity to exogenous TGFβ and activin A and showed that 
growth of the ER+ve cell lines MCF7, T47D and ZR75-1 was inhibited by activin, 
whereas ER-ve cell lines including MDA-MB-231, MDA-MB-436 were resistant to 
activin growth inhibition.  The reason for the lack of growth inhibition in MDA-MB-231 
and MDA-MB-436 cell lines was not due to lack of activin receptors, or ability of activin 
to bind to receptors, and the authors suggested the resistance to the anti-proliferative 
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effects of activin may be located downstream of the activin receptor (Kalkhoven, Roelen 
et al. 1995).  However, the presence and/or effect of an exogenous secreted activin 
neutralizer such as follistatin was not measured in this study.  Burdette et al evaluated the 
effects of activin, follistatin and an ALK4/5 inhibitor in the ER+ve cell lines MCF7 and 
T47D.  Proliferation was significantly inhibited by activin, which was negated with 
addition of an ALK4/5 inhibitor.  Activin also increased the number of T47D cells which 
were in G0-1 phase, and the addition of follistatin reduced the number of G0-1 cells by 
30% with a concurrent increase in the number of cells in S phase (Burdette, Jeruss et al. 
2005), confirming the ability of follistatin to negate the tumour suppressor action of 
activin. 
Jeruss et al compared components of the activin signaling pathway in grade 1 (n=22), 
grade 2 (n=18) and grade 3 (n=19) breast cancer, evaluating activin ligand subunits (βA 
and βB), receptors (ActRIIA, ActRIIB and ActRIB) and downstream signaling proteins 
(Smad 2,3,4). Using immunohistochemistry, activin βA subunit was detectable in all 
tumour grades and in normal breast tissue, and there was no difference in staining 
between the benign and malignant cells. Both activin type II receptors were attenuated in 
grade 3 tumours compared to grade 1 and 2, and using immunofluorescent imaging, 
nuclear localization of all Smads were lower in grade 3 tumours compared to grade 1 and 
2.  These data indicate that as tumour grade increases the cellular production of activin A 
remains constant, however, the receptor and downstream signaling pathways are 
diminished.  This confirmed the tumour suppressive role of activin in breast cancer 
(Jeruss, Sturgis et al. 2003).  Interestingly, in this study ER+ve tumours had a 
significantly higher nuclear Smad3 staining compared to ER-ve tumours (77% vs 13% 
p=<0.001), but again follistatin was not measured. From my data it seems plausible that a 
common mechanism of resistance to activins tumour suppressor actions in ER-ve breast 
cancer, may be linked to breast cancer cell secretion of activin neutralizing molecules 
such as follistatin. 
 
Activin’s bioavailability is regulated by several proteins, including follistatin and 
follistatin related gene (FLRG).  Razanajoana et al showed that FLRG is expressed by 
breast cancer cells, and follistatin expression was detected in the two ER-ve cell lines 
MDA-MB-459 and HS578T cells.  The anti-proliferative effect of activin was weak in 
ER+ve MCF7 cells and undetectable in ER-ve MDA-MB-436 cells cultured over 4 days.   
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However, after washing cells to remove endogenous secreted inhibitors such as follistatin 
and FLRG, Smad2C was phosphorylated in response to activin in all cell lines.  After 
silencing FLRG expression in MCF7 and MDA-MB-436 cells, expression of pSmad2C 
was increased, and the proliferation of both cell lines was decreased.  These results 
suggest that in both ER-ve and ER+ve cell lines, endogenous activin inhibitors such as 
FLRG can promote cell growth by neutralizing the inhibitory effects of activin 
(Razanajaona, Joguet et al. 2007).  Using immunohistochemistry to detect follistatin and 
FLRG in clinical samples of breast proliferative disorders, follistatin expression was 
significantly increased in the stromal cells of fibroadenomas compared to normal breast 
tissue, and FLRG staining was significantly higher in invasive carcinoma compared to 
normal breast tissue (Bloise, Couto et al. 2009).  These data suggest that tumour cells 
may use activin inhibitors such as follistatin and FLRG to reduce or even negate the anti-
proliferative effects of activin. 
 
The differential effects of zoledronic acid on follistatin secretion according to ER status 
of breast cancer cell lines, has not been previously reported. However, other studies have 
shown a differential effect of zoledronic acid on proliferation of ER-ve and ER+ve cells 
via alternative mechanisms.  Zoledronic acid used in combination with cisplatin had an 
enhanced anti-proliferative effect in ER-ve cell lines but not the ER+ve cells via 
alteration in p21, pMAPK and m-TOR pathways (Ibrahim, Liverani et al. 2013).  Rachner 
et al confirmed the differential effect of zoledronic acid on proliferation according to ER 
status of cell lines showing that MCF7 cells did not demonstrate a significant change in 
proliferation in response to increasing doses of zoledronic acid whereas MDA-MB-231 
cells showed a dose- dependent inhibition of proliferation and increase in apoptosis via 
activation of caspase 3 and 7 (Rachner, Singh et al. 2010).  These results were supported 
by Fehm et al who showed the antitumour effect of zoledronic acid on primary breast 
cancer samples removed at surgery (n=116), was greatest in ER-ve tumours using an 
ATP-tumour chemosensitivity assay (Fehm, Zwirner et al. 2012).  Some studies have 
reported ER+ve cells to be more responsive to zoledronic acid (Fromigue, Lagneaux et al. 
2000), or no differential effect of zoledronic acid according to ER status (Senaratne, 
Pirianov et al. 2000; Jagdev, Coleman et al. 2001).  
A possible explanation for the differential effects of zoledronic acid on proliferation 
according to ER status may be due to differences in uptake of the drug.  Previously 
published data have shown that the maximal anti-tumour effects of zoledronic acid are 
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obtained in vivo when unprenylated Rap1a is detected in tumour lysates (Ottewell, 
Woodward et al. 2009; Ottewell, Lefley et al. 2010). I detected unprenylated Rap1a in 
both MDA-MB-231 and MCF7 cells after treatment with the same dose of zoledronic 
acid, However, addition of the mevalonate intermediate GGOH partly reversed the 
accumulation of Rap1a in MCF7 cells only, suggesting the ER-ve MDA-MB-231 cells 
either take up more zoledronic acid, or do not take up the GGOH as effectively as MCF7 
cells. 
 
A decrease in follistatin secretion from breast cancer cells would be expected to increase 
activin binding to its receptor by increasing bioavailability of ‘active’ activin.  This 
should then increase phosphorylation of the intracellular receptor associated pSmad2C 
protein.  My data showed that supernatant from MDA-MB-231 cells, which had reduced 
follistatin levels, increased the percentage of pSmad2/3C relative to total Smad2/3. 
Phosphorylation of Smad2 via the canonical pathway, resulting in c terminus 
phosphorylation, has been shown to suppress breast cancer cell invasion and metastases 
to bone in vitro and in vivo.  Knockdown of pSmad2C in MDA-MB-231 cells in vitro 
resulted in a lower growth rate and reduced migration compared to parental MDA-MB-
231 cells.  However, in a mouse model of bone metastases the Smad2 knockdown cells 
showed significantly faster establishment in bone compared to control, suggesting a 
tumour suppressive role for Smad2C in vivo (Petersen, Pardali et al. 2010).  
These data are in contrast to a study which showed inhibition of phosphorylation of 
pSmad2C signaling using an AKl5 inhibitor, reduced metastases to lung from 4T1 
(ER+ve) breast tumours (Park, Son et al. 2011), suggesting that inhibition of pSmad2C 
may have a differing anti-metastatic effect according to the site of metastases or breast 
cancer cell line used. 
In clinical studies, a large tissue microarray study of breast tumours from 426 patients 
showed loss of pSmad2 was associated with a shorter overall survival (median survival 
110.5 vs 306.5 weeks p=0.024), but did not correlate with tumour type, grade, receptor 
status or lymph node status, suggesting loss of pSmad2C may be an independent 
prognostic factor (Xie, Mertens et al. 2002).  Similar results were shown in a study of 61 
patients with T1-2 N0 tumours, confirming loss of pSmad2/3C was significantly 
associated with a shorter disease free survival (Koumoundourou, Kassimatis et al. 2007). 
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Phosphorylation of Smad2 at the linker region has been reported to alter the tumour 
suppressive action of Smad2 to a tumour promoter action.  Phosphorylation at this site is 
primarily via cytoplasmic RAS and nuclear cyclin dependent kinases (Matsuzaki 2011), 
as opposed to the canonical receptor mediated activin pathway leading to COOH-
terminus phosphorylation.  I have shown that zoledronic acid can decrease linker 
phosphorylation of Smad2 in ER-ve breast cancer cells both in vitro and in vivo.   
Zoledronic acid has recently been shown to decrease RAS expression and activity in 2 
ER-ve cell lines (MDA-MB-231 and BRC-230), with an associated inhibition of cell 
proliferation. ER+ve cell lines showed less effect of zoledronic acid on RAS expression 
and activity with no associated effect on cell proliferation (Ibrahim, Mercatali et al. 2012).  
Therefore a reduction is RAS activity could be expected to reduce RAS dependent linker 
phosphorylation of Smad2, as shown in my data. 
 
These data have demonstrated a potential dual mechanism of action of zoledronic acid on 
the activin signaling pathway in ER-ve breast cancer cells; firstly via a decrease in 
follistatin secretion in vitro and in vivo leading to an increase in pSmad2C, and secondly 
via a decrease in phosphorylation of pSmad2L in vitro and in vivo. These data provide a 
possible further anti-tumour mechanism of action of zoledronic acid, that could contribute 
to the differential effect seen in clinical trials of ER –ve and +ve breast cancer. 	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Chapter 6. The ovarian hormone 
inhibin A, and zoledronic acid, 
influence levels of activin and 
follistatin in the tumour and bone 
microenvironment. 
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6.1	  Summary	  	  
Inhibin A is an ovarian secreted hormone, which has been previously shown in vitro and 
in vivo to affect the bone microenvironment by increasing osteoblast activity and bone 
density. Supplies of the recombinant inhibin A protein extensively used in endocrine and 
bone research ceased to be commercially available several years ago, with no current gold 
standard recombinant protein used for in vitro or in vivo studies.  Therefore I sought to 
establish the effect of a human recombinant inhibin A protein not previously reported in 
the literature, on breast cancer cells in vitro and on the bone microenvironment in vivo. 
 
The effect of inhibin A and zoledronic acid on bone activin and follistatin levels has not 
been reported.  The ratio of activin:follistatin may influence tumour cell proliferation, 
since follistatin can negate the anti-proliferative effects of activin in breast cancer cells.  
Levels of these paracrine factors in the bone microenvironment may have the potential to 
affect disseminated tumour cells that seed to bone in early breast cancer.  The aim of the 
work described in this chapter was to evaluate the activity of a human recombinant 
inhibin A protein not previously used in vivo to assess effects on the bone 
microenvironment, and compare these to the effects of zoledronic acid in a murine bone 
metastases model.  The direct effects of inhibin A on activin and follistatin secretion from 
breast cancer cells was also evaluated in vitro. 
 
The results indicate that recombinant human inhibin A sourced from the National 
Institute for Biological Standards and Controls (NIBSC) is active in vivo, as it increased 
bone density in both ovariectomised (OVX) and sham operated mice.  In addition it 
decreased bone levels of activin in OVX animals.  Zoledronic acid, as expected, increased 
bone density in both OVX and sham animals via inhibition of osteoclast activity and 
caused a significant decrease in osteoblast numbers on the trabecular bone surface.  
Zoledronic acid decreased bone follistatin levels in OVX animals. In vitro, inhibin A 
prevented the zoledronic acid induced decrease in follistatin secretion from MDA-MB-
231 cells. 
 
These data suggest that addition of zoledronic acid to an inhibin A rich bone 
microenvironment with concurrently low activin levels, does not alter paracrine follistatin 
levels and therefore the low bioavailability of the tumour suppressor activin persists. This 
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is in contrast to an inhibin A-deficient, high activin containing bone microenvironment 
(OVX), where zoledronic acid is able to decrease paracrine follistatin levels, potentially 
further increasing the bioavailability of activin. This could have implications for 
proliferation of DTCs within these two different bone environments. In addition to the 
modification of the bone microenvironment, inhibin A can directly affect breast cancer 
cells in vitro, causing an increase in follistatin secretion from MDA-MB-231 cells.  These 
data suggest that the female hormone inhibin A can affect both the bone 
microenvironment and secretion of paracrine proteins from breast cancer cells and can 
potentially modify the response to zoledronic acid.  
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6.2	  Introduction	  
 
The direct effects of the two members of the TGFβ superfamily of paracrine proteins, 
activin and follistatin, on breast cancer cells, have been extensively reported and are 
discussed in previous chapters.  However, the direct effect of the TGFβ superfamily 
endocrine protein, inhibin, on breast cancer cells is not well defined in the literature.  
Sanz-Pamlona et al identified inhibin as a protein expressed in primary breast cancers, 
which predicted for formation of brain metastases (ROC AUC=0.91, 95% CI 0.11-1.00) 
(Sanz-Pamplona, Aragues et al. 2011), suggesting a metastasis promoting action of 
inhibin.  These data were supported in a further study of multiple primary tumours 
including ovarian, colorectal and breast, which found inhibin A to be overexpressed in 
tumour samples, and predictive for a stage of tumourigenesis that corresponded with the 
ability of the tumours to invade stromal tissue and metastasise (Kim, Watkinson et al. 
2010). Inhibin A has been shown to be over expressed in breast cancer cell lines 
compared to normal breast cell lines in vitro (Liang, Huuskonen et al. 2009), and an in 
vivo study of 334 breast cancer specimens found that inhibin A was expressed in 25% of 
invasive ductal carcinomas, 26% of DCIS and 33% of lobular carcinomas (Chang, Lee et 
al. 2005). However, other studies have found the opposite, with inhibin A expression 
being unchanged between normal breast tissue and invasive cancer (Reinholz, Iturria et al. 
2002), or upregulated in normal breast tissue compared to invasive cancer (Di Loreto, 
Reis et al. 1999).  The role of inhibin A in breast cancer therefore remains to be defined.  
 
In early breast cancer, without clinically identifiable metastatic disease, disseminated 
tumour cells (DTCs) can be detected in the bone marrow in 30-40% of patients. The 
presence of DTCs are an independent adverse prognostic factor associated with an 
increased overall rate of death from breast cancer and decreased disease free interval 
(Braun, Vogl et al. 2005).  The survival and fate of these DTCs is in part determined by 
their intrinsic properties, but is also influenced by cells in their surrounding environments 
including; bone cells (osteoblasts and osteoclasts), hematopoetic stem cells, endothelial 
stem cells, fibroblasts and immune cells.  DTCs in bone are thought to interact with 
osteoblasts and compete for occupancy in the bone marrow (Park, Soki et al. 2011).  In a 
murine prostate cancer model, cancer cells shed from sub-cutaneous tumours are 
demonstrated to occupy the hematopoetic stem cell niche, and expanding the niche by 
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increasing osteoblast numbers with parathyroid hormone (PTH) increased the number of 
tumour cells in the bone marrow (Shiozawa, Pedersen et al. 2011).  In a murine model of 
breast cancer, increasing osteoblast numbers and activity with PTH prior to intracardiac 
injection of MDA-MB-231 breast cancer cells resulted in an increased number of tumour 
foci (Brown HK 2013). In addition, tumour cells in direct contact with bone can alter 
bone cell numbers by decreasing osteoblast and increasing osteoclast numbers (Brown, 
Ottewell et al. 2012).  These data support the concept that cells of the bone 
microenvironment are influenced by tumour cells, and can themselves affect tumour cell 
survival.  The bone microenvironment will be altered by local paracrine factors but also 
by endocrine factors, including female hormones (Wilson, Holen et al. 2012).  As 
discussed in chapter 3, premenopausal women have high inhibin levels compared to 
postmenopausal women, where inhibin levels are undetectable in serum.  This could 
create two different bone microenvironments with the potential to differentially alter 
tumour cell colonization, growth and progression. 
 
It is well established that activin is produced locally in the bone marrow and stored in the 
bone matrix (Ogawa, Schmidt et al. 1992), whereas inhibin is not abundantly expressed 
in bone. As discussed in chapter 5, inhibin’s mechanism of action is via prevention of 
activin binding to its type 2 receptor, ActRIIA.  Both in vitro and in vivo studies have 
investigated the effects of blockade of ActRIIA. In vitro, blockade of ActRIIA with 
inhibin A suppressed osteoblast and osteoclast formation and differentiation from murine 
BM cultures (Gaddy-Kurten, Coker et al. 2002), human mesenchymal stem cells and 
peripheral blood mononuclear cells (Perrien, Akel et al. 2007).  In addition, despite 
secretion of activin from these cultures, the inhibitory effects of inhibin A on the ActRIIA 
receptor dominated. 
 
Radiolabelled inhibin A administered intravenously was shown to accumulate within 10 
minutes in the bone marrow of 25 day old rats, indicating that inhibin A can distribute to, 
and may have an effect on bone (Woodruff, Krummen et al. 1993).  Three key in vivo 
studies (Perrien, Akel et al. 2007; Pearsall, Canalis et al. 2008; Chantry, Heath et al. 
2010) have investigated the effect of blocking ActRIIA on bone, either with inhibin A or 
a soluble extracellular domain of ActRIIA fused to a murine IgG2a-Fc.  These studies 
have collectively demonstrated that blocking this receptor increases bone density in 
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mouse models (see Table 6.1), and the effect appears to be via an increase in the activity 
and number of osteoblasts (Ob). 
 
These data suggest that the inhibin A/activin ratio in bone can determine the activity and 
number of osteoblasts with a subsequent effect on bone density.  It could therefore be 
hypothesized that the bone microenvironment in an inhibin A rich (premenopausal) 
woman is different to that of an inhibin A deficient (postmenopausal) woman, and this 
may have subsequent effects on tumour growth/development (Fig 6.1) 
 
The effect of zoledronic acid on bone density and cellular composition of bone has been 
extensively researched in both preclinical and clinical studies. Bisphosphonates bind 
avidly to bone and are taken up by osteoclasts (Coxon, Thompson et al. 2008).  This leads 
to an inhibition of osteoclast mediated bone resorption in animal models, and can prevent 
bone loss in male and female animals who have or have not undergone 
OVX/gonadectomy (Gasser, Ingold et al. 2008) (Hornby, Evans et al. 2003).  
Maintenance of bone density does not therefore appear to be dependent upon sex or the 
hormonal status.  
How the osteoclast-mediated effect of zoledronic acid subsequently modifies tumor cells 
is not clearly defined, but the general consensus is that tumour cells in bone may 
potentially be exposed to significant concentrations of bisphosphonates during bone 
turnover and hence be directly affected by the drug (Holen and Coleman 2010). An in 
vivo study of the effects of zoledronic acid on B16 melanoma tumour growth in bone in 
mice that lacked functional osteoclasts, still showed a decrease in tumour growth with 
zoledronic acid (Hirbe, Roelofs et al. 2009), suggesting the osteoclast may not be the only 
bone cell that influences the anti-tumour effects of zoledronic acid. The differential anti-
tumour effects of zoledronic acid  
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Table 6.1 Summary of the main in vivo studies assessing the effect on bone of 
blockade of ActRIIA. 
 
 
Mouse&
strain,&sex&
and&age&at&
treatment&
Treatment&
schedule&
Dura6on&
of&
Treatment&
(weeks)&
BV/TV&& Osteoblast&
ac6vity&and&number&
(trabecular&surface)&
Osteoclast&
ac6vity&and&number&
(trabecular&surface)&
Ref&
Transgenic&&
Female&intact&
Male&sham/
ORCH&
22&week&
MFP&induced&
inhibin&A&&
(Serum&
inhibin&A&
levels&
400M800&pg/
ml)&
&
&
4&
Proximal&6bia;&
Treated&vs&control;&&
F&in&tact;17%&vs&10%*,&&
M&sham;35%&vs&25%*&
M&ORCH;&25%&vs&15%*&
F;NR&
M;&&increase&in&serum&
osteocalcin&&in&sham*,&
and&ORCH&NS.&
&
No&change&in&ObN&in&
sham&or&orch&
F;NR&
M;&no&change&in&serum&
CTx,&or&OcN&in&sham&or&
ORCH.&
&
&
Perrien&et#al#
(2007)&
C57/BL/6N&
&
&
Female&intact&
12&week&&
&
&
&
&
&
&
Female&sham/
OVX&
12&week&
&
&
&
&
&
ActRIIAMmFc&
10mg/kg&IP&
2x&per&week&
&
&
&
2,4,6,12&
&
&
&
&
&
&
&
&
12&
Distal&femur;&
Treated&vs&control&
2/52;&10%&vs7%*&
4/52;&15%&vs6.5%*&
6/52;&14%&vs&6%*&
12/52;&15%&vs&4%*&
&
&
&
&
Distal&femur&;&
HIgher&in&treated&vs&
control&&in&sham&and&
ovx&animals*&
2/52&increase&in&serum&
osteocalcin&in&treated&vs&
control*&
4/52&increase&in&serum&
osteocalcin&in&treated&vs&
control*&
&
ObN;&NR&
&
&
&
NR&
2/52;&no&change&in&
serum&TRAP&intreated&vs&
control&
4/52;&increase&in&serum&
TRAP&in&treated&vs&
control*&
&
OcN;&NR&
&
&
&
NR&
&
&
&
&
&
&
Pearsall&et#al#
(2008)&
C57/BL/6&
Female&intact&
8&weeks&
ACTRIIAMmFC,&
0.1,0.3,3.0,&
10mg/kg&IP&
2x&per&week&
&
&
6&
Proximal&6bia;&&
Dose&dependent&
increase&in&BV/TV,&
10mg/kg&22%&vs&
control&9%&
Increased&ObN&treated&
vs&control*&
No&signiﬁcant&eﬀect&
OcN&treated&vs&control.&
&
Chantry&et#al#
(2010)&
Key;&F&female,&M&male,&OVX&ovariectomy,&ORCH&orchidectomy,&IP&intraperitoneal,&*&p&value&<0.05,&NS&not&signiﬁcant,&ObN&osteoblast&number,&OcN&osteoclast&number,&NR&
not&recorded,&TRAP&tartrate&resistant&acid&phosphatase,&CTx&c&terminal&telopep6de,&MFP=mifepristone.&
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Figure 6.1.  The bone microenvironment in premenopausal women will differ from 
that of  postmenopausal women.   
 
Premenopausal women have high levels of ovarian secreted inhibin A, which may have 
relevant effects on disseminated tumour cells within bone, by decreasing the ability of 
activin to bind to ActRIIA and phosphorylate the downstream signaling tumour 
suppressors Smad2/3.  A postmenopausal woman has undetectable inhibin A due to 
natural ovarian failure, and therefore is likely to have a high level of paracrine secreted 
activin in bone that may influence disseminated tumour cells. 
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according to menopausal status seen in the clinical trials and discussed in chapters 3 and 4 
may therefore, in part, be due to mechanisms of action other than inhibition of bone 
resorption, since the inhibition of osteoclast activity is not a sex or hormone-mediated 
mechanism of action of zoledronic acid (Hadji, Coleman et al. 2012).   
 
There is very little published data on the effect of bisphosphonates on activin levels or 
release from bone.  Sakai et al reported that activin was released from mouse calvaria into 
medium in response to parathyroid-induced bone resorption, and that addition of a 
bisphosphonate (disodium dichlormethane-1,1-bisphosphonic acid) inhibited the release 
of activin from bone (Sakai, Eto et al. 2000).  This effect was not seen in primary culture 
of calvarial cells, suggesting the mechanism of action was via release of activin from 
bone during resorption, rather than direct secretion of activin from bone cells.   
 
To my knowledge there are no published in vivo studies evaluating the effect of either 
inhibin A or zoledronic acid on activin or follistatin release from bone, or the effect of 
inhibin A on follistatin secretion from breast cancer cells in vitro. The new information 
described in this chapter details how inhibin A and zoledronic acid differentially affect 
activin and follistatin release in both the bone microenvironment in vivo, and directly 
from MDA-MB-231 cells in vitro.  These data suggest a novel opposing action of the 
female hormone inhibin A and zoledronic acid on the activin:follistatin ratio in vivo and 
in vitro, with potential implications for development of bone metastases. 
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6.3	  Aims 
 
The overall purpose of this chapter was to evaluate the effect of inhibin A and zoledronic 
acid on activin and follistatin levels in the bone microenvironment in vivo, and the 
implications for breast tumour cell growth.  The following aims were set: 
 
1. To establish if inhibin A can alter secretion of activin or follistatin from breast 
cancer cells, and the interaction with zoledronic acid in vitro. 
 
2. To establish the tolerability and biological activity in vivo of a recombinant 
human inhibin A protein. 
 
3. To establish if recombinant human inhibin A can prevent ovariectomy-induced 
bone loss in vivo. 
 
4. To determine if inhibin A alters the level of activin and follistatin in the bone and 
liver in ovariectomised and sham operated mice. 
 
5. To confirm the effects of zoledronic acid on the bone microenvironment in 
ovariectomised and sham-operated mice, and to evaluate if zoledronic acid alters 
the level of activin and follistatin in the bone and liver microenvironment. 
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6.4.	  Materials	  and	  methods	  	  
See materials and methods chapter 2 for further information. 
Unless stated otherwise, all in vitro experiments were carried out with 3 replicates and 3 
repeats.   
 
6.4.1	  The	  effect	  of	   inhibin	  A	  on	  paracrine	  secretion	  of	  activin	  and	   follistatin	   in	  ER-­‐ve	  
and	  ER+ve	  breast	  cancer	  cells,	  and	  the	  interaction	  with	  zoledronic	  acid.	  
Two cell lines were used, the ER-ve MDA-MB-231 and the ER+ve MCF7. Cells were 
seeded in 6 well plates as detailed in chapter 2, at densities chosen to reflect specific cell 
line rate of replication, with an aim to achieve ~80% confluence of cells at the end of the 
experiment.  Cells were maintained in DMEM+10%FCS for 48 hours with or without 
10ng/ml inhibin A.  Live cell count was performed from each well at the end of the 
experiment, to enable normalization of ELISA level to cell count by expressing results as 
secretion/million cells.  Supernatant was collected at 48 hours and processed to activin 
and follistatin ELISA to quantify secreted levels of each protein.  Further secretion 
experiments were performed in MDA-MB-231 cells with addition of 10ng/ml inhibin A 
+/- 50µM zoledronic acid compared to medium only control.  To evaluate the effect of 
conditioned medium from zoledronic acid and inhibin A treated MDA-MB-231 cells, a 
fluorescent cell based immunoassay was used to quantify levels of pSmad2/3 relative to 
total Smad2/3 in MDA-MB-231 cells treated for 1 hour with conditioned medium.   
TGFβ secretion in response to 10ng/ml inhibin A was assessed by removing supernatant 
from control and inhibin A treated MDA-MB-231 cells at 48 hours and processing to 
TGFβ1 ELISA with levels normalized to cell count. 
 
6.4.2.	   To	   establish	   the	   tolerability	   and	   biological	   activity	   in	   vivo	   of	   a	   recombinant	  
human	  inhibin	  A	  protein	  sourced	  from	  NIBCS.	  	  
Sub-cutaneous osmotic pumps were inserted into 12-week old balb/c nude female mice 
and primed to deliver control vehicle (1xPBS), 10ng/day inhibin A or 60ng/day inhibin A 
for 28 days.  Details of surgical procedure are found in chapter 2.  To establish 
tolerability weight was recorded and liver was fixed in 4% PFA for 24 hours and then 
processed to wax and sectioned for H&E stain. To evaluate biological activity, blood was 
collected at termination of experiment for serum measurement of follicle stimulating 
hormone (FSH), and markers of bone resorption (TRAP) and bone formation (P1NP), and 
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right hind legs were fixed in 4% PFA, imaged using µCT software and subsequently 
decalcified for 2 weeks prior to processing to wax and sectioning for bone 
histomorphometry. 
 
6.4.3	  To	  establish	   if	   recombinant	  human	   inhibin	  A	   can	  prevent	  ovariectomy	   induced	  
bone	  loss	  in	  vivo.	  
12-week old balb/c nude female mice underwent ovariectomy or sham operation as 
detailed in chapter 2.  During the same surgical procedure, sub-cutaneous ALZET 
osmotic pumps were inserted having been primed to deliver control vehicle (1xPBS) or 
60ng/day inhibin A for 28 days. At termination of experiment, cardiac blood was 
collected and serum was processed for human inhibin A, mouse TRAP and P1NP ELISA.  
Right hind limbs were processed as described in 6.4.2.   
 
6.4.4	  To	  determine	  if	  inhibin	  A	  alters	  the	  level	  of	  activin	  and	  follistatin	  in	  the	  bone	  and	  
liver	  in	  ovariectomised	  and	  sham	  operated	  mice.	  
Liver and right hind limbs were processed from animals undergoing the procedure 
detailed in 6.4.3.  Liver was homogenized in 9mls of 1xPBS, centrifuged and supernatant 
processed to mouse activin and follistatin ELISA normalized to liver weight. 
Calvaria were processed as per chapter 2; briefly they were crushed in 2.5mls PBS, 
filtered and then centrifuged.  Supernatant was removed and cell count was performed 
using trypan blue.  Supernatant was processed to activin and follistatin ELISA normalized 
to cell count. 
 
6.4.5	   To	   determine	   if	   zoledronic	   acid	   alters	   the	   level	   of	   activin	   and	   follistatin	   in	   the	  
bone	  microenvironment	  and	  liver	  in	  ovariectomised	  and	  sham-­‐operated	  mice.	  
12-week old balb/c nude mice were treated for 4 weeks with weekly IP zoledronic acid 
100µg/kg staring on day 1 of experiment.  Mice underwent ovariectomy or sham 
operation on day 2 of the experiment.  At termination of the experiment, cardiac blood 
was collected and serum was processed to mouse TRAP and P1NP ELISA. 
The right hind limb, liver and calvaria were collected and processed as described in 6.4.3 
and 6.4.4
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6.5	  Results 	  
6.5.1	  The	  effect	  of	  inhibin	  A	  on	  secretion	  of	  activin	  and	  follistatin	  in	  ER-­‐ve	  and	  ER+ve	  
breast	  cancer	  cells,	  and	  the	  interaction	  with	  zoledronic	  acid.	  
To determine if inhibin A can alter the secretion of either activin or follistatin from 
MDA-MB-231 and MCF7 cells, cells were exposed to media alone or media plus 
10ng/ml of inhibin A for 48 hours.  In MDA-MB-231 cells inhibin A significantly 
increased secretion of activin compared to control (p value 0.0357), and although inhibin 
A increased follistatin secretion by 44%, this did not reach statistical significance.  MCF7 
cells showed no alteration in their secretion of activin or follistatin with the addition of 
inhibin A (Fig 6.2). 
 
To determine if inhibin A can affect the changes in follistatin seen with zoledronic acid in 
ER-ve breast cancer cells, MDA-MB-231 cells were exposed to either medium alone, 
medium plus 10ng/ml inhibin A +/- 50µM zoledronic acid for 48 hours.  The significant 
fall in follistatin secretion with zoledronic acid compared to control was lost with the 
addition of inhibin A, which increased follistatin levels by 30% compared to zoledronic 
acid alone (Fig 6.3). 
 
These data showed that inhibin A increases activin secretion from MDA-MB-231 cells, 
but that follistatin secretion is also increased.  This reduces the net effect of zoledronic 
acid on decreasing levels of follistatin.  To evaluate if these changes in protein secretion 
could influence the downstream phosphorylation of Smad2/3C, conditioned media from 
MDA-MB-231 cells treated for 48 hours with either medium alone or 50µM zoledronic 
acid +/- 10ng/ml inhibin A was added to MDA-MB-231 cells for 1 hour, in a cell based 
immunoassay (Fig 6.4). MDA-MB-231 cells treated with supernatant from zoledronic 
acid treated cells had a significantly higher percentage of pSmad2/3C to total Smad2/3C 
compared to all other groups (p=0.05).  Direct exposure of MDA-MB-231 cells to either 
50µM ZOL or 10ng/ml inhibin A for 1 hour had no significant effect on pSmad2/3C 
levels (Fig 6.4), indicating that the changes in follistatin secretion into supernatant from 
MDA-MB-231 cells treated with zoledronic acid and inhibin A was driving the changes 
in pSmad2/3C, rather than the direct effect of the hormone/drug themselves. 
 
	  	  	  	  
	   212	  
 
Figure 6.2 The effect of inhibin A on secretion of activin and follistatin from MDA-
MB-231 and MCF7 cells.   
 
MDA-MB-231 (A,B) and MCF7 (C,D) breast cancer cells were seeded in 6 well plates 
and maintained for 48 hours in either medium alone or medium+10ng/ml inhibin A.  At 
48 hours the supernatant was collected and processed to activin or follistatin ELISA and 
values normalized to cell count.  Data represent mean +SEM of 3 replicates and 3 repeats. 
Mann Whitney test for significance, * p value <0.05. 
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Figure 6.3 Secretion of 
follistatin from ER-ve MDA-
MB-231 in response to inhibin 
A and zoledronic acid.  
 
Cells were seeded in 6 well 
plates and exposed for 48 hours 
to medium alone +/- 50µM 
zoledronic acid and/or 10ng/ml 
inhibin A.  At 48 hours 
supernatant was processed to 
follistatin ELISA and values 
normalized to cell count.  Data 
represent mean +SEM of 3 
replicates and 3 repeats, Mann 
Whitney test for significance, 
*p value <0.05. 
Figure 6.4 Effect of supernatant 
from inhibin A and zoledronic 
acid treated MDA-MB-231 cells 
on pSmad2/3 levels in MDA-
MB-231 breast cancer cells.   
 
Cells were seeded per well in a 96 
well plate and exposed to 1 hour 
of conditioned medium from 
MDA-MB-231 cells previously 
treated for 48 hours with 10ng/ml 
inhibin A +/- 50µM zoledronic 
acid (Fig 6.3).  MDA-MB-231 
cells were also exposed to 1 hour 
of 10ng/ml inhibin A and 50µM 
zoledronic acid.  Results are 
expressed as % of pSmad2/3 to 
total Smad2/3.  Data represents 
mean+SEM of percentages from 3 
replicates of 3 repeated 
experiments, Mann Whitney test 
for significance, * p value <0.05 
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As discussed in chapter 5, Smad2/3 is phosphorylated in response to both activin and 
TGFβ binding to cell surface receptors. Previous data (see Fig 5.14) showed that 
zoledronic acid does not significantly alter TGFβ secretion from MDA-MB-231 cells. To 
ensure that the changes in pSmad2/3 seen with addition of inhibin A to zoledronic acid 
were due to alterations in the activin pathway, a further experiment was done to 
determine if inhibin A affected TGβ secretion from MDA-MB-231 cells. Medium was 
collected after 48 hours of exposure to medium+/-10ng/ml inhibin A and processed to 
TGFβ1 ELISA with values normalized to cell count. Inhibin A did not significantly alter 
TGFβ1 secretion from MDA-MB-231 cells after 48 hours (Fig 6.5). 
 
These data show that inhibin A decreases the inhibitory effect zoledronic acid has on 
follistatin secretion from MDA-MB-231 cells, with subsequent reduction in 
phosphorylation of the intracellular Smad 2/3 proteins downstream of the ActRII receptor. 
6.5.2	   To	   establish	   the	   tolerability	   and	   biological	   activity	   in	   vivo	   of	   a	   recombinant	  
human	  inhibin	  A	  protein	  sourced	  from	  NIBCS.	  
Recombinant inhibin A has not been commercially available for several years since the 
major supplier (Beckman Coulter) stopped producing the ligand (personal communication 
with Professor Gaddy, University of Arkansas, Texas).  A potential source of inhibin A 
was identified from the suppliers of the World Health Organisation (WHO) standard 
inhibin A (NIBSC).  The concern at this stage was that inhibin A preparations can be 
contaminated with activin A, which will affect in vivo results.  After discussion with the 
WHO suppliers and advice from Professor Gaddy, a small in vivo pilot study was 
undertaken to evaluate if the recombinant protein was biologically active, as assessed by 
measuring follicle stimulating hormone levels and evaluation of the effects on bone in 12-
week old female balb/c nude mice.  To establish the expected physiological levels of 
inhibin A from mice of this age, serum from a previous in vivo experiment (carried out by 
Dr Penny Ottewell) was used.  Mice were treated with weekly intra-peritoneal (IP) saline 
or 100mg/kg zoledronic acid after ovariectomy (OVX) or sham operation for 28 days.  
Serum previously collected and stored at -80oC was thawed and analysed using a mouse 
specific inhibin A ELISA.  The mean serum level of inhibin A from mice that had 
undergone OVX was not statistically different from sham-operated mice (Fig 6.6).  The 
physiological level of inhibin A from the control mice was then used to calculate planned 
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Figure 6.5 TGFβ1 secretion from MDA-MB-231 cells in response to inhibin A.   
 
Cell were seeded in 6 well plates and exposed for 48 hours to medium alone or 
medium+10ng/ml of inhibin A.  After 48 hours the supernatant was removed and 
processed to TFGβ1 ELISA with values normalized to cell count.  Data represents 
mean+SEM.  Mann Whitney test for significance, NS = not significant 
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Figure 6.6.  Serum inhibin A levels in 12-week old balb/c nude female mice following 
sham or ovariectomy.  
 
Serum was collected at cull from female balb/c nude 12-week old female mice either 
ovariectomised or sham operated, that had been maintained for 6 weeks and treated with 
weekly IP saline injections. Dots represent serum values in sham animals, squares 
represent OVX animals.  Mann Whitney test for significance, NS=not significant. 
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doses of recombinant inhibin A to add to the ALZET pumps. 
To evaluate the effect of inhibin A in vivo, ALZET pumps were loaded with either 
10ng/day inhibin A (n=3) or 60ng/day inhibin A (n=3) in addition to PBS vehicle control 
(n=3) (as described in section 2.2.3). 12-week old female balb/c nude mice were 
anaethetised and the sub-cutaneous pumps were inserted and wound closed with staples.  
Mice were maintained for 28 days and then sacrificed by cervical dislocation with 
collection and tissues were collected and processed as detailed in 6.4.2. 
6.5.2.1	  Assessment	  of	  tolerability	  to	  inhibin	  A	  
Tolerance was assessed by observing behaviour and general well-being of animals by 
monitoring the weight of the animals during the procedure, and evaluation of hepatic 
architecture at termination of experiment since inhibin A is metabolised by the liver. No 
abnormal behaviour was observed in the animals treated with either dose of inhibin A and 
no problems were encountered with wound healing or closure.  Weights increased during 
the course of the experiment in all mice apart from a single animal in the 60ng/day group. 
This mouse was smaller than all others at baseline, and by day 9 had begun to lose weight 
(-0.4% compared to baseline) increasing to -6% at day 15 and -15% at day 26, and was 
therefore culled at this time-point and was excluded from further analysis. To evaluate 
gross hepatic toxicity, liver sections were stained with H&E.  No difference was seen in 
the overall structure of liver sections from control or inhibin A treated mice indicating no 
severe hepatic toxicity resulted from treatment with the recombinant inhibin A (Fig 6.7). 
6.5.2.2	  Evaluation	  of	  the	  biological	  activity	  of	  recombinant	  inhibin	  A	  
To evaluate the biological activity of inhibin A, serum levels of FSH, P1NP and TRAP 
were measured and right hind leg was analysed for bone volume and effects on 
osteoblast/osteoclast numbers by histomorphometry. 
Secretion of pituitary FSH is under negative feedback from both oestrogen and inhibin A 
(Welt, Pagan et al. 2003); therefore inhibin A would be predicted to decrease serum FSH. 
Serum FSH did not significantly differ between the treatment groups (Fig 6.8 A), this 
may reflect a lack of biological activity of the inhibin A, or may be due to timing of 
sample collection at day 28. 
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Figure 6.7 Evaluation of the toxicity of inhibin A in vivo. 
 
A Experimental outline; animals were anaesthetized on day 0 and implanted with sub-
cutaneous osmotic pumps primed to deliver vehicle only (control), inhibin A 10ng/day or 
60ng/day.  Mice were maintained for 28 days and evaluated for signs of toxicity from 
inhibin A. B; serial measurements of weight over duration of experiment, data represent 
mean +SEM percentage change from baseline weight over 28 days. C; Representative 
H&E stained sections of liver from control, inhibin A 10ng/day and inhibin A 60ng/day. 
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  Figure 6.8 Assessment of biological activity of inhibin A in vivo. 
 
Mice were treated for 28 days with continuous sub-cutaneous infusion of inhibin A via 
ALZET pump delivered at 10ng/day or 60ng/day dissolved in 1x PBS, or PBS control. A; 
serum FSH levels shown per animal and expressed as mean+SEM. B Bone volume:tissue 
volume (BV/TV) per treatment group. C+D; Osteoblast and osteoclast number per mm 
bone per treatment group. All data represent mean+SEM, student t test for significance, 
NS not significant. E+F; Serum P1NP as a marker of osteoblast activity, and serum 
TRAP as a marker of osteoclast activity from pooled serum from each treatment group.  
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Bone volume: tissue volume (BV/TV) did not differ significantly between groups 
although there was a consistent trend for an increase in BV/TV with increasing doses of 
inhibin A (Fig 6.8 B+6.9), this was reflected by a trend towards higher number of 
osteoblasts per mm of bone and a lower number of osteoclasts per mm of bone in the 
60ng/day inhibin A group compared to control, although this did not reach statistical 
difference (p=0.18) (Fig 6.8 C+D and 6.9).  There was no consistent trend in changes in 
the bone formation marker P1NP or bone resorption marker TRAP in pooled serum 
samples (Fig 6.8 E +F) 
 
These data showed that the recombinant inhibin A protein was well tolerated in vivo and 
the method of delivery via osmotic pump was safe.  The biological activity of the protein 
was inconclusive at this stage due to small numbers of animals per group, however, a 
trend to increasing bone: tissue volume was seen, with an associated rise in osteoblast 
number and a fall in osteoclast number.  In order to evaluate the effect of inhibin A on the 
bone microenvironment in a larger cohort of mice, a second in vivo experiment was 
performed with 5 mice per group treated with the higher dose of inhibin A (60ng/day) or 
vehicle control, in both OVX and sham animals.  
 
6.5.3	  To	  establish	   if	   recombinant	  human	   inhibin	  A	   can	  prevent	  ovariectomy	   induced	  
bone	  loss	  in	  vivo.	  
Intact animals (sham) and ovariectomised (OVX) were treated with 60ng/day inhibin A 
or PBS control for 28 days. Weights fell in all groups, except the sham inhibin A group 
for the first 11 days post-surgery, but then recovered to ≥ baseline.  This is likely to 
reflect the invasiveness of the OVX/sham procedure, and use of opiates as analgesia at 
surgery affecting appetite (Fig 6.10)  
6.5.3.1	  Effects	  of	  60ng/day	  inhibin	  A	  on	  bone.	  
To evaluate the effect of inhibin A on bone structure and bone cell numbers, the right 
proximal tibia was fixed in 4% PFA and scanned using µCT (as previously described in 
chapter 2).  The tibia was then decalcified for 2 weeks and processed to wax for 
sectioning.  2 serial sections were stained for TRAP to identify osteoclasts, and the whole 
trabecular surface quantified using osteomeasure software. 
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Figure 6.9.  Representative µCT images and TRAP stained sections of proximal 
right tibia from mice treated with PBS or 60ng/day inhibin.   
 
A; Representative cross sectional images of right hind leg were obtained using µCT in 
control and inhibin treated mice. B; Sections from right tibia were TRAP stained to allow 
identification of osteoblasts and osteoclasts on bone trabecular surface in control and 
inhibin treated mice, blue arrows represent osteoblasts, orange arrows represent bone-
lining cells and green arrows represent osteoclasts. 
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Figure 6.10.  Experimental outline to assess effect of inhibin A on the bone 
microenvironment in OVX and sham operated mice 
 
A; On day 0 animals underwent OVX (n=10) or sham (n=10) operation and were 
implanted with sub-cutaneous ALZET osmotic pumps primed to deliver PBS only or 
inhibin 60ng/day dissolved in PBS.  Mice were maintained for 28 days with tissue 
collected for downstream analyses as outlined. B; Serial measurements of weight over 
duration of experiment, data represent mean +SEM percentage change from baseline 
weight over 28 days.  
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OVX induced bone volume loss compared to sham, and although this was partly reversed 
by inhibin A it did not reach statistical significance (p=0.2) (Fig 6.11a and 6.12 A).  
Inhibin A significantly increased bone volume compared to vehicle in sham-operated 
mice (p=0.0079).  Bone cells were counted on TRAP stained sections allowing 
identification of osteoblasts and osteoclasts covering the trabecular bone surface of the 
proximal right tibia (Fig 6.11b and 6.12 B+C). OVX significantly decreased osteoblasts 
number and increased osteoclast number compared to sham.  Inhibin A did not 
significantly alter the number of osteoblasts/mm bone compared to control in OVX or 
sham animals, however, there was a significant increase in osteoclasts/mm bone in sham 
operated mice receiving inhibin A compared to sham control (p=0.03). 
 
Serum TRAP (a marker of osteoclast activity), and P1NP (a marker of osteoblast activity) 
was measured in pooled samples due to insufficient individual sample volumes for 
analysis. P1NP levels were higher in sham animals vs. OVX animals, and addition of 
inhibin A did not alter TRAP or P1NP in OVX or sham animals (Fig 6.12 D+E).  
No significant difference was found in serum levels of inhibin A between control and 
inhibin A treated animals in either the OVX or sham group (p=0.3) (Fig 6.13).   
Taken together, these results show that the inhibin A appeared to have relevant biological 
effects in bone by increasing BV/TV, however, this was only apparent in sham operated 
mice. Measurement of the serum inhibin A levels suggested that the dose of inhibin A 
delivered by the pumps was insufficient to cause an increase in serum inhibin A 
compared to physiological levels in control mice.   In order to evaluate if a higher dose of 
inhibin A could induce effects on bone in OVX mice, the experiment was repeated with 
the osmotic pumps primed to deliver 120ng/day inhibin A. 
6.5.3.2	  Effects	  of	  120ng/day	  inhibin	  A	  on	  bone.	  
The increased dose of inhibin A (120ng/day) was well tolerated, and although weights 
fell in all groups for the first 7 days post-surgery, it recovered to ≥ baseline (Fig 6.14), 
which was comparable to the effects seen with 60ng/day inhibin A 
	  	  	  	  
	   224	  
  
 
 
 
O
VX
$C
on
tr
ol
$
O
VX
$In
hi
bi
n$
Sh
am
$c
on
tr
ol
$
Sh
am
$In
hi
bi
n$
	  
 F
ig
ur
e 
6.
11
a 
Ef
fe
ct
 o
f 6
0 
ng
/d
ay
 in
hi
bi
n 
A
 o
n 
bo
ne
 in
 O
V
X
 a
nd
 sh
am
 m
ic
e-
 r
ep
re
se
nt
at
iv
e 
µ
C
T 
im
ag
es
 o
f p
ro
xi
m
al
 r
ig
ht
 ti
bi
a 
 Re
pr
es
en
ta
tiv
e 
µC
T 
cr
os
s s
ec
tio
na
l i
m
ag
es
 o
f t
he
 p
ro
xi
m
al
 ri
gh
t t
ib
ia
 (t
op
) w
ith
 a
ss
oc
ia
te
d 
ra
di
og
ra
ph
s (
bo
tto
m
) f
ro
m
 O
V
X
 a
nd
  
sh
am
 m
ic
e 
tre
at
ed
 w
ith
 a
nd
 w
ith
ou
t 6
0n
g/
da
y.
 
 
	  	  	  	  
	   225	  
 
Figure 6.11b Effect of 60ng/day inhibin A on osteoblasts and osteoclasts in OVX and 
sham mice -representative TRAP stained sections in OVX and sham mice  
 
Arrowheads represent osteoblasts sitting on the surface of the bone.  Purple box 
represents the area of magnification increased from x1.6 (left) to x20 (right).  Scale bar 
represents 100µm.
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Figure 6.12.  Effect of 60ng/day inhibin A on bone volume, osteoblast and osteoclast 
number and activity in animals following OVX or sham operation. 
 
Mice were treated for 28 days with continuous sub-cutaneous infusion of 60ng/day 
inhibin A via ALZET pump, or PBS control, post OVX or sham operation.  A; BV/TV in 
OVX and sham animals assessed using µCT imaging. B+C; Osteoblast and osteoclast 
number per mm bone quantified using TRAP stained sections. D+E Serum P1NP as a 
marker of osteoblast activity and serum TRAP as a marker of osteoclast activity. Data A-
C represent mean +SEM, Mann Whitney U test for significance, ** p value <0.01, * p 
value <0.05, NS not significant. Data D+E represent pooled serum samples from each 
group therefore no further statistical analysis was possible.
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Figure 6.13.  Serum levels of human inhibin A in mice treated with and without 
60ng/day inhibin A following OVX or sham operation. 
 
Mice were treated for 28 days with continuous sub-cutaneous infusion of 60ng/day 
inhibin A via ALZET pump, or PBS control, post OVX or sham operation. 
Serum was collected at the end of experiment and processed for human inhibin A ELISA.  
Dots represent values from individual animals. Mann Whitney test for significance. 
NS=not significant. 
Red line represents lower limit of detection for assay used. 
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Figure 6.14. Percentage change in weight from baseline in mice treated with 
120ng/day inhibin A after OVX or sham operation.    
 
Mice were ovariectomised or sham-operated on day 0 followed by insertion of sub-
cutaneous osmotic pump primed to deliver PBS or 120ng/day inhibin A.  Baseline weight 
was measured after pump insertion and at regular timepoints over the 28-day course of 
the experiment.   Data represents mean +SEM  percentage change in weight over 28 days. 
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Serum inhibin A was significantly increased in OVX mice treated with inhibin A 
compared to OVX control (p=0.0079), Serum levels were also increased in sham animals 
treated with inhibin A compared to sham control, but this did not reach statistical 
significance (p=0.34) (Fig 6.15). 
OVX induced bone loss compared to sham, and this was reversed by 120ng/day inhibin A 
(p=0.0079) (Fig 6.16A and 6.17A).  Inhibin A also significantly increased bone volume 
compared to vehicle in sham-operated and OVX mice.  Quantification of bone cell 
numbers on TRAP stained sections showed that OVX did not significantly alter 
osteoblast or osteoclast numbers compared to sham. In addition, inhibin A did not 
significantly alter the number of osteoblasts or osteoclasts compared to control in OVX or 
sham operated mice (Fig 6.16 B and 6.17 B+C).  
Serum TRAP and P1NP were measured to determine the effects of OVX and inhibin A 
on bone cell activity. OVX did not significantly affect serum P1NP or TRAP compared to 
sham.  Inhibin A did not significantly affect P1NP levels in OVX or sham operated 
animals, or alter TRAP levels in sham animals.  However, administration of inhibin A in 
OVX mice significantly increased serum TRAP compared to OVX control mice 
(p=0.0079) (Fig 6.17 D+E).   
6.5.4 Effects of inhibin A on activin and follistatin in the bone and liver in 
ovariectomised and sham-operated mice 
Since inhibin A had a direct effect on breast cancer cell secretion of follistatin (section 
6.5.1) which will change the activin:follistatin ratio in the paracrine tumour environment 
and potentially affect proliferation, the effects of inhibin A on the bone and liver 
microenvironment levels of activin and follistatin were evaluated.  Calvaria and liver 
were collected from mice treated with 60ng/day inhibin A and 120ng/day inhibin A or 
PBS control for 28 days, calvaria were crushed in PBS and liver was homogenized in 
PBS to release soluble factors with storage of supernatant for processing to follistatin or 
activin ELISA (section 6.4.4) The calvaria from either sham operated or OVX mice 
treated with inhibin A 60ng/day showed no significant change in bone levels of either  
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Figure 6.15.  Serum levels of inhibin A in mice treated with and without 
120ng/day inhibin A following OVX or sham operation. 
 
Serum was collected at cull and precessed to human specific inhibin A ELISA.  Data 
represents mean +SEM from (A) the overall population and (B) OVX and sham sub-
groups of mice. Mann whitney test for significance. * p value <0.05, ** p value 
<0.01, NS not significant. 
Red line represents lower limit of detection for assay 
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OVX$Control$
OVX$Inhibin$
Sham$Control$
Sham$Inhibin$
Figure 6.16b.  Effect of 120ng/day inhibin A on osteoblasts and osteoclasts in OVX 
and sham mice- representative TRAP stained sections. 
 
Arrowheads represent osteoblasts sitting on the surface of the bone.  Purple box 
represents the area of magnification increased from x1.6 (left) to x20 (right).   
Scale bar represents 100µM. 
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Figure 6.17.  Effect of 120ng/day inhibin A on bone volume, osteoblast and osteoclast 
number and activity in animals following OVX or sham operation. 
 
Mice were treated for 28 days with continuous sub-cutaneous infusion of 120ng/day 
inhibin A via ALZET pump, or PBS control, post OVX or sham operation. 
A; BV/TV in OVX and sham animals assessed using µCT imaging. B+C; Osteoblast and 
osteoclast number per mm bone quantified on TRAP stained histological sections. D+E 
Serum P1NP as a marker of osteoblast activity and serum TRAP as a marker of osteoclast 
activity. All data represent mean +SEM, Mann Whitney U test for significance, ** p 
value <0.01, * p value <0.05, NS not significant. 
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activin or follistatin compared to control (Fig 6.18 A +B).  Calvaria from OVX mice 
treated with 120ng/day inhibin A showed a significant decrease in activin levels 
compared to OVX control (p=0.01) (Fig 6.18 A+C).  This effect was not seen in the 
sham-operated animals.  There was no significant change in follistatin levels with inhibin 
A from calvaria in either OVX or sham animals (Fig 6.18 B+D).Inhibin A did not alter 
activin levels in the liver of either sham or OVX animals.  The levels of liver follistatin 
were below the level of detection for the ELISA in all groups. 
6.5.5	  Effects	  of	  zoledronic	  acid	  on	  the	  bone	  microenvironment	  in	  ovariectomised	  and	  
sham-­‐operated	  mice.	  Are	  levels	  of	  follistatin	  and	  activin	  altered?	  
In order to evaluate the effects of zoledronic acid on the bone microenvironment 
zoledronic acid treatment was commenced on day 1 of treatment protocol, and mice 
underwent OVX or sham operation on day 2. Mice were maintained for 28 days and 
treated weekly with either 100µg/kg of zoledronic acid or saline control via intra 
peritoneal injection.  Weights were recorded over the duration of the experiment and 
showed a decrease from baseline for the first 5 days, with recovery to baseline and above 
thereafter (Fig 6.19). 
As expected OVX induced bone loss compared to sham and weekly administration of 
zoledronic acid significantly increased bone volume compared to control in both OVX 
and sham operated mice compared to saline control (OVX p= 0.016, sham p= 0.0079) 
(Fig 6.20A and 6.21A).  Quantification of bone cell numbers showed that OVX did not 
alter osteoblast or osteoclast number compared to sham and zoledronic acid did not 
significantly alter the number of osteoclasts/mm bone compared to control in the 
OVX/sham animals.  However, there was a significant decrease in osteoblasts/mm bone 
in zoledronic acid treated mice compared to control in both the OVX and sham animals 
(OVX p=0.007, sham p=0.009) (Fig 6.20 B and 6.21B+C).  
Serum TRAP and P1NP levels were measured to assess effects on osteoclast and 
osteoblast activity. OVX did not alter P1NP or TRAP levels compared to sham.  
Zoledronic acid significantly decreased TRAP in both OVX and sham animals (OVX 
p=0.0079, sham p=0.016). 
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Figure 6.18  Effect of inhibin A on bone levels of activin and follistatin in 
OVX and sham operated mice. 
 
Mice were treated for 28 days with either PBS control,  60ng/day or 120ng/day of 
inhibin A post OVX or sham operation.  A+B; Calvaria levels of activin and 
follistatin in mice treated with 60ng/day inhibin or PBS control. C+D; Clavaria 
levels of activin and follistatin in mice treated with 120ng/day inhibin or PBS 
control. All data represent mean+SEM, Mann Whitney test for significance, * p 
value <0.05, *** p value <0.001, NS not significant. 
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Figure 6.19.  Experimental outline to determine the effects of zoledronic acid (zol) on 
the bone microenvironment in OVX and sham operated mice. 
 
A; Weekly IP injections commenced on day 1 with 100µg/kg of zoledronic acid. On day 
2 they underwent OVX (n=10) or sham (n=10) operation.  Mice were maintained for 28 
days with tissue collected for downstream analyses as outlined. B; Serial measurements 
of weight over duration of experiment, data represent mean +SEM percentage change 
from baseline weight over 28 days.
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•  Right hind limb fix in 4%PFA for uCT and histology. 
•  Calvaria for assessment of changes in activin/follistatin levels by 
ELISA 
•  Liver for homogenising and supernatant collected and processed for 
activin/follistatin ELISA 
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Figure 6.20b Effect of zoledronic acid on osteoblast and osteoclast numbers in bone 
in OVX and sham operated mice- representative TRAP stained sections. 
 
Black arrowheads represent osteoblasts. Purple box represents section magnified from 
x1.6 (left) to x20 (right). Scale bar represents 100µm. 
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Figure 6.21.  Effect of zoledronic acid (zol) on bone volume, osteoblast and osteoclast 
number and activity in animals following OVX or sham operation. 
 
Mice were treated for 28 days with weekly IP injection of 100µg/kg of zoledronic acid or 
PBS control, post OVX or sham operation.  A; BV/TV in OVX and sham animals 
assessed using µCT imaging. B+C; Osteoblast and osteoclast number per mm bone 
quantified on TRAP stained histological sections. D+E Serum P1NP as a marker of 
osteoblast activity and serum TRAP as a marker of osteoclast activity. All data represent 
mean +SEM, Mann Whitney U test for significance, * p value <0.05,** p value <0.01, 
NS not significant. 
 
 
 
B
V
/T
V
  (
%
)
ov
x c
on
tro
l (n
=5
)
ov
x z
ol 
(n=
5)
sh
am
 co
ntr
ol 
(n=
5)
sh
am
 zo
l (n
=5
)
0
5
10
15
20
*
*
*
N
um
be
r o
f o
st
eo
bl
as
ts
/m
m
 b
on
e
OV
X c
on
tro
l (n
=5
)
OV
X z
ol 
(n=
5)
Sh
am
 co
ntr
ol 
(n=
5)
Sh
am
 zo
l (n
=5
)
0
5
10
15
20
25
**
**
NS
N
um
be
r o
f o
st
eo
cl
as
ts
/m
m
 b
on
e
OV
X c
on
tro
l (n
=5
)
OV
X z
ol 
(n=
5)
Sh
am
 co
ntr
ol 
(n=
5)
Sh
am
 zo
l (n
=5
)
0.0
0.5
1.0
1.5
2.0
NS
NS
NS
S
er
um
 T
R
A
P
 (U
/l)
ov
x c
on
tro
l (n
=5
)
ox
v z
ol 
(n=
5)
sh
am
 co
ntr
ol 
(n=
5)
sh
am
 zo
l (n
=5
)
0
1
2
3
4
**
*
NS
S
er
um
 P
1N
P
 n
g/
m
l
ov
x c
on
tro
l (n
=5
)
ox
v z
ol 
(n=
5)
sh
am
 co
ntr
ol 
(n=
5)
sh
am
 zo
l (n
=5
)
0
20
40
60
80
100
NS
NS
NS
A
B C
D E
	  	  	  	  
	   240	  
There was no significant change in P1NP in either OVX or sham animals with zoledronic 
acid (Fig 6.21 D +E). Zoledronic acid did not significantly alter activin levels in the 
calvaria in OVX or sham animals, However, follistatin was significantly decreased by 
zoledronic acid in the OVX animals compared to control (p=0.036), this effect was not 
seen in sham animals (Fig 6.22).  Liver activin levels were unaffected by zoledronic acid 
in both groups. 
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.  
 
 
 
 
Figure 6.22  Effect of zoledronic acid on bone levels of activin and follistatin in OVX 
and sham operated mice. 
 
Mice were treated for 28 days with weekly IP injection of 100µg/kg zoledronic acid or 
PBS control, post OVX or sham operation.  At the end of the experiment calvaria were 
collected and crushed in a fixed volume of PBS to release soluble factors. PBS + bone 
was filtered and centrifuged and supernatant was removed for processing to activin and 
follistatin ELISA.  A; Calvaria levels of activin in mice treated with zoledronic acid or 
PBS control. B; Calvaria levels of follistatin in mice treated with zoledronic acid or PBS 
control. All data represent mean+SEM, Mann Whitney test for significance, *p value 
<0.05, NS not significant. 
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6.6	  Discussion 
The data presented in this chapter suggest that inhibin A can prevent the decrease in 
secreted follistatin induced by zoledronic acid in ER-ve breast cancer cells in vitro.  In 
vivo the recombinant inhibin A protein from NIBSC appears to be biologically active, and 
at the highest dose used (120ng/day for 28 days) increases bone volume in both OVX and 
sham animals.  It also decreases activin levels in calvaria in OVX animals.  Zoledronic 
acid, as expected, increases bone volume in both OVX and sham animals, via a reduction 
in activity of osteoclasts, with a concurrent decrease in osteoblast numbers. It also 
decreases follistatin levels in calvaria in OVX animals.  This would indicate that in an 
OVX animal, with low inhibin A, bone volume will be reduced but bone (calvaria) 
activin levels are high; if zoledronic acid is present then bone volume will increase, and 
bone follistatin levels will fall, further increasing bioavailability of activin in bone.  In an 
animal with high inhibin A levels (i.e. OVX+inhibin A), bone volume will be high but 
bone activin levels are low; if zoledronic acid is present then bone volume will be further 
increased but no change in bone follistatin will occur.  This may potentially create two 
different bone microenvironments, which could differentially affect tumour cell growth 
and progression (Fig 6.24). 
However, there are limitations to interpretation of this data.  As previously discussed the 
direct effect of inhibin A on breast cancers is not clear.  The data presented in this chapter 
suggests that inhibin A counteracts the effects of zoledronic acid on follistatin secretion 
from MDA-MB-231 cells in vitro by increasing follistatin secretion from the cells. 
Although there are no previously published studies, to my knowledge, of the effect of 
inhibin A on follistatin secretion from breast cancer cells, there has been published data 
from both ex vivo and in vivo pituitary cultures suggesting inhibin A can affect follistatin 
expression.  Rat anterior pituitary cells treated with inhibin A for 24 hours showed a 
significant decrease in the expression of follistatin mRNA (34% of control) (Bilezikjian, 
Corrigan et al. 1996).  This was recently confirmed in an in vivo experiment using 
ovariectomised 3 month old female rats, showing a significant increase in mRNA levels 
of follistatin in the pituitary at day 28 post OVX compared to 1 day post OVX (Popovics, 
Rekasi et al. 2011).  These data suggest high inhibin A levels suppress follistatin 
expression in pituitary cells. 
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Figure 6.24 Summary of changes in the bone microenvironment with both inhibin A 
and zoledronic acid. 
 
In a low inhibin bone environment activin levels are high.  Addition of zoledronic acid to 
a low inhibin environment (OVX) decreases bone follistatin levels thus further increasing 
bioavailability of activin.  In a high inhibin bone environment activin levels are low and 
zoledronic acid does not affect follistatin. 
  
	  	  	  	  
	   244	  
This is in contrast to my findings in MDA-MB-231 cells, however, it does demonstrate 
that inhibin A can directly affect follistatin secretion from cells, but the direction of affect 
is likely to be cell type dependent. 
 
The serum levels attained with the use of the ALZET osmotic pumps were lower than 
expected considering the high doses added to the pumps, with only the 120ng/day 
delivery system significantly increasing serum inhibin A in OVX animals. The serum 
follicle stimulating hormone (FSH) were not consistent with published literature.  Inhibin 
A is a negative regulator of FSH, therefore as serum inhibin A levels increase, FSH levels 
would be expected to fall.  Carl et al used a rat model of ovariectomy to demonstrate the 
effects of a continuous infusion of porcine follicular fluid  (containing high doses of 
inhibin A, but charcoal stripped of oestrogen) on serum FSH levels.  FSH was suppressed 
in treated animals compared to control up to a 20 day time-point, However, the 
suppression of FSH was lost at the 25 day time-point in treated animals and FSH fell to 
comparable levels with control rats (Carl L 1984).  These data suggest that a continuous 
exposure to high doses of inhibin A over 25 days will negate the suppressive effect of 
inhibin A on FSH secretion.  This may explain why FSH was not significantly altered 
compared to control when mice were treated with continuous inhibin A for 28 days in the 
current study. 
 
 
Although FSH levels did not convincingly demonstrate biological activity of the 
recombinant inhibin A used, the effects in bone were more supportive of biological 
activity.  The effect on the bone microenvironment can be compared to the published in 
vivo studies using either transgenic mice overexpressing inhibin A or mice treated with an 
ActRIIA inhibitor, which will have the same molecular effect as recombinant inhibin A.  
Perrien et al used transgenic mice induced to secrete large quantites of inhibin A from 
liver in response to mifepristone (MFP).  Serum levels of inhibin A in the transgenic mice 
were 400-800pg/ml; they found inhibin A increased bone density in intact females and in 
sham/orchidectomy males.  They found no significant change in osteoblasts or osteoclasts 
with inhibin A, but a significant increase in serum osteocalcin, a marker of osteoblast 
activity (Perrien, Akel et al. 2007).  My data recorded lower levels of serum inhibin A 
(maximum 110pg/ml sham+inhibin A), but a consistent increase in bone density in both 
OVX and sham females, however, there was no significant increase in either osteoblast 
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number or P1NP, a marker of osteoblast activity.  In fact the opposite was demonstrated 
in OVX animals with an increase in serum TRAP, a marker of osteoclast activity.  This 
may reflect the different doses of serum inhibin A achieved in the two experiments and 
the different markers of bone formation evaluated.  
 
Rissanen et al performed a longitudinal study in OVX and sham rats to evaluate the 
correlation of serum P1NP with other markers of bone formation; osteocalcin and bone 
resorption; CTX, and trabecular bone assessment.  P1NP increased significantly in the 
first 2 weeks after OVX but returned to baseline at 8 weeks, and the changes in P1NP 
correlated significantly with changes in serum osteocalcin and CTX at the 2-week time-
point only, but with trabecular bone parameters at 8 weeks (Rissanen, Suominen et al. 
2008).  This suggests that changes in P1NP occur early after an intervention such as OVX, 
and that these levels subsequently normalize, however, changes in bone trabecular 
measurements occur later when serum markers have normalized.  Therefore the lower 
serum level of inhibin A in my experiments compared to the transgenic model, may have 
induced changes in osteoblast activity that had normalised by the 4-week time-point.  The 
expected coupling of bone formation to bone resorption could then have caused a later 
effect on osteoclast activity, which was detectable at the 4-week time-point.   
This theory is supported by the work of Peasall et al who injected 12-week old female 
intact mice with an activin receptor inhibitor, ActRIIA-mFC (10mg/kg), and evaluated 
the effect on bone in a timecourse experiment at 2, 4, 6 and 12-weeks.  They found the 
ActRIIA-mFC caused a significant increase in serum osteocalcin at 2 and 4 weeks, but 
also that serum TRAP significantly increased at week 4 in the treatment group.  The 
results indicate that the coupling of bone formation to bone resorption cause a delayed 
detectable effect on osteoclast activity after the earlier changes in osteoblast activity.  
Osteoblast and osteoclast numbers were not reported in this paper (Pearsall, Canalis et al. 
2008).   
Chantry et al performed a similar experiment in 8-week old intact female C57/BL/6 mice 
treated for 6 weeks with increasing doses of ActRIIA-mFC. There was a significant 
increase in osteoblast numbers in treated vs control mice which was reflected by a dose 
dependent increase in bone volume (Chantry, Heath et al. 2010).  These data therefore 
suggest that blocking the ActRIIA receptor with either inhibin A or ActRIIA-mFC causes 
an early increase in osteoblast activity detectable at 2-4 weeks, with a coupled delayed 
effect on osteoclasts detectable from 4 weeks onwards, and a net effect on osteoblast 
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numbers that is detectable at a later time-point of 6 weeks.  These data therefore support 
my findings, adding confidence that the recombinant inhibin A protein from NIBSC had 
biologically relevant effects in bone. 
 
Several in vivo studies have demonstrated that bisphosphonates reduce osteoclast 
numbers in both the absence (Kuroshima, Go et al. 2012) (Hughes, Wright et al. 1995; Ito, 
Amizuka et al. 1999) and presence of tumour cells (Walker, Medhurst et al. 2002; 
Ottewell, Woodward et al. 2009) (Martin, Werbeck et al. 2010).  However, the effect of 
zoledronic acid on osteoblasts is less well documented.  In vitro studies have suggested 
zoledronic acid inhibits osteoblast activity (Naidu, Dechow et al. 2008; Basso, Silveira 
Turrioni et al. 2013), and in an in vivo study of 6-week old balb/c nude mice treated with 
a single dose of 100µg/kg zoledronic acid, with bone assessment at day 1, 3, 5 and 10 
days post treatment, showed a significant reduction in osteoblast number and serum P1NP 
as early as day 3 (Haider M 2013).  Brown et al evaluated the treatment effects of 
doxorubicin or zoledronic acid or combination therapy on MDA-MB-231 tumour growth 
in bone after intracardiac injection in 6-week old female balb/c nude mice.  In the control, 
non-tumour bearing animals, a single IP injection of 100µg/kg of zoledronic acid 
significantly decreased osteoblast number at day 15 and 23 after injection, with a 
concurrent decrease in P1NP at day 15 that was lost at day 23 (Brown HK 2012).  My 
data show that zoledronic acid does not significantly alter osteoclast numbers after 4 
weeks of weekly treatment but does impair their activity as evidenced by a significant 
decrease in serum TRAP in OVX and sham animals.  There was a significant reduction in 
osteoblast numbers in both sham and OVX animals treated with zoledronic acid; whether 
this is a direct effect of zoledronic acid on the osteoblast, or a delayed effect due to 
uncoupling of bone turnover due to an earlier effect on osteoclasts is not clear.   
 
In summary inhibin A increased bone volume and decreased bone (clavaria) levels of 
activin.  Zoledronic acid increased bone volume and decreased osteoblast numbers and 
osteoclast activity in sham and OVX animals.  Moreover, zoledronic acid decreased bone 
(calvaria) levels of follistatin only in the absence of inhibin A (OVX animals).  These 
data suggest that inhibin A has biological effects in bone, and could potentially influence 
the effect of zoledronic acid on bone levels of the paracrine tumour suppressor activin 
and tumour promoter follistatin.  These data are hypothesis generating, and a combined in 
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vivo experiment with both inhibin A and zoledronic acid would be needed to identify if 
the combination treatment would have the suggested effect on bone activin and follistatin 
levels, and subsequent effect on tumour cells within the bone microenvironment 
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Chapter 7. General discussion. 
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The differential anti-tumour effect of adjuvant zoledronic acid, according to the 
menopausal status of breast cancer patients, was a novel finding in the AZURE trial.  
Zoledronic acid significantly decreased bone and non-bone distant recurrences in women 
who were clinically >5 years postmenopausal, however, non-bone recurrences were 
increased in all other women (Coleman, Marshall et al. 2011).  It was therefore 
considered a priority to reliably categorised menopausal status to prevent administration 
of zoledronic acid to patients who may derive harm from the drug.  Moreover, the 
molecular mechanisms driving this hormone:zoledronic acid interaction were unknown, 
and whether it was due to single or multiple reproductive hormones. 
 
The evaluation of pretreatment FSH, oestradiol and inhibin A from 806 patients in the 
AZURE trial attempted to assess if selection of patients for adjuvant zoledronic acid on 
the basis of a biochemical postmenopausal status was possible, rather than relying on 
patient reported recall in clinic which can be prone to error (Colditz, Stampfer et al. 1987).  
The concordance of clinically reported menopausal status and biochemical menopausal 
status was not 100%.  This was likely due to older menstruating patients appearing 
biochemically postmenopausal due to anovulatory menstrual cycles, and patients many 
years postmenopausal appearing biochemically non-postmenopausal due to oestradiol 
levels that were above the specified postmenopausal cut point (<50pmol/l). However, 
notwithstanding this disparity, the IDFS outcomes with zoledronic acid in patients 
defined as postmenopausal solely using a pretreatment biochemical evaluation of FSH, 
oestradiol and inhibin A, continued to select a population that derived improvements in 
IDFS both in bone and outside of bone.  This suggested that a baseline reproductive 
hormones have a role in selection of patients for adjuvant zoledronic acid, but since 
clinical and biochemical menopausal status is not always concordant, they should both be 
evaluated and interpreted with respect to one another.  In patients who’s clinical 
menopausal status was unknown or they were within a dynamic period of change in 
hormone levels i.e. <5 years since menopause, the AZURE results indicated biochemical 
evaluation of reproductive hormones may assist in selecting these patients for adjuvant 
zoledronic acid, but they are likely to need serial evaluations rather than a single 
pretreatment levels due to fluctuations in hormone levels over time (Burger 2011). These 
data were reassuring in that a biochemical pretreatment evaluation of reproductive 
hormones may be able to prevent zoledronic acid being administered to patients with an 
active HPG axis who may potentially experience a detrimental effect from the drug.   
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However, the concern over harm and increased non-bone recurrences in non- 
postmenopausal women treated with zoledronic acid has not been confirmed in large 
meta-analyses of adjuvant bisphosphonates recently reported. A meta-analysis of 
adjuvant zoledronic acid trials evaluated overall survival from 5 randomised trials 
(n=6414) (Valachis, Polyzos et al. 2013).  Zoledronic acid therapy commenced at the 
time of diagnosis resulted in a significant improvement in overall survival (HR 0.81; 95% 
CI 0.70-0.94 p value 0.007).  The trials included in this analysis were in either a mixed 
menopausal population AZURE (n=3370)(Coleman, Marshall et al. 2011) and Aft et al 
(n=119) (Aft, Naughton et al. 2010), a postmenopausal population ZO-FAST (n=1065) 
(Eidtmann, de Boer et al. 2010) and Leal et al (n=68)(Leal, Tevaarwerk et al. 2010), and 
a premenopausal population with chemically induced menopause ABCSG-12 
(n=1803)(Gnant, Mlineritsch et al. 2011).  The authors stressed that the beneficial effect 
of zoledronic acid in low oestrogen environments may be even greater than that 
demonstrated in these mixed menopausal population trials. Reassuringly the potential 
‘harm’ seen in the AZURE trial in non-postmenopausal women was not confirmed in this 
meta-analysis.  The largest meta-analysis of adjuvant bisphosphonate trials was presented 
in December 2013 at the San Antonio Breast Cancer Symposium and included data from 
~23,000 pre- and postmenopausal patients treated with adjuvant bisphosphonates, 
including both non-nitrogen, and nitrogen-containing bisphosphonates.  Primary outcome 
measures were time to recurrence, time to distant recurrence including bone and non-bone 
and breast cancer mortality.  Bisphosphonates significantly decreased bone recurrence in 
the overall population compared to control (6.9% vs. 8.4% p=0.0009) but had no effect 
on non-bone recurrence. The reduction in bone recurrence was driven by postmenopausal 
patients (natural or chemically induced) (Fig 7.1). In addition there was a non-significant 
trend to a reduction in non-bone recurrence in postmenopausal women (9%, 95%CI 5%-
19%), and 10-year breast cancer mortality was significantly improved in these women 
with addition of bisphosphonates to standard adjuvant therapy (15.2% vs. 18.3% 
p=0.004) (Coleman RE 2013).  The clinical definition of postmenopausal used in the 
meta-analysis did not differentiate between women 1-5 years postmenopausal and >5 
years postmenopausal as in the AZURE trial.  The standard World Health Organization 
clinical definition of natural menopause is; ‘the permanent cessation of menstruation 
determined retrospectively after 12 months of amenorrhoea without any other 
pathological or physiological cause’ (WHO 1996).  In the meta-analysis, the beneficial 
effect of zoledronic acid on bone recurrence in women who were clinically   
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Figure reproduced with permission from RE Coleman.  Effects of bisphosphonate treatment on recurrence and cause-specific mortality 
in women with early breast cancer: A meta-analysis of individual patient data from randomized trials.  Presented at San Antonio Breast 
Cancer Symposium, Dec 2013. Abst; S4:07 
 
 
 
Figure 7.1 Bone recurrences according to menopausal status from a large meta-
analysis of adjuvant bisphosphonate trials. 
 
Bone recurrence was significantly reduced in the overall meta-analysis population (n= 
22982).  This effect was driven by the postmenopausal population, with a significant 
difference in the benefit gained from bisphosphonates in premenopausal patients (HR 
0.93, SE 0.11) compared to postmenopausal patients (HR 0.66, SE 0.08) p value 0.02. 
  
San Antonio Breast Cancer Symposium –  December 10-14, 2013 
Cancer Therapy and Research Center at UT Health Science Center !
This%presenta,on%is%the%intellectual%property%of%the%author/presenter.%Contact%r.e.coleman@sheﬃeld.ac.uk%%for%permission%to%reprint%and/or%distribute.%
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postmenopausal (natural or chemically induced) was confirmed, despite some of these 
women being within 1-5 years of menopause.  However, no significant anti-tumour effect 
of zoledronic acid on recurrences outside of bone was shown, in contrast to the AZURE 
patients who were >5 years postmenopausal. These data suggest that as women are 
chronologically further away from menopause, the effects of adjuvant bisphosphonates on 
disease recurrence may be greater, with beneficial effects both in bone and outside of 
bone.  Moreover, the detrimental effect of zoledronic acid on disease recurrences outside 
of the bone in patients <5 years postmenopausal in the AZURE trial, was not confirmed 
in the large meta-analysis.  It therefore conceivable that a clinical definition of 
postmenopausal based on the widely accepted WHO definition (12 months of 
amenorrhoea) will be utilised in selecting patients for adjuvant zoledronic acid.  
Pretreatment biochemical classification of menopausal status may therefore be of more 
importance in patients whose clinical status is unknown, and the data presented in chapter 
3 (Fig 3.4) has shown this may be possible using FSH, oestradiol and inhibin A. 
 
As discussed earlier, the molecular mechanisms driving this hormone:zoledronic acid 
interaction were also unknown, including whether this was due to single or multiple 
reproductive hormones.  At a molecular level it was undetermined if this was a direct 
effect on tumour cells or an indirect effect by differential modification of the bone 
microenvironment.  The AZURE data presented in chapter 3 showed that high versus low 
levels of FSH/oestradiol/inhibin A were not predictive of a response to zoledronic acid on 
disease recurrence in or outside of bone, However, there was a trend to benefit from 
zoledronic acid in patients with hormone levels in the postmenopausal range (high FSH, 
low oestradiol and inhibin)(table 3.4).  This indicated that no single hormone was 
modifying the effects of zoledronic acid, and that the overall activity of the hypothalamic 
pituitary axis is more important in determining response to the drug.  The patient cohorts 
recruited to the clinical trials that showed a beneficial effect of zoledronic acid in 
reducing disease recurrence, included both naturally postmenopausal women (Coleman, 
Marshall et al. 2011; Coleman, de Boer et al. 2013) and chemically induced 
postmenopausal women (Gnant, Mlineritsch et al. 2011). Both naturally and chemically 
induced postmenopausal women will have low oestradiol and inhibin A but they will 
have different FSH levels, being high in the former and low in the later.  This suggests 
that ovarian hormones, rather than pituitary hormones are more important in modifying 
the anti-tumour effects of zoledronic acid. 
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Although ovarian hormones may be driving the anti-tumour interaction with zoledronic 
acid, both the pituitary hormone FSH and the ovarian hormone oestradiol may be 
influencing where tumour cells home to and survive.  The evaluation of the prognostic 
value of individual hormone levels from AZURE was presented in chapter 3 and showed 
a low follicle stimulating hormone (premenopausal levels) was borderline significant as a 
prognostic marker for bone recurrence (Fig 3.5).  This suggests that either breast cancer 
cells have an increased propensity to spread to premenopausal bone, or that the tumour 
cells that arrive in bone are more likely to survive and subsequently develop autonomous 
growth and form bone metastases. In addition, a low oestradiol (postmenopausal levels) 
was borderline significant as a prognostic marker for distant but not bone recurrence (Fig 
3.6).  This suggests that a postmenopausal bone may not be attractive for tumour cells and 
therefore they may preferentially spread to alternative distant sites. This differential effect 
of reproductive hormone levels on tumour cell homing to bone and subsequent tumour 
growth is supported by work carried out within Sheffield Medical School using an in vivo 
model of bone metastases. 12-week old female balb/c nude mice were injected 
intracardiac with DiD labeled ER-ve MDA-MB-231 breast cancer cells 7 days post 
ovariectomy (OVX) or sham procedure. Mice were culled at either 24 hours post tumour 
cell injection for evaluation of homing of tumour cells to bone, or maintained for 48 days 
for evaluation of tumour growth in bone. At the 24 hour time-point there was a higher 
number of tumour cells in bone in sham animals compared to OVX (personal 
communication from Dr Ning Wang, Academic Department of Human Metabolism, 
Sheffield University) (Fig 7.2).  Serum levels of reproductive hormones were not 
evaluated in this study, however, sham animals would be expected to have a lower FSH 
level than OVX animals, since the OVX procedure removes the negative feedback of the 
ovarian hormones on pituitary FSH secretion, indicating a low FSH at the time of tumour 
cell injection may increase bone homing.  At the 48-day time-point, tumour growth in 
bone was significantly higher in the OVX than sham group (89% vs. 18%) (personal 
communication from Dr Penny Ottewell, Academic Department of Clinical Oncology, 
Sheffield University). These data suggest that ER-ve breast cancer cells home 
preferentially to sham (premenopausal) bone, but subsequent growth into metastases may 
be more dependent upon low levels of reproductive hormones (OVX/postmenopausal).  
Tumour cells outside of bone were not evaluated in this study and therefore data on non-
bone tumour growth is not available. 
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Data kindly provided by Dr Penny Ottewell and Dr Ning Wang, Medical School, Sheffield University. 
 
 
Figure 7.2  Tumour cell homing to bone in ovariectomised and sham operated mice. 
 
Mice were injected intracardiac with 1x105 DiD labeled MDA-MB-231 cells 7 days post 
sham or OVX procedure.  After a further 7 days mice were culled and hind limbs 
collected for analysis using multi-photon microscopy or flow cytometry of flushed bone 
marrow. Data represents mean+SEM. Students t test for significance, *=p value <0.05. 
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The molecular mechanisms of how reproductive hormones such as inhibin A+/ oestradiol 
could modify the effects of zoledronic acid on DTCs in early breast cancer had not been 
identified to date. The data presented on the ANZAC trial in chapter 4 showed a novel 
differential effect of zoledronic acid on serum levels of the TGFβ superfamily of proteins, 
according to menopausal status. The ANZAC trial was a neo-adjuvant clinical study 
evaluating the addition of zoledronic acid to first cycle of standard FEC100 chemotherapy. 
Follistatin significantly fell and TGFβ1 significantly increased at day 21 compared to 
baseline in patients receiving zoledronic acid plus chemotherapy compared to 
chemotherapy alone (Fig 4.6 + Fig 4.8).  The change in follistatin with zoledronic acid 
was driven by postmenopausal patients, who also had a significant increase in serum 
activin at day 21 (Table 4.7).  These data suggested a new novel anti-tumour mechanism 
of zoledronic acid via alterations in serum follistatin, activin and TGFβ1.  Whether 
alterations in serum levels of these proteins with zoledronic acid reflected a direct effect 
on the primary breast tumour secretion of proteins, or an indirect effect on bone secretion 
could not be determined in this study. 
 
The differential direct anti-tumour effects of zoledronic acid according to menopausal 
status had been confirmed from other neo-adjuvant clinical studies.  NEOZOTAC was a 
phase III randomized trial of neo-adjuvant taxane based chemotherapy +/- zoledronic acid 
in HER2 –ve, stage II/II breast cancer patients (n=250).  The primary endpoint was 
pathological complete response (pCR) of the primary breast tumour.  pCR results from 
228 patients were presented at ASCO 2013 and did not differ between treatment groups, 
but a trend was observed for an increased pCR in postmenopausal women receiving 
zoledronic acid (18% vs 11%) (Charehbili A 2013).  A further trial in a similar population 
group randomised patients to neo-adjuvant taxane containing chemotherapy +/- 
zoledronic acid, and data from 188 patients were presented at ASCO 2013.  There was no 
significant difference in pCR rates with zoledronic acid in the overall population, but a 
trend to increased pCR rates with zoledronic acid in postmenopausal women (18.4% vs 
5.4%) and women with ER-ve tumours (35.3% vs 11.8%) was shown.  In patients who 
were both postmenopausal and had ER-ve tumours, pCR rates were increased with 
zoledronic acid to a greater degree than in the individual sub-groups (50% vs 0%, 
p=0.077)(Horiguchi J 2013).  These data suggested that both oestrogen receptor status 
and menopausal status could influence the direct anti-tumour efficacy of zoledronic acid,  
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and they may be synergistic with one another. However, the molecular mechanism of this 
direct anti-tumour effect remained to be established.  
 
A novel differential direct effect of zoledronic acid on the secretion of activin and 
follistatin, according to ER status of breast cancer cell lines in vitro, was shown in chapter 
5. Zoledronic acid decreased follistatin secretion from ER-ve breast cancer cell lines but 
not ER+ve cell lines (Fig 5.6). This alteration in follistatin secretion had relevant effects 
on downstream signaling pathways in the ER-ve breast cancer cell line MDA-MB-231, 
by increasing phosphorylation of the activin receptor associated protein Smad2C (Fig 
5.18), a known tumour suppressor in breast cancer.  Moreover, activin inhibited 
proliferation of both cell lines, and this was negated in the presence of follistatin (Fig 
5.13). These data suggested that in ER-ve cell lines, zoledronic acid can inhibit 
proliferation partly by increasing the bioavailability of the tumour suppressors activin and 
Smad2C, by decreasing the extracellular activin inhibitor, follistatin. This effect was 
confirmed in vivo in a xenograft model of sub-cutaneous ER-ve tumours treated with 
zoledronic acid or PBS control. A significant decrease in the area of tumour expressing 
follistatin was shown in mice treated with zoledronic acid compared to PBS control (Fig 
5.21 a+b).  The ability of zoledronic acid to decrease follistatin secretion from ER-ve 
MDA-MB-231 cells was diminished if the ovarian hormone inhibin A was added to 
conditioned medium (Fig 6.3 and 6.4), suggesting that this novel direct anti-tumour effect 
of zoledronic acid is more pronounced when there are low levels of female hormones in 
the tumour microenvironment. 
 
These data supported the hypothesis that zoledronic acid could directly affect activin and 
follistatin secretion from breast cancer cell lines in vitro, and this novel effect was 
influenced by the ER-status of the tumour cells and levels of inhibin A in the tumour 
microenvironment. Recent data from the final efficacy analysis of adjuvant zoledronic 
acid in the AZURE trial (Coleman RE 2013) showed a synergistic improvement in 
invasive disease free survival outcomes, in bone and outside of bone, in patients who 
were both > 5 years postmenopausal and had ER-ve breast tumours (HR 0.687; 95% CI 
0.474-0.996) (Fig 7.3).  In the adjuvant setting, when primary breast tumours have been 
surgically removed, the anti-tumour effect of zoledronic acid is likely to be indirect, via 
modification of the bone microenvironment, with subsequent effects on DTCs that have  
	  	  	  	  
	   257	  
 
 
 
 
Figure reproduced with permission from RE Coleman. Adjuvant therapy for stage II/III breast cancer with or without zoledronic acid. 
Final efficacy analysis of the AZURE trial.  Presented at Cancer and Bone Society, Miami, Nov 2013. Abst; LBA001 
 
 
 
Figure 7.3 Effect of both ER status and menopausal status on invasive disease free 
survival outcomes with addition of zoledronic acid to standard therapy 
 
Women > 5 years postmenopausal and with ER-ve tumours derived the most benefit from 
adjuvant zoledronic acid with a higher proportion of women being alive without invasive 
disease recurrence at 120 months follow up (HR 0.687, 95%CI 0.474-0.996). 
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spread to bone. These results indicated that zoledronic acid’s indirect anti-tumour effect 
was also influenced by the ER status of the DTCs located in bone as well as levels of 
reproductive hormones. Data from the ANZAC study (chapter 4) showed changes in 
serum levels of follistatin post zoledronic acid treatment, were also affected by ER-status 
of patients primary breast tumours.  There was a significant reduction in serum follistatin 
secretion at day 5-post zoledronic acid plus chemotherapy compared to those receiving 
chemotherapy alone in patients with ER-ve tumours only (Table 4.8). As discussed 
previously these changes in serum levels could not be attributed to either changes in the 
primary tumour secretion or alternative sources such as bone.  It was therefore necessary 
to evaluate if zoledronic acid could alter the levels of activin and follistatin in the bone 
microenvironment.  
 
The data from chapter 6 showed a novel indirect affect of both zoledronic acid and 
inhibin A on activin and follistatin levels in the bone microenvironment in vivo.  
Zoledronic acid decreased levels of the activin inhibitor follistatin in bone, but was only 
able to do so in the absence of ovarian hormones i.e. animals that had undergone 
ovariectomy (Fig 6.22). Exogenous recombinant inhibin A decreased activin levels in the 
bone (Fig 6.18).  This may create two different bone environments that DTCs would be 
exposed to; an inhibin A rich + low activin environment (modeling premenopausal) and a 
low inhibin A + activin rich environment (modeling postmenopausal).  Addition of 
zoledronic acid in the low inhibin environment would be expected to further increase 
activin’s bioavailability by decreasing its inhibitor follistatin.  These results suggest that 
zoledronic acid may have differential effects on bone activin:follistatin levels in the 
presence or absence of inhibin A. The data presented in chapter 6 however, did not 
confirm whether inhibin A was the primary ovarian hormone responsible for the 
interaction with zoledronic acid, since ovariectomy will remove the biological effects of 
both inhibin A and oestradiol.  Oestradiol has well documented anabolic effects in bone 
(Nicks, Fowler et al. 2010).  To assess the affect of oestradiol on bone levels of activin 
and follistatin, calvaria were collected from 12-week old balb/c nude mice that underwent 
OVX on day 1 of experiment and sub-cutaneous oestradiol pellets (1.5mg) were inserted 
on day 5, with mice maintained for 28 days (in vivo work carried out by Dr Penny 
Ottewell).  Oestradiol had a profound effect on bone volume and significantly decreased 
activin levels in bone with a concurrent increase in follistatin (Fig 7.4).  This novel effect 
suggested that both inhibin A and oestradiol may influence the bioavailability of the  
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Figure 7.4  Effect of oestradiol (E2) on bone volume and bone levels of activin and 
follistatin in ovariectomised mice. 
 
12-week old balb/c nude female mice underwent ovariectomy on day 1 with insertion of 
sub-cutaneous oestradiol pellets (1.5mg) on day 5.  Mice were maintained for 28 days and 
calvaria were collected at termination of experiment, crushed in PBS, filtered and 
supernatant processed to activin or follistatin ELISA.  A. Change in bone volume B 
Change in activin levels in calvaria, C. Change in follistatin levels in calvaria.  Data 
represents mean +SEM. ****p value <0.0001, * p value <0.05. 
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tumour suppressor activin in bone. This may have an effect on DTCs, in particular ER-ve 
DTCs, in the bone microenvironment and requires further investigation. 
 
Future work is planned to investigate the effects of inhibin A and zoledronic acid on ER-
ve (MDA-MB-231) tumour cell growth in bone using established in vivo models of breast 
cancer metastases to bone, in conjunction with the recombinant inhibin A used in this 
thesis. This will assess if the effects of inhibin A and zoledronic acid on activin and 
follistatin levels within the bone microenvironment (discussed in chapter 6) can indirectly 
affect ER-ve tumour cell growth in bone.  In addition, to further characterize the direct 
effect of zoledronic acid on follistatin secretion from breast tumours, primary breast 
tumour tissue blocks from the neo-adjuvant ANZAC study (FEC100 chemotherapy +/- 
zoledronic acid at first cycle) will be evaluated for follistatin expression using the 
optimized follistatin antibody used in chapter 5, comparing baseline with day 5 and day 
21 breast biopsies.  Identification of the source of serum follistatin in breast cancer 
patients would assist in understanding if tumour cell secretion or bone secretion of 
follistatin were driving the changes in serum levels seen in postmenopausal patients in the 
ANZAC study.  To assess this, serum from breast cancer patients receiving zoledronic 
acid with adjuvant chemotherapy would be an ideal resource for comparison, and could 
potentially be evaluated if adjuvant zoledonic acid becomes standard therapy in 
postmenopausal breast cancer patients.  
 
In summary, the data presented in this thesis has shown a novel direct anti-tumour 
mechanism of zoledronic acid in ER-ve breast cancer cells both in vitro and in vivo, by 
decreasing follistatin secretion from tumour cells and thus increasing bioavailability of 
the tumour suppressor activin.  The ability of zoledronic acid to affect follistatin secretion 
from tumour cells was modified by the presence of the ovarian hormone inhibin A in 
vitro.  Zoledronic acid may also have an indirect effect on DTCs in the bone 
microenvironment that is enhanced in the presence of low levels of ovarian hormones, 
with evidence in vivo, that zoledronic acid decreased follistatin levels in bone, only in 
OVX animals. Moreover, serum follistatin levels in neo-adjuvant patients receiving a 
single treatment of 4mg IV zoledronic acid significantly fell at day 21 compared to 
baseline in postmenopausal women, and at day 5 in patients with ER-ve breast tumours, 
suggesting zoledronic acid may be modifying secretion of the protein into serum.  
Although no single reproductive hormone was identified to be a significant predictor of 
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response to adjuvant zoledronic acid in the AZURE trial analysis, these data together 
suggest that ovarian hormones can interact with zoledronic acid to affect the 
activin:follistatin signaling proteins in both the tumour and in the bone microenvironment, 
with potential implications for tumour cell proliferation and survival.	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Appendix 1. AZURE laboratory manual for collection of serum 
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